<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="pediatricmusic/PMC5709272/results/search/disease/results.xml">
  <result pre="may in some cases be challenging. The clinical syndrome of" exact="idiopathic intracranial hypertension" post="results from an increase in intracranial pressure without an"/>
  <result pre="In addition to the headache patients commonly suffer from a" exact="papilledema" post="that leads to a progressive visual deficit which, if"/>
  <result pre="and preventive drugs in migraine. Development of therapies to treat" exact="migraine" post="has previously been hampered by a lack of biomarkers"/>
  <result pre="as a consequence of the increasing use of a human" exact="migraine" post="provocation model that demonstrates the importance of naturally occurring"/>
  <result pre="headache and focal neurologic signs includes primary etiologies, such as" exact="migraine" post="with aura, and secondary etiologies, such as trauma, infection,"/>
  <result pre="and understanding of its pathophysiology starts with the acknowledgment that" exact="migraine" post="is not simply a disease of intermittently occurring pain,"/>
  <result pre="If one wants to interpret the most recent findings in" exact="migraine" post="pathophysiology it is important to again discuss the clinical"/>
  <result pre="again discuss the clinical presentation of all phases of a" exact="migraine" post="attack. There are three clinical features of migraine which"/>
  <result pre="of a migraine attack. There are three clinical features of" exact="migraine" post="which point towards the limbic system and hypothalamus as"/>
  <result pre="functions, has only recently become a site of interest in" exact="migraine" post="research. Another neurotransmitter system involving the hypothalamus is the"/>
  <result pre="hypothalamus is the central dopaminergic system. Recent neuroimaging studies in" exact="migraine" post="patients undermine hypothalamic involvement in the premonitory and acute"/>
  <result pre="premonitory and acute pain phase of migraine. Most recently one" exact="migraine" post="patient went into the scanner daily over a whole"/>
  <result pre="in the prodromal phase (within the last 24 h before" exact="migraine" post="headache onset) as compared to the interictal state. More"/>
  <result pre="a crucial role in generating premonitory symptoms but also the" exact="migraine" post="attack itself. Moreover, using a recently developed protocol for"/>
  <result pre="These data corroborate a crucial role of the HT for" exact="migraine" post="chronification but also as for the sustainment of acute"/>
  <result pre="migraine chronification but also as for the sustainment of acute" exact="migraine" post="pain. References 1. Schulte LH, Sprenger C, May A."/>
  <result pre="high resolution fMRI. Neurology 2017 88:2011–2016 3. May A. Understanding" exact="migraine" post="as a cycling brain syndrome: reviewing the evidence from"/>
  <result pre="whether CGRP antagonists penetrate the blood brain barrier and abort" exact="migraine" post="headaches in part via central mechanisms. As migraine is"/>
  <result pre="and abort migraine headaches in part via central mechanisms. As" exact="migraine" post="is a CNS disorder a central abortive or preventative"/>
  <result pre="headache disorders such as migraine, tension-type headache, trigeminal autonomic cephalalgias," exact="trigeminal neuralgia" post="and persisting secondary headaches. S7 CGRP PNS models in"/>
  <result pre="sensory afferents that may be involved in the pathophysiology of" exact="migraine" post="as well as in the development of potential side"/>
  <result pre="which reflects the phenotype well. Understanding the non-pain phases of" exact="migraine" post="will lead to be a better formulation of the"/>
  <result pre="lead to be a better formulation of the pathophysiology of" exact="migraine" post="and eventually to better treatment. References 1. Disease GBD,"/>
  <result pre="4. Karsan N, Prabakhar P, Goadsby PJ. Premonitory symptoms of" exact="migraine" post="in childhood and adolescence. Current Pain and Headache Reports."/>
  <result pre="PJ. Brain activations in the premonitory phase of nitroglycerin triggered" exact="migraine" post="attacks. Brain. 2014;137:232-42. 6. Giffin NJ, Lipton RB, Silberstein"/>
  <result pre="NJ, Lipton RB, Silberstein SD, Olesen J, Goadsby PJ. The" exact="migraine" post="postdrome. An electronic diary study. Neurology (Minneap). 2016;87:1-5. 7."/>
  <result pre="of patients (90%) treated in primary care, the more complex" exact="migraine" post="and tension-type headache patients (7-8%) in secondary care with"/>
  <result pre="predictors are important for future planning. S11 GWAS studies in" exact="migraine" post="Arn M.J.M. van den Maagdenberg Departments of Human Genetics"/>
  <result pre="headache attacks with various associated neurological symptoms. About one-third of" exact="migraine" post="patients experience an aura preceding the headache phase: hence"/>
  <result pre="migraine patients experience an aura preceding the headache phase: hence" exact="migraine" post="with and without aura. Many migraine patients also suffer"/>
  <result pre="the headache phase: hence migraine with and without aura. Many" exact="migraine" post="patients also suffer from comorbid neurological disorders, such as"/>
  <result pre="of single nucleotide polymorphisms (SNPs) in tens of thousands of" exact="migraine" post="patients in genome-wide association studies (GWAS), made it feasible"/>
  <result pre="the common forms of migraine. Whereas GWAS performed in various" exact="migraine" post="subtypes yielded different top hits for the different subtypes,"/>
  <result pre="for diseases comorbid with migraine. Unlike gene mutations in monogenic" exact="migraine" post="subtypes, the effect size of gene variants in common"/>
  <result pre="migraine subtypes, the effect size of gene variants in common" exact="migraine" post="is small, thus complicating direct translation to diagnostic tests,"/>
  <result pre="epidermal nerve fibres in various peripheral nerve diseases, such as" exact="diabetic neuropathy," post="infectious and inflammatory neuropathies and neuropathies associated with systemic"/>
  <result pre="epidermal nerve fibre density was significantly lower in patients with" exact="neuropathy" post="than in controls. S13 Neuromodulation and Headache. Future perspectives"/>
  <result pre="placebo effect is a challange particularly for headache specialists.In chronic" exact="migraine" post="and chronic cluster headache patients occurrence of psychiatric comorbidities"/>
  <result pre="an addiction behavior - is frequently observed both in chronic" exact="migraine" post="and chronic cluster headache. The role of psychosocial factors"/>
  <result pre="is not there (3). Similarly other neurostimulation procedures tried in" exact="migraine" post="and cluster headache have shown poor, unsatisfactory ability to"/>
  <result pre="trust An underlying concept in the new ICHD-3 classification of" exact="trigeminal neuralgia" post="is the postulation that clinical presentations matter because they"/>
  <result pre="clinical symptoms and signs. Yet, the relatively strict criteria for" exact="trigeminal neuralgia" post="and its subgroups yield homogenous populations that allow advantage"/>
  <result pre="and Obstetrics, University of Szeged One third of women with" exact="epilepsy" post="(WWE) are in reproductive age, and nearly 50% of"/>
  <result pre="child; and/or c) changes in seizure activity. Nowadays, women with" exact="epilepsy" post="do not always get the right information; thus, it"/>
  <result pre="from trigeminal nerve endings. Animal studies investigating the mechanisms of" exact="migraine" post="and CSD are usually conducted under anesthesia, despite the"/>
  <result pre="Therefore CSD studies in awake animals are crucial for translational" exact="migraine" post="research. CSD in freely moving lissencephalic animals, led to"/>
  <result pre="of sensory stimulus and transient disruption of sensorial perception during" exact="migraine" post="headache attacks was reported (Boran et al, 2016). Disruption"/>
  <result pre="temporal discrimination of two consecutive sensorial stimuli seems specific to" exact="migraine" post="headache attacks (Vurallı et al, 2016, Vurallı et al,"/>
  <result pre="cortical event is important to explain several clinical features of" exact="migraine" post="such as 1) Dysfunction of the GABAergic neurons in"/>
  <result pre="sleep, 4) Thalamo-cortical gating could be a novel target in" exact="migraine" post="as valproate, triptans and CGRP antagonists MK-8825 suppressed CSD"/>
  <result pre="disorders that will ensure correct diagnosis. S19 The concept of" exact="trigeminal neuralgia" post="Giorgio Cruccu Trigeminal neuralgia (TN) is a neurological disease"/>
  <result pre="brain. SD is widely accepted as the pathophysiological event underlying" exact="migraine" post="aura, and may play a role in headache pathogenesis"/>
  <result pre="disorders in which invasive recordings are not possible. SD explains" exact="migraine" post="aura and progression of neurological deficits associated with other"/>
  <result pre="the chief complaint have a primary headache disorder, such as" exact="migraine" post="or tension-type headache, the diagnosis of which relies on"/>
  <result pre="artery dissection, cerebral venous thrombosis, reversible cerebral vasoconstriction syndrome and" exact="pituitary apoplexy" post="may present with isolated headache and normal physical examination,"/>
  <result pre="the ER should be based on the etiology. A severe" exact="migraine" post="attack can be treated by SC sumatriptan, intravenous non-steroidal"/>
  <result pre="the pain intensity. S23 Progestin-only contraception and beneficial effects on" exact="migraine" post="Gabriele S. Merki-Feld In women migraine prevalence peaks during"/>
  <result pre="and beneficial effects on migraine Gabriele S. Merki-Feld In women" exact="migraine" post="prevalence peaks during reproductive years. Menstruation is a significant"/>
  <result pre="during reproductive years. Menstruation is a significant risk factor for" exact="migraine" post="with attacks most likely to occur between 2 days"/>
  <result pre="contraception. Migraine with aura (MA) and to a lesser extent" exact="migraine" post="without aura (MO) increase the risk for cardiovascular events,"/>
  <result pre="shown that COC can initiate migraine, worsen the course of" exact="migraine" post="and induce a change from MO to MA. Several"/>
  <result pre="from MO to MA. Several clinical trials report improvements in" exact="migraine" post="frequency and intensity in users of the progestin-only pill"/>
  <result pre="into the IHS classification system. The current version defines the" exact="trigeminal neuralgia" post="and trigeminal neuropathy. Trigeminal neuralgia is subdivided into classical"/>
  <result pre="S26 Within person variation in headache days in persons with" exact="migraine" post="Richard Lipton Objective To determine persistence of and transitions"/>
  <result pre="Lipton Objective To determine persistence of and transitions between episodic" exact="migraine" post="(EM) and chronic migraine (CM) and to describe and"/>
  <result pre="persistence of and transitions between episodic migraine (EM) and chronic" exact="migraine" post="(CM) and to describe and model the natural variability"/>
  <result pre="of a year. These findings my influence case definitions of" exact="migraine" post="subtypes, the design and interpretation of epidemiologic studies and"/>
  <result pre="showing that cortical spreading depression (CSD), the neural correlate of" exact="migraine" post="aura, closes the paravascular space and impairs glymphatic flow."/>
  <result pre="glymphatic system in altered cortical and endothelial functioning of the" exact="migraine" post="brain, which can explain the increased risk of stroke"/>
  <result pre="the migraine brain, which can explain the increased risk of" exact="stroke" post="among migraine aura patients. S28 Photophobia and Hypothalamus Rami"/>
  <result pre="brain, which can explain the increased risk of stroke among" exact="migraine" post="aura patients. S28 Photophobia and Hypothalamus Rami Burstein, Rodrigo"/>
  <result pre="(a) hypothalamic-mediated autonomic responses such as chest tightness, throat tightness," exact="shortness" post="of breath, fast breathing, faster than usual heart rate,"/>
  <result pre="population) and of Cluster Headache 0.01% (n=0.74K of population). Chronic" exact="migraine" post="one-year prevalence was 1% (n=0.7K of population). Females tend"/>
  <result pre="in neurogenic inflammation, is now discussed throughout the communities of" exact="migraine" post="researchers, headache therapists and even migraine patients. The reason"/>
  <result pre="throughout the communities of migraine researchers, headache therapists and even" exact="migraine" post="patients. The reason for this surprising career of CGRP"/>
  <result pre="at elevated concentrations in the cranial outflow during attacks of" exact="migraine" post="and some trigemino-autonomic headaches; infusion of CGRP into patients"/>
  <result pre="is more-or-less stand-alone, in order to act as practical management" exact="aids" post="as well as educational resources. There is a set"/>
  <result pre="headache disorders and their management. LTB and EHF offer these" exact="aids" post="freely available for use without restriction. We hope for"/>
  <result pre="of L’Aquila, L’Aquila, Italy Several data indicate that migraine, especially" exact="migraine" post="with aura, is associated with an increased risk of"/>
  <result pre="with aura, is associated with an increased risk of ischemic" exact="stroke" post="and other vascular events. Of concern is whether the"/>
  <result pre="vascular events. Of concern is whether the risk of ischemic" exact="stroke" post="in migraineurs is magnified by the use of hormonal"/>
  <result pre="is magnified by the use of hormonal contraceptives (HCs). As" exact="migraine" post="prevalence is high in women of reproductive age, it"/>
  <result pre="reproductive age, it is common to face the issue of" exact="migraine" post="and HC use in clinical practice. To improve decision-making"/>
  <result pre="document pointed out that evidence addressing the risk of ischemic" exact="stroke" post="associated with the use of HCs is generally poor."/>
  <result pre="and in most cases results are not provided according to" exact="migraine" post="type. Despite those limitations, available data pointed toward an"/>
  <result pre="limitations, available data pointed toward an increased risk of ischemic" exact="stroke" post="associated with the use of HCs in women with"/>
  <result pre="and Reproductive Health (ESC). Hormonal contraceptives and risk of ischemic" exact="stroke" post="in women with migraine: a consensus statement from the"/>
  <result pre="used when the nervous system damage is due to a" exact="neurological disorder" post="such as stroke or peripheral diabetes neuropathy. In peripheral"/>
  <result pre="system damage is due to a neurological disorder such as" exact="stroke" post="or peripheral diabetes neuropathy. In peripheral neuropathic pain there"/>
  <result pre="of clinical neurophysiological and functional imaging studies have suggested that" exact="migraine" post="might be associated with cerebellar dysfunction. These studies all"/>
  <result pre="greater or lesser extent. Therefore, it is still uncertain whether" exact="migraine" post="is associated with cerebellar dysfunction, and, if so, to"/>
  <result pre="due to the increased prevalence of cerebellar ischemic lesions in" exact="migraine" post="patients or is there a more functional explanation similar"/>
  <result pre="there a more functional explanation similar to what’s seen in" exact="familial hemiplegic migraine" post="type 1 (FHM1)? Recent anatomical studies demonstrated that the"/>
  <result pre="more functional explanation similar to what’s seen in familial hemiplegic" exact="migraine" post="type 1 (FHM1)? Recent anatomical studies demonstrated that the"/>
  <result pre="revealed with almost all the sensory modalities of stimulation in" exact="migraine" post="between attacks, with its normalization during the attacks. Recently,"/>
  <result pre="on the point where the patient is recorded during the" exact="migraine" post="cycle. Thalamic/thalamocortical drives were found to be less active"/>
  <result pre="their site of release. Given the evidence for CGRP in" exact="migraine" post="and potential roles for other hypothalamic peptides, it seems"/>
  <result pre="integrates peripheral and central CGRP actions in photophobia. S38 Classical" exact="trigeminal neuralgia" post="– clinical and MRI findings Stine Maarbjerg Department of"/>
  <result pre="Maarbjerg Department of Neurology, Helse Fonna, Haugesund, Norway Background Classical" exact="trigeminal neuralgia" post="(TN) is a unique neuropathic facial pain disorder. As"/>
  <result pre="Background Classical trigeminal neuralgia (TN) is a unique neuropathic facial" exact="pain disorder." post="As there are no diagnostic tests to confirm the"/>
  <result pre="thorough history and exam. MRI is used to exclude symptomatic" exact="trigeminal neuralgia," post="not to confirm the diagnosis of TN. Knowing how"/>
  <result pre="both a clinical and a scientific perspective. S39 PACAP in" exact="migraine" post="László Vécsei 1,2, Délia Szok 1, János Tajti 1"/>
  <result pre="first evidence for potential role of PACAP in pathomechanism of" exact="migraine" post="was the intravenous administration of PACAP-38 caused headache and"/>
  <result pre="preclinical and clinical publications in the field of PACAP and" exact="migraine" post="in the database of MEDLINE/PubMed up to 31 May"/>
  <result pre="[5]. The recent functional imaging study pointed that intravenous PACAP-38-induced" exact="migraine" post="attacks was associated with alterations in brain network connectivity"/>
  <result pre="[6] Clinical investigation provided evidence of a clear association between" exact="migraine" post="phases (during a spontaneous migraine attack versus pain-free period)"/>
  <result pre="of a clear association between migraine phases (during a spontaneous" exact="migraine" post="attack versus pain-free period) and the alteration of plasma"/>
  <result pre="system by vasoactive neuropeptides might be crucial factors of the" exact="migraine" post="pathogenesis [8]. The recent preclinical and clinical studies suggest"/>
  <result pre="suggest the importance of PACAP as a future biomarker of" exact="migraine" post="headache. Acknowledgements This work was supported by the projects"/>
  <result pre="J., Ashina, M. PACAP38 induces migraine-like attacks in patients with" exact="migraine" post="without aura. Brain. 2009; 132:16-25. 3. Tuka, B., Helyes,"/>
  <result pre="Olesen, J., Ashina, M. Investigation of the pathophysiological mechanisms of" exact="migraine" post="attacks induced by pituitary adenylate cyclase-activating polypeptide-38. Brain 2014;"/>
  <result pre="T., Ashina, M. Change in brain network connectivity during PACAP38-induced" exact="migraine" post="attacks: A resting-state functional MRI study. Neurology 2016; 86:180-187."/>
  <result pre="immunoreactivity in the plasma during ictal and interictal periods of" exact="migraine" post="patients. Cephalalgia 2013; 33:1085-1095. 8. Vécsei L, Tuka B,"/>
  <result pre="Vécsei L, Tuka B, Tajti J. Role of PACAP in" exact="migraine" post="headaches. Brain 2014; 137:650-651. S40 Comorbidity Grounds Noemi Faedda"/>
  <result pre="The most frequently described comorbidities include anxiety, mood disorders [1]," exact="sleep disorder" post="[2] and attention hyperactive disorder [3]. The association between"/>
  <result pre="the consequence of a link between neurotransmitter systems involved in" exact="migraine" post="and psychiatric disorder, such as depression and anxiety [4]."/>
  <result pre="genotype, that seem to be associated with migraine, major depression," exact="generalized anxiety disorder," post="panic attacks and phobia [5]. It has been suggested"/>
  <result pre="that seem to be associated with migraine, major depression, generalized" exact="anxiety disorder," post="panic attacks and phobia [5]. It has been suggested"/>
  <result pre="vulnerability to anxiety disorders and affective disorders as well as" exact="migraine" post="might be attributed to the dysregulation of the serotonergic"/>
  <result pre="Twin studies have shown that the genetic liability related to" exact="migraine" post="amounts to 40-60%, while the contribution of non-shared environmental"/>
  <result pre="5. Peroutka SJ, Price SC, Wilhoit TL, Jones KW. Comorbid" exact="migraine" post="with aura, anxiety, and depression is associated with dopamine"/>
  <result pre="Roccella M, Carotenuto M. Attachment styles in children affected by" exact="migraine" post="without aura. Neuropsychiatr Dis Treat. 2013;9:1513-9. 11. Barone L,"/>
  <result pre="INVITED SPEAKERS S41 Application of &quot;very low-calorie ketogenic diet&quot; in" exact="migraine" post="treatment Cherubino Di Lorenzo 1, Roberta Ienca 2, Simona"/>
  <result pre="weight-loss was suggested as a useful strategy to improve both" exact="migraine" post="and metabolic syndrome. Among different approaches to achieve a"/>
  <result pre="suggested as a useful strategy to improve both migraine and" exact="metabolic syndrome." post="Among different approaches to achieve a rapid weight loss,"/>
  <result pre="headache in migraineurs. To assess if the favorable outcome on" exact="migraine" post="was due to the caloric restriction, instead of KBs,"/>
  <result pre="trigeminal and the cervical systems as a trait symptom in" exact="migraine" post="[6, 7]. The ICHD-III also does recommend the use"/>
  <result pre="RB, Hajiyeva N, Jensen R. Prevalence of neck pain in" exact="migraine" post="and tension-type headache: a population study. Cephalalgia. 2015;35(3):211-9. doi:10.1177/0333102414535110."/>
  <result pre="7. Luedtke K, Starke W, May A. Musculoskeletal dysfunction in" exact="migraine" post="patients. Cephalalgia. 2017; Jan 1:333102417716934. doi: 10.1177/0333102417716934. 8. Headache"/>
  <result pre="common neurological symptom in pediatric age. Among the primary headaches," exact="migraine" post="is far more prevalent than tension-type headache and cluster"/>
  <result pre="the possibility to classify some patients, such as children with" exact="migraine" post="with aura [2], they turned out to be unsuitable"/>
  <result pre="30 minutes, thus they could not be classified either in" exact="migraine" post="or in tension-type headache [3]. Several studies have shown"/>
  <result pre="role played by psychological factors in determining the severity of" exact="migraine" post="in children [4]. Therefore, a psychological examination is often"/>
  <result pre="B, Vigevano F, Valeriani M. Features of aura in paediatric" exact="migraine" post="diagnosed using the and ICHD 3III beta criteria. Cephalalgia,"/>
  <result pre="scrutiny but several reasons are called in cause: an appetite" exact="suppression" post="induced by proteins and (maybe) by ketone bodies (KBs),"/>
  <result pre="to be a promising approach in the early management of" exact="obesity" post="and in the preparation phase for patients that must"/>
  <result pre="by headache. A stronger association exists between TMD and chronic" exact="migraine" post="in comparison with other types of headache. Myofascial TMD"/>
  <result pre="nucleus by the TMD symptoms can favor the triggering of" exact="migraine" post="episode. Beside the epidemiological studies and the neurophysiologic hypothesis,"/>
  <result pre="TMD symptoms parallels an increase of frequency and intensity of" exact="migraine" post="and the simultaneous treatment of both conditions results in"/>
  <result pre="to be associated with the degree of widespread pressure pain" exact="hypersensitivity" post="in TTH patients, supporting the role of TrPs on"/>
  <result pre="Ther Assoc 2014; 17(1):31-38. S48 The use of nutraceuticals in" exact="migraine" post="Cherubino Di Lorenzo (cherub@inwind.it) Don Carlo Gnocchi Onlus Foundation,"/>
  <result pre="obtain some health benefits. Several nutraceutical products are proposed for" exact="migraine" post="and sold around the world, but researchers adequately study"/>
  <result pre="find researches that support the use of nutraceutical molecules in" exact="migraine" post="management. Results Available good quality data support the use"/>
  <result pre="of a combination of coenzyme Q10, feverfew and magnesium for" exact="migraine" post="prophylaxis: a prospective observational study. A double blind versus"/>
  <result pre="combination of riboflavin, coenzyme Q10, feverfew, andrographis and magnesium for" exact="migraine" post="prophylaxis is currently in progress. Conclusions Usually patients appreciate"/>
  <result pre="neurological patients .Usually, neuroimaging is unnecessary in patients with episodic" exact="migraine" post="or tension type headache with typical headache features and"/>
  <result pre="same study, after 5 years, a patient with a new" exact="migraine" post="has a 40% chance of receiving a neuroimaging examination[1]."/>
  <result pre="history of HIV or active infections, and prior history of" exact="stroke" post="or intracranial bleeding [2, 3]. A recent consensus recommends"/>
  <result pre="A recent consensus recommends brain MRI for the case of" exact="migraine" post="with aura that persists on one side or in"/>
  <result pre="headachedisorders. J Headache Pain. 2015;17:5. S51 Risk factors for chronic" exact="migraine" post="Cristina Tassorelli 1,2, Grazia Sances 1, Sara Bottiroli 1,"/>
  <result pre="Correspondence: Cristina Tassorelli (cristina.tassorelli@unipv.it) Migraine frequency fluctuates over time. Chronic" exact="migraine" post="is defined by the occurrence of headache on more"/>
  <result pre="more than 15 days/month for at least 3 months. Chronic" exact="migraine" post="affects 1–2% of the general population, and about 8%"/>
  <result pre="the literature, the most important recognized factors associated to chronic" exact="migraine" post="are overuse of acute migraine medication, ineffective acute treatment,"/>
  <result pre="recognized factors associated to chronic migraine are overuse of acute" exact="migraine" post="medication, ineffective acute treatment, obesity, depression, presence of allodynia"/>
  <result pre="of additional noncephalic pain site is a risk factor for" exact="migraine" post="chronification. For many of these factors the relationship with"/>
  <result pre="migraine chronification. For many of these factors the relationship with" exact="migraine" post="chronification may however be bi-directional. For instance, in the"/>
  <result pre="is possible that depression may negatively affect the response of" exact="migraine" post="to acute and prophylactic treatments, but it is also"/>
  <result pre="alterations. In the case of obesity, the association with chronic" exact="migraine" post="may simply be ascribed to the effect of fat"/>
  <result pre="of evidence suggest that the progression from episodic to chronic" exact="migraine" post="is associated to a progressive increase and stabilization of"/>
  <result pre="frame, it appears obvious that an additional cause for chronic" exact="migraine" post="is quite likely represented by the low rate of"/>
  <result pre="the American Migraine Prevalence and Prevention Study, nearly 40% of" exact="migraine" post="sufferers should be considered for preventive migraine therapy, while"/>
  <result pre="nearly 40% of migraine sufferers should be considered for preventive" exact="migraine" post="therapy, while only 13% of all patients with migraine"/>
  <result pre="preventive migraine therapy, while only 13% of all patients with" exact="migraine" post="currently use preventive therapy to control their attacks. The"/>
  <result pre="AM, Franznick DA, Adams AM, Lipton RB. Comorbid pain and" exact="migraine" post="chronicity: The Chronic Migraine Epidemiology and Outcomes Study. Neurology."/>
  <result pre="Silberstein SD, Diamond S, Loder E, et al. Prevalence of" exact="migraine" post="sufferers who are candidates for preventive therapy: results from"/>
  <result pre="who are candidates for preventive therapy: results from the American" exact="migraine" post="study (AMPP) study. Headache 2005; 45: 770– 771. Tassorelli"/>
  <result pre="headaches and their comorbidities are focused on migraine. Comorbidities of" exact="migraine" post="may include neurological and psychiatric conditions, as mood disorders"/>
  <result pre="conditions, as mood disorders (depression, mania, anxiety, panic attacks), epilepsy," exact="essential tremor," post="stroke, and the presence of white matter abnormalities [2]."/>
  <result pre="matter abnormalities [2]. Particularly, a complex and bidirectional relation between" exact="migraine" post="and stroke has been described, including migraine as a"/>
  <result pre="[2]. Particularly, a complex and bidirectional relation between migraine and" exact="stroke" post="has been described, including migraine as a risk factor"/>
  <result pre="bidirectional relation between migraine and stroke has been described, including" exact="migraine" post="as a risk factor for cerebral ischemia, migraine caused"/>
  <result pre="described, including migraine as a risk factor for cerebral ischemia," exact="migraine" post="caused by cerebral ischemia, migraine mimicking cerebral ischemia, migraine"/>
  <result pre="risk factor for cerebral ischemia, migraine caused by cerebral ischemia," exact="migraine" post="mimicking cerebral ischemia, migraine and cerebral ischemia sharing a"/>
  <result pre="ischemia, migraine caused by cerebral ischemia, migraine mimicking cerebral ischemia," exact="migraine" post="and cerebral ischemia sharing a common cause, and migraine"/>
  <result pre="ischemia, migraine and cerebral ischemia sharing a common cause, and" exact="migraine" post="associated with subclinical vascular brain lesions [2]. A recent"/>
  <result pre="vascular brain lesions [2]. A recent meta-analysis pointed out that" exact="migraine" post="is associated with increased ischemic stroke risk [3], and"/>
  <result pre="meta-analysis pointed out that migraine is associated with increased ischemic" exact="stroke" post="risk [3], and according to a systematic review and"/>
  <result pre="a systematic review and meta-analysis [4] the risk of hemorrhagic" exact="stroke" post="in migraineurs is increased with respect to non-migraineurs. Besides,"/>
  <result pre="in migraineurs compared to non-migraineurs [6]. Concerning the association between" exact="migraine" post="and vascular risk factors (arterial hypertension, diabetes mellitus, dyslipidemia,"/>
  <result pre="the association between migraine and vascular risk factors (arterial hypertension," exact="diabetes mellitus," post="dyslipidemia, obesity, alcohol consumption, family history of cardiovascular disease),"/>
  <result pre="vascular risk factors in migraineurs, with the only exceptions of" exact="dyslipidemia" post="and cigarette smoking, while a systematic review and meta-analysis"/>
  <result pre="and cigarette smoking, while a systematic review and meta-analysis regarding" exact="migraine" post="and body mass index categories [8] found an increased"/>
  <result pre="mass index categories [8] found an increased risk of having" exact="migraine" post="in underweight subjects and in obese women as compared"/>
  <result pre="(TTH) is highly prevalent, and may be as debilitating as" exact="migraine" post="[9]. It is noteworthy that, according to a review,"/>
  <result pre="been described the comorbidity of TTH with psychiatric disorders and" exact="fibromyalgia" post="[10]. References 1. Headache Classification Committee of the International"/>
  <result pre="Jayakumar M, Dalal D, Nazarian S. Migraine headache and ischemic" exact="stroke" post="risk: an updated meta-analysis. Am J Med. 2010; 123:612-624."/>
  <result pre="5. Sacco S, Kurth T. Migraine and the risk for" exact="stroke" post="and cardiovascular disease. Curr Cardiol Rep. 2014;16:524. 6. Sacco"/>
  <result pre="S, Kurth T. Migraine and the risk for stroke and" exact="cardiovascular disease." post="Curr Cardiol Rep. 2014;16:524. 6. Sacco S, Ornello R,"/>
  <result pre="Conventional vascular risk factors: Their role in the association between" exact="migraine" post="and cardiovascular diseases. Cephalalgia. 2015; 35:146-164. 8. Ornello R,"/>
  <result pre="RB, Hajiyeva N, Jensen R. Prevalence of neck pain in" exact="migraine" post="and tension-type headache: a population study. Cephalalgia. 2015;35(3):211-9. doi:10.1177/0333102414535110."/>
  <result pre="of pain. Pain. 2013;154 Suppl 1:S44-53. doi:10.1016/j.pain.2013.07.021. S55 OnabotulinumtoxinA for" exact="migraine" post="treatment Andrea Negro 1,2 (andrea.negro@uniroma1.it) 1Regional Referral Headache Centre,"/>
  <result pre="Italy Since 2010 the armamentarium of preventative drugs for chronic" exact="migraine" post="(CM) has become wider with the introduction of OnabotulinumtoxinA"/>
  <result pre="was more effective than 155 U in reducing headache days," exact="migraine" post="days, pain medication intake days and Headache Impact Test"/>
  <result pre="patients close to developing MOH, patients with high frequency episodic" exact="migraine" post="(HFEM), and those already abusing of drugs require special"/>
  <result pre="approval shown that it is ineffective in patients with episodic" exact="migraine" post="[4]. Those studies had important limitations as range doses"/>
  <result pre="represented in the majority by patients with low frequency episodic" exact="migraine" post="(an average of 6-7 attacks per month). Interestingly post"/>
  <result pre="6-7 attacks per month). Interestingly post hoc analyses including episodic" exact="migraine" post="patients with a greater mean frequency of headache days"/>
  <result pre="of botulinum toxin type A for the prophylaxis of episodic" exact="migraine" post="headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials. Pharmacotherapy"/>
  <result pre="symptom (conjunctival injection, lacrimation, nasal congestion, rhinorrhea, facial sweating, miosis," exact="ptosis" post="and eyelid edema). Trigger factors can include alcohol, volatile"/>
  <result pre="high economic burden (1). The most common forms include chronic" exact="migraine" post="(CM) and medication overuse headache (MOH), which are frequently"/>
  <result pre="In the primary headache group the most common disorders were" exact="migraine" post="without aura (26.0%), chronic tension-type headache (23.0%) and chronic"/>
  <result pre="migraine without aura (26.0%), chronic tension-type headache (23.0%) and chronic" exact="migraine" post="(20.3%). As for patients with migraine and chronic tension-type"/>
  <result pre="headache (23.0%) and chronic migraine (20.3%). As for patients with" exact="migraine" post="and chronic tension-type headache, the onset of headache occurred"/>
  <result pre="occurred in most cases before 45, in particular in chronic" exact="migraine" post="(89.2%), while in migraine with aura patients the headache"/>
  <result pre="before 45, in particular in chronic migraine (89.2%), while in" exact="migraine" post="with aura patients the headache started over 45 in"/>
  <result pre="cervicogenic headache, frequently associated with tension-type headache. Among cranial neuropathies," exact="trigeminal neuralgia" post="was by far the most commonly diagnosed headache. Conclusions"/>
  <result pre="diagnosed headache. Conclusions In our population of elderly headache patients," exact="migraine" post="without aura, chronic tension-type headache and chronic migraine accounted"/>
  <result pre="headache patients, migraine without aura, chronic tension-type headache and chronic" exact="migraine" post="accounted for 61.3% of the total cases. There was"/>
  <result pre="headaches, a medication overuse was found more frequently in chronic" exact="migraine" post="(71.6%), than in chronic tension-type headache (33.3%). The choice"/>
  <result pre="Brussels, Belgium Correspondence: Fenne Vandervorst Treatment of patients with chronic" exact="migraine" post="remains challenging in daily clinical practice due to several"/>
  <result pre="studies with anti-CGRP monoclonal antibodies for the treatment of chronic" exact="migraine" post="were conducted and some are still ongoing. Here, we"/>
  <result pre="next to the efficacy results of established prophylactics for chronic" exact="migraine" post="the ‘change in monthly migraine days compared to placebo’"/>
  <result pre="of established prophylactics for chronic migraine the ‘change in monthly" exact="migraine" post="days compared to placebo’ of each agent will be"/>
  <result pre="patients treated with Topiramate. The overall mean reduction of monthly" exact="migraine" post="days (compared to placebo) for the anti-CGRP monoclonal antibodies"/>
  <result pre="results of anti-CGRP monoclonal antibodies in the treatment of chronic" exact="migraine" post="are promising and at least comparable with the effect"/>
  <result pre="effect on biomarkers of inflammation and clinical indexes in chronic" exact="migraine" post="with medication overuse: results at 12 months after withdrawal."/>
  <result pre="Neurol Sci 2017;38(Suppl 1):173-175. P3 Outcome of microvascular decompression in" exact="trigeminal neuralgia" post="is highly dependent on sex and degree of neurovascular"/>
  <result pre="(MVD) is first choice neurosurgical treatment option in medically refractory" exact="trigeminal neuralgia" post="patients with an MRI verified neurovascular contact (NVC). There"/>
  <result pre="characteristics and outcome data were systematically recorded prospectively from consecutive" exact="trigeminal neuralgia" post="patients, using standardized semi-structured interviews and schemes. A pre-surgical"/>
  <result pre="need to develop new consensus criteria that define refractory chronic" exact="migraine" post="(rCM) and refractory chronic cluster headache (rCCH). These new"/>
  <result pre="BL, Siegel SE, Markley HG, Lipton RB (2008) Defining refractory" exact="migraine" post="and refractory chronic migraine: proposed criteria. Headache 48:778–782 3."/>
  <result pre="ganglion block using Tx360 device. First results in refractory chronic" exact="migraine" post="in Spain Jose M Sanchez, Maria Rico, Elena Ameijide,"/>
  <result pre="Serrano D, Reed ML, Turkel CC, Lipton RB. (2012) Chronic" exact="migraine" post="prevalence, disability, and sociodemographic factors: results from the American"/>
  <result pre="Headache. 2015;55:529-42. P6 Efficacy of erenumab (AMG 334) in chronic" exact="migraine" post="patients with prior prophylactic treatment failure: Subgroup analysis of"/>
  <result pre="erenumab (70 mg and 140 mg) in patients with chronic" exact="migraine" post="(CM), with a safety profile comparable to placebo. We"/>
  <result pre="(N=667; aged ≥18–65 years) with CM (≥15 headache days/month; ≥8" exact="migraine" post="days) were randomised (2:2:3) to once-monthly subcutaneous erenumab 70"/>
  <result pre="140 mg or placebo. Efficacy endpoints were change in monthly" exact="migraine" post="days (MMD), achievement of ≥50% reduction in MMD, change"/>
  <result pre="cognitive performance in subjects affected by different headache types including:" exact="migraine" post="without aura (MWA), chronic migraine (CM), tension type headache"/>
  <result pre="by different headache types including: migraine without aura (MWA), chronic" exact="migraine" post="(CM), tension type headache (TTH) and chronic tension type"/>
  <result pre="R, Oliveira AG, Martins IP. Assessment of cognitive dysfunction during" exact="migraine" post="attacks: a systematic review. J Neurol. 2015 Mar;262(3):654-65. P9"/>
  <result pre="tolerability of onabotulinumtoxinA and topiramate for preventive treatment of chronic" exact="migraine" post="(CM) in adults. Materials and Methods The FORWARD Study"/>
  <result pre="topiramate patients; serious AEs by 1.4% and 4.2%, respectively. Only" exact="sinusitis" post="was reported in ≥5% of 220 patients receiving onabotulinumtoxinA"/>
  <result pre="0 Funding Allergan plc Trial Registration ClinicalTrials.gov, NCT02191579 P10 Chronic" exact="migraine" post="treatment with erenumab: Responder rates Hans-Christoph Diener 1, Jan"/>
  <result pre="(CGRP) receptor antibody being evaluated as preventive treatment for chronic" exact="migraine" post="(CM). When assessing efficacy of CM treatments by responder"/>
  <result pre="with CM (≥15 headache days/month over 3 months with ≥8" exact="migraine" post="days), patients (N=667) were randomised to erenumab (70 mg"/>
  <result pre="of patients with ≥50%, ≥75%, or 100% reduction in monthly" exact="migraine" post="days (MMD) from baseline to last 4 weeks of"/>
  <result pre="Systematic Cochrane review of botulinum toxins for the prevention of" exact="migraine" post="in adults Alexandra Sinclair 1, Clare P Herd 2,"/>
  <result pre="treatment or different dose for prevention of episodic or chronic" exact="migraine" post="in adults. Background Many migraine patients suffer prolonged and"/>
  <result pre="prevention of episodic or chronic migraine in adults. Background Many" exact="migraine" post="patients suffer prolonged and frequent migraine attacks despite optimised"/>
  <result pre="in adults. Background Many migraine patients suffer prolonged and frequent" exact="migraine" post="attacks despite optimised acute and prophylactic treatments. Botulinum toxin"/>
  <result pre="toxin type A has been licensed for use in chronic" exact="migraine" post="in some countries, based largely on two commercially sponsored"/>
  <result pre="toxin in chronic migraineurs showed a reduced frequency of -3.1" exact="migraine" post="days/month (95% confidence interval (CI) -4.73 to -1.41) compared"/>
  <result pre="with placebo. Addition of one trial (418 participants) in episodic" exact="migraine" post="lowered this pooled estimate of effect to -2.39 days/month"/>
  <result pre="toxin. Secondary efficacy measures were inconsistent. Data for number of" exact="migraine" post="attacks from six trials including chronic and episodic migraineurs"/>
  <result pre="showed no significant between group difference (P=0.30), but severity of" exact="migraine" post="(10 cm visual analogue scale), was improved by -3.30"/>
  <result pre="In chronic migraine, botulinum toxin type A reduces frequency of" exact="migraine" post="by three days/month, reduces migraine severity by 30% and"/>
  <result pre="type A reduces frequency of migraine by three days/month, reduces" exact="migraine" post="severity by 30% and has a favourable safety profile"/>
  <result pre="support or refute the efficacy of botulinum toxin in episodic" exact="migraine" post="was not identified. P12 Complete detoxification is the most"/>
  <result pre="primary outcome. Results: We included 72 MOH-patients with a primary" exact="migraine" post="and/or tension-type headache diagnosis. Fifty-nine completed detoxification, 58 (81%)"/>
  <result pre="million €. References 1) Steiner TJ, et al GBD 2015:" exact="migraine" post="is the third cause of disability in under 50s."/>
  <result pre="three month, as recommended in local guidelines. Monthly headache and" exact="migraine" post="days before and after OnabotA injections were recorded in"/>
  <result pre="first procedure was 41.8 ± 11.4 years (18-71). Latency between" exact="migraine" post="onset and inclusion was 24 ± 12.9 years (2-61),"/>
  <result pre="age at inclusion (40.5±11 vs 47±12, p:0.02) and latency between" exact="migraine" post="onset and OnabotA therapy (22.3±11.71 vs 20.4±15.4 years, p:0.021)"/>
  <result pre="factors associated with (a) occurrence and (b) severity of both" exact="migraine" post="vs non-migraine headaches. Because profiles of headache triggers /"/>
  <result pre="daily data on headache occurrence, severity (level of pain), ICHD-3beta" exact="migraine" post="symptom criteria, and exposure to 70 migraine risk factors."/>
  <result pre="of pain), ICHD-3beta migraine symptom criteria, and exposure to 70" exact="migraine" post="risk factors. Nearly 88% of participants were female, 41%"/>
  <result pre="severity, 50% of risk factors were statistically associated with both" exact="migraine" post="and non-migraine headaches whereas the other half were unique"/>
  <result pre="of migraines both overlap and differ from the factors of" exact="migraine" post="severity. Moreover, these two sets of associations differ between"/>
  <result pre="migraine severity. Moreover, these two sets of associations differ between" exact="migraine" post="and non-migraine headaches. These observations imply that etiological factors"/>
  <result pre="the pain (and thus impairment) that patients experience during a" exact="migraine" post="headache, a strategy that could be particularly important for"/>
  <result pre="This investigation compared two within-individual analytic approaches to understand daily" exact="migraine" post="occurrence and severity patterns in relation to a spectrum"/>
  <result pre="a spectrum of suspected risk factors . Cox regression modelled" exact="migraine" post="occurrence whereas headache severity was modelled using a form"/>
  <result pre="of which risk factors were identified as possible &quot;triggers&quot; of" exact="migraine" post="occurrence versus possibly contributing to severity of a migraine."/>
  <result pre="on headache occurrence and severity (level of pain), ICHD- 3beta" exact="migraine" post="criteria, and exposure to 70 migraine risk factors. Nearly"/>
  <result pre="of pain), ICHD- 3beta migraine criteria, and exposure to 70" exact="migraine" post="risk factors. Nearly 88% of participants were female, 41%"/>
  <result pre="use, and travel. Cox regression modelled the binomial occurrence of" exact="migraine" post="attacks per individual participant; hazard ratios quantified their strength"/>
  <result pre="association with suspected triggers. The continuous measure of severity of" exact="migraine" post="headache was modelled using mixed model trajectory analysis (MMTA),"/>
  <result pre="Numerous risk factors were associated with occurrence and severity of" exact="migraine" post="headaches. Cox regression detected potential triggers that were associated"/>
  <result pre="triggers that were associated only with occurrence (not severity) of" exact="migraine" post="attacks. Consistent with past evidence, the profile of risk"/>
  <result pre="which only consider sample-aggregate results do not generalize to many" exact="migraine" post="patients. Conclusions Cox regression and MMTA each provide unique"/>
  <result pre="each provide unique insights regarding within-person patterns and correlates of" exact="migraine" post="occurrence and severity, respectively. Cox regression’s detection of unique"/>
  <result pre="Cox regression’s detection of unique risk factors for occurrence of" exact="migraine" post="headaches suggests that different risk factors are associated with"/>
  <result pre="suggests that different risk factors are associated with occurrence of" exact="migraine" post="attacks versus severity of migraine pain. Moreover, treatment of"/>
  <result pre="are associated with occurrence of migraine attacks versus severity of" exact="migraine" post="pain. Moreover, treatment of migraine headaches could aim to"/>
  <result pre="migraine attacks versus severity of migraine pain. Moreover, treatment of" exact="migraine" post="headaches could aim to not only prevent occurrence of"/>
  <result pre="but also reduce pain level (and thus impairment) during a" exact="migraine" post="headache, which could be especially important for patients with"/>
  <result pre="cervicogenic headache and neck pain. The C-spine MRI revealed the" exact="osteoarthritis" post="at the facet joints of left C 3-4, 4-5"/>
  <result pre="one of the most frequent neurological diseases. Specific features of" exact="migraine" post="are moderate to severe pain associated with photophobia, phonophobia,"/>
  <result pre="months with at least 8 attacks having the features of" exact="migraine" post="headache) [2]. The pain intensity and the frequency may"/>
  <result pre="excessive intake of medication for acute or symptomatic treatment of" exact="migraine" post="(triptans, AINS drugs, analgesics) leading to Medication Overuse Headache"/>
  <result pre="drugs, analgesics) leading to Medication Overuse Headache (MOH) [1]. Chronic" exact="migraine" post="condition has a negative influence on many aspects of"/>
  <result pre="The American Migraine Prevalence and Prevention Study (AMPP) showed that" exact="migraine" post="has a role both on absenteeism and presenteeism (reduced"/>
  <result pre="Buse DC, Lipton RB. Employment and work impact of chronic" exact="migraine" post="and episodic migraine. Journal of occupational and environmental medicine."/>
  <result pre="A systematic literature review and meta-analysis of prevalence estimates in" exact="migraine" post="Akaterini Bilitou 1, Pamela Vo 2, Sandra Lopez-Leon 3,"/>
  <result pre="Los Angeles/USA Correspondence:Akaterini Bilitou (katerina.bilitou@novartis.com) Introduction Reported epidemiological estimates in" exact="migraine" post="vary widely across studies, mainly because of geographic variations,"/>
  <result pre="study aimed to identify and summarize population-based prevalence estimates of" exact="migraine" post="in the last decade, after the revised International Classification"/>
  <result pre="Methods A systematic literature review (SLR) of epidemiological studies in" exact="migraine" post="published from 2006 until October 2016 from MEDLINE and"/>
  <result pre="extraction (Fig. 1). In total 31 studies reported 1- year" exact="migraine" post="prevalence, while 7 studies reported lifetime prevalence. Significant variation"/>
  <result pre="publications did not report the diagnostic criteria used. The estimated" exact="migraine" post="prevalence by any definition was 14.2% (n=19, range 5.7%"/>
  <result pre="range 5.7% to 25.6%, 95% CI 13%-15.5%). The prevalence of" exact="migraine" post="was higher among studies based on ICHD-II or later"/>
  <result pre="later definitions (15.1%, 95% CI 13.6%-16.6%) than those using other" exact="migraine" post="definitions (11.4%, 95% CI 10.4%-12.5%). The prevalence of episodic"/>
  <result pre="(11.4%, 95% CI 10.4%-12.5%). The prevalence of episodic and chronic" exact="migraine" post="were 13.6% (95%CI 10.4%-16.7%) and 0.9% (95%CI 0.32%-1.39%), respectively."/>
  <result pre="summary and evidence synthesis of the available prevalence estimates in" exact="migraine" post="during the last decade. Fig. 1 (abstract P22.) PRISMA"/>
  <result pre="P22.) PRISMA diagram for the SLR of epidemiologic studies in" exact="migraine" post="Competing interest This study was funded by Novartis AG,"/>
  <result pre="Vo (pamela.vo@novartis.com) Background A key measure of successful therapy in" exact="migraine" post="is the ability to sustain efficacy. Numerous prophylactic medications"/>
  <result pre="novel CGRP receptor antagonist erenumab, relative to other approved prophylactic" exact="migraine" post="therapies. Materials and Methods Potential trials for inclusion were"/>
  <result pre="only) were retained as comparators as they are approved for" exact="migraine" post="prophylaxis and available in the majority of European countries."/>
  <result pre="magnitude of LHH consistently favored erenumab. Conclusions While all prophylactic" exact="migraine" post="treatments were more likely to help than harm (LHH"/>
  <result pre="profile of erenumab to patients across the entire spectrum of" exact="migraine" post="compared with other migraine prophylactic treatments available in Europe."/>
  <result pre="patients across the entire spectrum of migraine compared with other" exact="migraine" post="prophylactic treatments available in Europe. Table 1 (abstract P24)."/>
  <result pre="NNH and LHH for CM and EM prophylactic treatments Chronic" exact="migraine" post="(CM) Episodic migraine (EM) Erenumab 140 mg Topiramate 100"/>
  <result pre="for CM and EM prophylactic treatments Chronic migraine (CM) Episodic" exact="migraine" post="(EM) Erenumab 140 mg Topiramate 100 mg Onabotulinum-toxin A"/>
  <result pre="7-10th September 2017, Vancouver, Canada. P25 Healthcare resource utilization among" exact="migraine" post="sufferers in the EU5 from the patient perspective Pamela"/>
  <result pre="of this study was to understand the incremental burden of" exact="migraine" post="on healthcare resource utilization (HRU) in adults in Europe"/>
  <result pre="was performed. Adult (≥18 years old) respondents with a self-reported" exact="migraine" post="diagnosis who completed the migraine module and with migraine"/>
  <result pre="old) respondents with a self-reported migraine diagnosis who completed the" exact="migraine" post="module and with migraine experienced for ≥4 headache days"/>
  <result pre="self-reported migraine diagnosis who completed the migraine module and with" exact="migraine" post="experienced for ≥4 headache days in the past month"/>
  <result pre="matched by propensity scores using sociodemographic characteristics to respondents without" exact="migraine" post="(controls). HRU was evaluated via the number of healthcare"/>
  <result pre="to determine significant differences between groups. Results Among respondents with" exact="migraine" post="(≥4 headache days/month; n=218), 79.4% were female, the mean"/>
  <result pre="ED visits (0.46 vs. 0.21, p=0.011) were significantly higher for" exact="migraine" post="patients than those without migraine. The number of hospitalizations"/>
  <result pre="those without migraine. The number of hospitalizations was higher among" exact="migraine" post="patients (0.18 vs. 0.11, p=0.056) but marginally significant. Compared"/>
  <result pre="significant. Compared with matched controls, a significantly higher proportion of" exact="migraine" post="respondents had ≥1 visits to a general/family practitioner (77.1%"/>
  <result pre="of individuals with ≥1 ED visit was significantly higher for" exact="migraine" post="patients than those without migraine (20.6% vs. 12.4%, p=0.02)"/>
  <result pre="visit was significantly higher for migraine patients than those without" exact="migraine" post="(20.6% vs. 12.4%, p=0.02) whereas the proportion hospitalized (12.8%"/>
  <result pre="in terms of HCPs, neurologists, psychiatrists, and ED visits for" exact="migraine" post="patients compared with non-migraine controls. To help reduce the"/>
  <result pre="compared with non-migraine controls. To help reduce the burden of" exact="migraine" post="on the European healthcare system better treatment options for"/>
  <result pre="Headache Society, 7-10th September 2017, Vancouver, Canada. P26 Burden of" exact="migraine" post="in the 5EU from the patient perspective: A cross-sectional"/>
  <result pre="of this study was to characterize the incremental burden of" exact="migraine" post="on quality of life (QoL), productivity, and healthcare resource"/>
  <result pre="productivity, and healthcare resource utilization (HRU) by the frequency of" exact="migraine" post="in adults using European data from the National Health"/>
  <result pre="Spain, and UK (5EU). Adult NHWS respondents with a self-reported" exact="migraine" post="diagnosis who completed the migraine module were matched by"/>
  <result pre="NHWS respondents with a self-reported migraine diagnosis who completed the" exact="migraine" post="module were matched by propensity scores to those without"/>
  <result pre="were stratified by frequency of migraines (headache days/month): 4-7 episodic" exact="migraine" post="(EM), 8-14 EM, and chronic migraine (≥15; CM). Independent"/>
  <result pre="(headache days/month): 4-7 episodic migraine (EM), 8-14 EM, and chronic" exact="migraine" post="(≥15; CM). Independent sample t-tests were used to determine"/>
  <result pre="to determine significant differences between controls and the frequency of" exact="migraine" post="groups. Results Results from the propensity score matched analysis"/>
  <result pre="that there is a statistically significant incremental burden due to" exact="migraine" post="on QoL, HRU and work productivity amongst the migraineurs"/>
  <result pre="in comparison to matched controls. P27 Understanding the impact of" exact="migraine" post="on work productivity using self-reported migraine diary data using"/>
  <result pre="Understanding the impact of migraine on work productivity using self-reported" exact="migraine" post="diary data using the Migraine Buddy application in Europe"/>
  <result pre="purpose of the study was to evaluate the impact of" exact="migraine" post="on work productivity as perceived by individuals suffering from"/>
  <result pre="migraine on work productivity as perceived by individuals suffering from" exact="migraine" post="in the real world using a self-reported smartphone application"/>
  <result pre="during the study period June 2015-July 2016. Data from chronic" exact="migraine" post="(CM: ≥15 headache days/month, N=900), 4-7 episodic migraine (EM)"/>
  <result pre="from chronic migraine (CM: ≥15 headache days/month, N=900), 4-7 episodic" exact="migraine" post="(EM) (n=1500) and 8-14 EM (n=1500) individuals were randomly"/>
  <result pre="was performed. Results A total of 10,347, 11,301 and 6,504" exact="migraine" post="records were retrieved from CM, 8-14 EM and 4-7"/>
  <result pre="respectively corresponding to a total of 16,815, 14,398, and 7,693" exact="migraine" post="days. Among employed migraineurs (n=3,106) who declared ‘work’ either"/>
  <result pre="Among employed migraineurs (n=3,106) who declared ‘work’ either as their" exact="migraine" post="location or in ‘affected activities’ at least once, an"/>
  <result pre="symptoms impacting the work productivity of employed migraineurs irrespective of" exact="migraine" post="frequency. Table 1 (abstract P27). Symptoms reported by working"/>
  <result pre="Symptoms reported by working migraineurs at least once in absenteeism-related" exact="migraine" post="records. Number and proportion of users reporting each of"/>
  <result pre="with the user-level data analysis. CM chronic migraine, EM episodic" exact="migraine" post="Funding: This study was funded by Novartis AG, Switzerland."/>
  <result pre="24-27, 2017. P28 A descriptive analysis of the burden of" exact="migraine" post="based on self-reported migraine diary data using the Migraine"/>
  <result pre="descriptive analysis of the burden of migraine based on self-reported" exact="migraine" post="diary data using the Migraine Buddy application in Europe"/>
  <result pre="07936-1080, USA Correspondence: Aikaterini Bilitou (katerina.bilitou@novartis.com) Introduction Migraine is a" exact="neurological disorder" post="that can cause severe disabling pain. The purpose of"/>
  <result pre="purpose of the study was to describe the burden of" exact="migraine" post="on health-related quality of life (HRQOL) as perceived by"/>
  <result pre="quality of life (HRQOL) as perceived by individuals suffering from" exact="migraine" post="in the real world using a self-reported mobile application."/>
  <result pre="based on data completeness (fill rates &amp;gt;70%) and stratified by" exact="migraine" post="headache days/month: 4-7 episodic migraine (EM) (n=1500), 8-14EM (n=1500),"/>
  <result pre="rates &amp;gt;70%) and stratified by migraine headache days/month: 4-7 episodic" exact="migraine" post="(EM) (n=1500), 8-14EM (n=1500), and chronic migraine (≥15; CM)"/>
  <result pre="days/month: 4-7 episodic migraine (EM) (n=1500), 8-14EM (n=1500), and chronic" exact="migraine" post="(≥15; CM) (n=900). Descriptive analysis was performed. Results More"/>
  <result pre="Results More than 95% of 3900 self-reported migraineurs reported that" exact="migraine" post="negatively impacted their daily activities in at least one"/>
  <result pre="migraine negatively impacted their daily activities in at least one" exact="migraine" post="attack. Attacks were estimated to affect 50.5% (184.4 days/year),"/>
  <result pre="of 4-7EM sufferers respectively reported anxiety and/or depression symptoms during" exact="migraine" post="attacks. Social or home activities, productivity, or sleep were"/>
  <result pre="self-reported as the most common medicines used by migraineurs across" exact="migraine" post="records (n=28152). Conclusion This study highlights the high burden"/>
  <result pre="records (n=28152). Conclusion This study highlights the high burden of" exact="migraine" post="on HRQOL and overall well-being of individuals suffering from"/>
  <result pre="and overall well-being of individuals suffering from migraines irrespective of" exact="migraine" post="frequency. Funding: This study was funded by Novartis AG,"/>
  <result pre="by Novartis AG, Switzerland. Table 1 (abstract P28). Impact of" exact="migraine" post="on daily activities as reported by migraineurs in at"/>
  <result pre="as reported by migraineurs in at least one of their" exact="migraine" post="records. Number and proportion of users, by migraine frequency"/>
  <result pre="of their migraine records. Number and proportion of users, by" exact="migraine" post="frequency and overall, reporting type of activity affected is"/>
  <result pre="one activity affected in their records; pooled results across all" exact="migraine" post="records are presented for the most recent 28-day period"/>
  <result pre="are presented for the most recent 28-day period reported by" exact="migraine" post="patients during the study (June 2015-July 2016) CM Chronic"/>
  <result pre="P29 Evaluating clinically meaningful within-subject change in functioning associated with" exact="migraine" post="prevention using the Migraine Physical Function Impact Diary (MPFID)"/>
  <result pre="item. We report a clinically meaningful within-patient change (CMWPC) in" exact="migraine" post="impact scores and evaluation of CMWPCs in the STRIVE"/>
  <result pre="CMWPCs in the STRIVE study (NCT02456740) in subjects with episodic" exact="migraine" post="(EM). Methods CMWPCs for MPFID were developed using anchor-"/>
  <result pre="observational study of patients who recently initiated or changed their" exact="migraine" post="preventive regimen. Clinically relevant anchor variables (≥30% and ≥50%"/>
  <result pre="Clinically relevant anchor variables (≥30% and ≥50% reduction in monthly" exact="migraine" post="days [MMD] and ≥20% and ≥50% reduction in MPFID"/>
  <result pre="was related to clinically meaningful reductions in the impact of" exact="migraine" post="on physical functioning versus placebo, based on greater proportions"/>
  <result pre="This supports the utility of MPFID as a marker for" exact="migraine" post="clinical benefit and demonstrates the value of erenumab as"/>
  <result pre="‘avoidance’. Cephalalgia. 2010; 30:634-637. 3. Martin PR. Behavioral management of" exact="migraine" post="headache triggers: Learning to cope with triggers. Current Pain"/>
  <result pre="(MU) and sleep quality (SQ) to be significant predictors of" exact="migraine" post="frequency, F (2, 367) = 78.21, p &amp;lt; .001,"/>
  <result pre="Mediation analysis revealed MU had a significant direct effect on" exact="migraine" post="(Predictor coefficient = .417, p &amp;lt; .001), which was"/>
  <result pre="1. Sullivan DP, Martin PR: Sleep and headaches: Relationships between" exact="migraine" post="and non-migraine headaches and sleep duration, sleep quality, chronotype,"/>
  <result pre="3:33-36. P32 State and Trait anger and its expression in" exact="migraine" post="and cluster headache Marialuisa Rausa 1,3, Sabina Cevoli 2,"/>
  <result pre="experience of pain [1]. It is reported that individuals with" exact="migraine" post="and tension type headache are more likely to hold"/>
  <result pre="study evaluated anger in cluster headache (CH) and differences between" exact="migraine" post="(M) and CH patients. The objective is to evaluate"/>
  <result pre="CH during cluster period have higher state anger than chronic" exact="migraine" post="patients, while CH patients in headache free period did"/>
  <result pre="was effective and well-tolerated as a preventive treatment of episodic" exact="migraine" post="and chronic migraine in phase 2 and phase 3"/>
  <result pre="well-tolerated as a preventive treatment of episodic migraine and chronic" exact="migraine" post="in phase 2 and phase 3 trials. The present"/>
  <result pre="injection site reactions, abdominal pain, headache, upper respiratory tract infection," exact="constipation" post="and nasopharyngitis. Local tolerability of the SC fremanezumab injection"/>
  <result pre="consecutive headache free days for patients with high frequency episodic" exact="migraine" post="Robert Noble, Ernesto Aycardi, Marcelo Bigal, Mirna McDonald, Pippa"/>
  <result pre="to be effective and well-tolerated as a preventive treatment for" exact="migraine" post="in phase 2 and 3 studies. Previously reported data"/>
  <result pre="of consecutive headache free days in the high frequency episodic" exact="migraine" post="(HFEM) study. Methods This was a randomized 3-month phase"/>
  <result pre="patients who were 80% compliant in diary entry and had" exact="migraine" post="headaches at least 8 but less than 14 days"/>
  <result pre="endpoint of the HFEM study, change in the number of" exact="migraine" post="days at month 3 relative to baseline; herein we"/>
  <result pre="was effective and well-tolerated as a preventive treatment of episodic" exact="migraine" post="and chronic migraine in phase 2 and phase 3"/>
  <result pre="well-tolerated as a preventive treatment of episodic migraine and chronic" exact="migraine" post="in phase 2 and phase 3 trials. The present"/>
  <result pre="injection site reactions, abdominal pain, headache, upper respiratory tract infection," exact="constipation" post="and nasopharyngitis. Local tolerability of the SC fremanezumab injection"/>
  <result pre="site reactions across four placebo controlled trials of erenumab for" exact="migraine" post="prevention Julio Pascual 1, David Doležil 2, Brendan Davies"/>
  <result pre="inhibits the calcitonin gene-related peptide (CGRP) receptor under investigation for" exact="migraine" post="prevention. Erenumab is administered monthly by subcutaneous injection. Here"/>
  <result pre="and injection site reaction, injection site induration, and injection site" exact="urticaria" post="(one subject each, &amp;lt;0.1%). There were no ISR-AEs of"/>
  <result pre="in both dose levels P37 Ipoglycemia a trigger factor for" exact="migraine" post="chronification in migraineurs: diagnosis with glycemic load Claudio Mostardini"/>
  <result pre="Headache Center, Ospedale G.B. Grassi, ASL Roma 3 Chronification of" exact="migraine" post="has many known factors and many others under study,"/>
  <result pre="research. Careful observation of headache diaries shows sometimes that some" exact="migraine" post="attacks may be recurrent and methodically after 2-3h after"/>
  <result pre="fact that nutritional and metabolic factors can worse and chronify" exact="migraine" post="is well known, but body weight and body mass"/>
  <result pre="evaluate in these patients. We therefore identify patients with chronic" exact="migraine" post="diagnosis in which a diary with a methodically post-prandial"/>
  <result pre="next 3h. Based on the data obtained, we have diagnosed" exact="metabolic syndrome" post="in 6 patients, for the correlation between hyperinsulinaemia and"/>
  <result pre="between hyperinsulinaemia and high BMI, and insulin resistance related to" exact="polycystic ovary syndrome" post="in 22 patients with hypoglicemya and PCOS history. Both"/>
  <result pre="with hypoglicemya and PCOS history. Both group of patients with" exact="metabolic syndrome" post="and insulin resistance, were then subjected low charb diet."/>
  <result pre="reduction in body weight and the reduction/ansence of post meal" exact="migraine" post="attack with a mean reduction of more than 50%"/>
  <result pre="Sci. 2017 May;38(Suppl 1):111-115 P38 Peripheral Vagal Nerve Stimulation attenuates" exact="migraine" post="aura: a case report Grazia Sances 1, Vito Bitetto"/>
  <result pre="Background Noninvasive neuromodulation techniques promise efficacy in the treatment of" exact="migraine" post="[1]. Interestingly, Ayata et al. have recently reported that"/>
  <result pre="report The subject is a 38-year-old female patient with both" exact="migraine" post="with (MA) and without aura (MwA), diagnosed according to"/>
  <result pre="was 4-5 per year. Usual aura consisted in monolateral negative" exact="scotoma" post="with gradual onset, progressively evolving in homonymous hemianopia (either"/>
  <result pre="was 1-2 hours, being followed almost immediately by severe unilateral" exact="migraine" post="(either left or right) resistant to triptans. MRI and"/>
  <result pre="relevance. The patient was taking cinnarizine, 25 mg daily, for" exact="migraine" post="prevention. She was also on combined oral contraception since"/>
  <result pre="device during a clinical study for the acute treatment of" exact="migraine" post="attacks. She was trained to deliver one 120&quot; stimulation"/>
  <result pre="the study, the patient had the possibility to treat multiple" exact="migraine" post="attacks. During the 3 treated MA attacks, the patient"/>
  <result pre="in patients with encephalitis, but it's an uncommon finding in" exact="migraine" post="and status migrainosus with or without aura. We present"/>
  <result pre="of a 14-year old male patient, without known history of" exact="migraine" post="or neurologic issues, who came to our attention for"/>
  <result pre="long persistent (&amp;gt;72h) symptomatology characterized by headache, confusional state, dysarthria," exact="aphasia" post="and visual disturbances. Clinical evaluation, laboratory tests and instrumental"/>
  <result pre="María-José Sánchez, Emili Comes. Cortical laminar necrosis related to migrainous" exact="cerebral infarction." post="World Journal of Clinical Cases 2013 November 16; 1(8):"/>
  <result pre="Cephalalgia 2007; 27: 965-975 - Tietjen EG. Migraine and ischaemic" exact="heart disease" post="and stroke: potential mechanisms and treatment implications. Cephalalgia 2007;"/>
  <result pre="2007; 27: 981-987 - Bousser MG, Welch KM. Relation between" exact="migraine" post="and stroke. Lancet Neurol 2005; 4: 533-542 - Komiyama"/>
  <result pre="Obach, J Rumia. Cortical laminar necrosis related to prolonged focal" exact="status epilepticus." post="J Neurol Neurosurg Psychiatry 2006;77:104–106. - Alexander M. McKinney,"/>
  <result pre="has recently been described as a distinct event from persistent" exact="migraine" post="aura and classification criteria have been proposed [1]. The"/>
  <result pre="headache outpatient clinic with the diagnosis of cerebral ischaemia and" exact="migraine" post="aura. Nine months before he was admitted to the"/>
  <result pre="to the neurological ward with the diagnosis of possible protracted" exact="migraine" post="aura. He was discharged 6 days later, with the"/>
  <result pre="inferior cerebral artery. Few weeks after the discharge, a paroxysmal" exact="atrial fibrillation" post="was detected on 24-hours ECG and a treatment with"/>
  <result pre="referred no significant headache ever. After the occurrence of the" exact="stroke" post="the same symptoms became persistent and localised at his"/>
  <result pre="a diagnosis of persistent partial VN phenomenon secondary to occipital" exact="stroke" post="was done and Magnetic Resonance Imaging (MRI) prescribed together"/>
  <result pre="field affected by ischaemic occipital stroke, as typically happens in" exact="migraine" post="stroke. This fact may open a new scenario in"/>
  <result pre="be the result rather then the actual cause of the" exact="stroke" post="itself. Consent for publication: Written informed consent was obtained"/>
  <result pre="Goadsby P. ‘Visual snow’ – a disorder distinct from persistent" exact="migraine" post="aura. Brain 2017:137; 1419-1428 2. Olesen J. Headache classification"/>
  <result pre="2015;84 (Supplement) P1.291 P41 Treatment patterns and medication use among" exact="migraine" post="patients in Finland Timo Purmonen, Hanna Wahlman, Minna Korolainen"/>
  <result pre="population, it presents significant indirect costs to society, especially when" exact="migraine" post="attacks are frequent. The aim of this study was"/>
  <result pre="In addition, we aimed to define the current primary care" exact="migraine" post="treatment patterns in Finland. Materials and methods We conducted"/>
  <result pre="they had ≥ 1 prescription for an acute or prophylactic" exact="migraine" post="medication during 1.1.2012-30.9.2016. Patients of all ages were included"/>
  <result pre="to confirm the accuracy of migraine-related use. Results Altogether 61,077" exact="migraine" post="patients were identified. Among these patients 94% were receiving"/>
  <result pre="20% at least one prophylactic treatment (n=12,082). The prevalence of" exact="migraine" post="was 2,9% in the overall population, and 4,2%-5,3% among"/>
  <result pre="(n=3,832) of patients on prophylactic treatment. Conclusions Medical treatment of" exact="migraine" post="in Finnish primary care is based on combinations of"/>
  <result pre="impact of fremanezumab on headache-related disability in patients with chronic" exact="migraine" post="using the Headache Impact Test Paul K Winner 1,"/>
  <result pre="19355, USA Correspondence: Paul K Winner Background Patients with chronic" exact="migraine" post="(CM) experience substantially impaired daily functioning and reduced quality"/>
  <result pre="duration of headaches in patients with CM. The impact of" exact="migraine" post="cannot be fully understood only by assessment of headache"/>
  <result pre="approach, with baseline HIT-6 score and years since onset of" exact="migraine" post="used as covariates. P-values for treatment comparisons were based"/>
  <result pre="Aging Sciences, Second University of Naples, Naples, Italy Background Chronic" exact="migraine" post="is an underdiagnosed and undertreated condition. Tools to improve"/>
  <result pre="is an underdiagnosed and undertreated condition. Tools to improve chronic" exact="migraine" post="detection by health care professionals may promote proper referral"/>
  <result pre="Korean Hand Therapy (KHT) as a tool for diagnosis of" exact="migraine" post="and tension type headache. Subjects and methods This procedure"/>
  <result pre="presented as Gallbladder and Urinary Bladder Meridian of KHT. The" exact="migraine" post="belonged to Gallbladder and tension-type headache belonged to Urinary"/>
  <result pre="to various combined Gallbladder and Urinary Bladder Meridian. The pure" exact="migraine" post="groups are divided into three, pure tension type headache"/>
  <result pre="might improve the diagnostic accuracy of primary headache such as" exact="migraine" post="and tension-type headache. P45 Use of nutraceutical Clevia, in"/>
  <result pre="Roma 3 The use of nutraceuticals in the prevention of" exact="migraine" post="is increasingly spreading, both for a more holistic approach"/>
  <result pre="forms of migraine, that is pure menstrual migraine, consisting of" exact="migraine" post="attacks closely related to the menstrual cycle. We selected"/>
  <result pre="selected 7 women with age between 25 and 46 with" exact="migraine" post="attacks exclusively during the menstrual phase, with the possibility"/>
  <result pre="such as Clevia can be useful in the management of" exact="migraine" post="patients and in particular of once with pure menstrual"/>
  <result pre="Res Int. 2017;2017:3804356. 6. Thompson DF, Saluja HS. Prophylaxis of" exact="migraine" post="headaches with riboflavin: A systematic review. J Clin Pharm"/>
  <result pre="recent study, we found an association between ambivalent attachment style," exact="migraine" post="severity and psychological symptoms in children/adolescents. There is evidence"/>
  <result pre="role of maternal alexithymia and attachment style on their children’s" exact="migraine" post="severity (intensity and frequency) and psychological profile (anxiety, depression,"/>
  <result pre="Materials and methods. We enrolled 84 consecutive patients suffering from" exact="migraine" post="without aura (female: 45, male: 39; age range 8-18"/>
  <result pre="were divided into two groups according to frequency of the" exact="migraine" post="episodes (high or low). According to headache attack intensity,"/>
  <result pre="show any relationship between TAS-20 and ASQ questionnaires and children’s" exact="migraine" post="intensity and frequency. Conclusions. Maternal alexithymia and attachment style"/>
  <result pre="Maternal alexithymia and attachment style have no impact on children's" exact="migraine" post="frequency and intensity. However, our results suggest that, although"/>
  <result pre="maternal alexithymic traits don’t play a causative role on children’s" exact="migraine" post="severity, they show a relationship with patients’ attachment style"/>
  <result pre="style and psychological symptoms, which in turn may impact on" exact="migraine" post="severity. P47 Post accidental dural puncture headache: 3 years"/>
  <result pre="more frequently as first or almost second choice for treating" exact="migraine" post="attack in adolescents. [5] Methods: 20 children (age 5"/>
  <result pre="20 children (age 5 – 16 years) with ≥ three" exact="migraine" post="attacks per month are treated with Aurastop. The treatment"/>
  <result pre="at the end of the 3-month-treatment-phase for days with migraine," exact="migraine" post="pain, burden of disease (HIT-6) and subjective evaluation of"/>
  <result pre="testing the synergistic effect of AurastopR as symptomatic treatment of" exact="migraine" post="aura and related symptoms in childhood and prophylaxis of"/>
  <result pre="health-related quality of life and overall health status in chronic" exact="migraine" post="Richard B Lipton 1, Sanjay K Gandhi 2, Timothy"/>
  <result pre="Frazer, Pennsylvania, 19355, USA Correspondence: Richard B Lipton Background Chronic" exact="migraine" post="(CM) is characterized by frequent attacks, which adversely affect"/>
  <result pre="using a mixed-effects repeated-measures model (with years since onset of" exact="migraine" post="and baseline MSQoL domain score as covariates). EQ-5D-5L analyses"/>
  <result pre="an analysis of covariance approach (with years since onset of" exact="migraine" post="and baseline EQ-5D-5L score as covariates). Results The study"/>
  <result pre="Teva Pharmaceutical Industries. P50 Clinical presentation and diagnostic evaluation of" exact="idiopathic intracranial hypertension" post="in children and adolescents Barbara Battan, Laura Papetti, Irene"/>
  <result pre="chronic, incapaciting disorder, characterized by attacks of severe headache. Episodic" exact="migraine" post="can progress to chronic migraine, which is defined as"/>
  <result pre="Italy in 2013 for symptom relief in patients with chronic" exact="migraine" post="who have failed, or do not tolerate, oral prophylactic"/>
  <result pre="free days on headache-related disability and productivity among people with" exact="migraine" post="with ≥4 headache days in the past month Lulu"/>
  <result pre="a self-administered, sample of adults (≥18 years). Patients with a" exact="migraine" post="diagnosis and reported experiencing ≥4 headache days a month"/>
  <result pre="associated with a decrease in headache-related disability among those with" exact="migraine" post="who are at risk for disease progression. Migraine places"/>
  <result pre="intended to reduce the frequency, severity, and disability associated with" exact="migraine" post="attacks, and faster onset of action could increase benefit"/>
  <result pre="the 12-week randomization period in the monthly average number of" exact="migraine" post="days, and results at Weeks 1, 2, 3 and"/>
  <result pre="and quarterly subcutaneous injections. P54 Burden of illness among treated" exact="migraine" post="patients with ≥4 headache days in the past month"/>
  <result pre="To determine the burden of illness among patients treated for" exact="migraine" post="with ≥4 headache days in the past month. Methods:"/>
  <result pre="respondents meeting the above criteria were matched with people without" exact="migraine" post="on age, gender, comorbidities (Charlson Comorbidity Index), annual household"/>
  <result pre="in each cohort. A statistically significantly greater proportion of treated" exact="migraine" post="patients reported being diagnosed with depression than non-migraine controls"/>
  <result pre="long-term disability compared to non-migraine controls (13.7% vs. 5.6%,p&amp;lt;0.003). Treated" exact="migraine" post="patients reported greater losses in work productivity and increases"/>
  <result pre="the previous 6 months. Greater work productivity loss among treated" exact="migraine" post="patients resulted in higher estimated annual indirect costs ($14,770.57"/>
  <result pre="($14,770.57 vs. $5,764.93, p&amp;lt;0.001) compared to non-migraine patient controls. Treated" exact="migraine" post="patients utilized more healthcare services than non-migraine patients ($24,499.90"/>
  <result pre="($24,499.90 vs. $15,318.91, p=0.013). Conclusions: The overall burden associated with" exact="migraine" post="is substantial despite the availability of treatment options. Migraine"/>
  <result pre="to people without migraine. As a result, patients treated for" exact="migraine" post="incurred substantially greater direct and indirect costs compared to"/>
  <result pre="Korea Background: Nausea and vomiting are a frequent accompaniment of" exact="migraine" post="and prokinetic medications are frequently used in its management."/>
  <result pre="in its management. Most prokinetic medications that are used in" exact="migraine" post="are dopamine antagonists and therefore have the potential to"/>
  <result pre="and safety of motilitone, a recently developed prokinetic drug, in" exact="migraine" post="patients with gastrointestinal symptoms. Materials and Methods: From two"/>
  <result pre="Methods: From two outpatient neurological clinics, we prospectively included 100" exact="migraine" post="patients with nausea and vomiting and treated them with"/>
  <result pre="treatment. Conclusions: Our study shows that medication including motiltione for" exact="migraine" post="patients with gastrointestinal symptoms is effective and there is"/>
  <result pre="setting topiramate may have additional advantages in IIH due to" exact="migraine" post="prevention and weight loss effects, though the potential for"/>
  <result pre="of key stakeholders. P58 Alcohol as a risk factor for" exact="migraine" post="attacks: an exploration Pablo Prieto 1, Gabriel Boucher 1,"/>
  <result pre="Pablo Prieto Background Alcohol has long been suspected as a" exact="migraine" post="trigger commonly resulting in avoidance and possible impact on"/>
  <result pre="intake of alcohol and occurrence of migraine. Methods Individuals with" exact="migraine" post="registered to use Curelator Headache (1) through a physician"/>
  <result pre="entering details about headaches and tracking factors that may affect" exact="migraine" post="occurrence. Alcohol consumption was recorded daily as ‘YES/NO’ and"/>
  <result pre="with attacks was determined [2]. Results Of 531 individuals with" exact="migraine" post="(Table 1), alcohol was suspected as a risk factor"/>
  <result pre="did suspect alcohol as a trigger showed no association with" exact="migraine" post="in the majority in both groups; alcohol as a"/>
  <result pre="Donoghue S, Torres F, Mian A, Wöber C. Towards improved" exact="migraine" post="management: Determining potential trigger factors in individual patients. Cephalalgia."/>
  <result pre="patterns in a cohort of US and UK individuals with" exact="migraine" post="using a digital platform Pablo Prieto 1, Gabriel Boucher"/>
  <result pre="Correspondence: Pablo Prieto Background Overuse of acute medications may worsen" exact="migraine" post="and lead to medication overuse headache (MOH) [1]. Here"/>
  <result pre="of overuse (MO) in users of a digital platform for" exact="migraine" post="(Curelator Headache TM). The objective is to compare medication"/>
  <result pre="patterns in individuals’ with both chronic (CM) and episodic (EM)" exact="migraine" post="from the US and the UK. Methods Individuals with"/>
  <result pre="migraine from the US and the UK. Methods Individuals with" exact="migraine" post="registered to use Curelator Headache (1) through a physician"/>
  <result pre="headache epidemiology study. Cephalalgia. 2010 Mar;30(3):321-8 P60 Individual self-prediction of" exact="migraine" post="attacks: longitudinal analysis of cohort of migraine patients using"/>
  <result pre="Individual self-prediction of migraine attacks: longitudinal analysis of cohort of" exact="migraine" post="patients using a digital platform Pablo Prieto 1, Gabriel"/>
  <result pre="Prediction of attacks might be expected to be difficult as" exact="migraine" post="premonitory symptoms, and the potential risk factors that trigger"/>
  <result pre="to self-predict attacks on an individual level. Methods: Individuals with" exact="migraine" post="registered to use a digital platform (Curelator Headache™) via"/>
  <result pre="about lifestyle factors, possible headaches, and medications as well as" exact="migraine" post="expectation for the next 24 hours (low/moderate/high). Patients with"/>
  <result pre="at least 10 low and 10 high expectations instances of" exact="migraine" post="were included in the analysis. Prediction was considered successful"/>
  <result pre="the analysis. Prediction was considered successful when 24hr expectation of" exact="migraine" post="was high and an attack occurred on the next"/>
  <result pre="24 hr expectation was low and was followed by a" exact="migraine" post="free day. Results: Of 497 episodic migraineurs examined in"/>
  <result pre="predictors were defined as those with ≤25% accuracy predicting a" exact="migraine" post="or a migraine-free day. In this study we found"/>
  <result pre="this study we found 9% ( n= 13) were good" exact="migraine" post="predictors and 27% ( n=40) were defined as bad"/>
  <result pre="migraine predictors and 27% ( n=40) were defined as bad" exact="migraine" post="predictors (Table 1), and both groups stood up as"/>
  <result pre="statistical significance ( p&amp;lt;0.001). Only 5% ( n=7) were good" exact="migraine" post="and migraine-free predictors. Conclusion: A substantial proportion (64%, n="/>
  <result pre="A substantial proportion (64%, n= 93) of users predict their" exact="migraine" post="with only moderate accuracy (&amp;gt;25% but &amp;lt;75%). A small"/>
  <result pre="and just 5% ( n=7) were able to accurately predict" exact="migraine" post="or migraine-free days. A next step would be to"/>
  <result pre="of their attacks. Table 1 (abstract P60). Ability to predict" exact="migraine" post="or a migraine-free day Good predictors (≥75% accuracy) Rest"/>
  <result pre="Donoghue S, Torres F, Mian A, Wöber C. Towards improved" exact="migraine" post="management: Determining potential trigger factors in individual patients. Cephalalgia."/>
  <result pre="P61 Withdrawn P62 A rapidly progressive cerebral hematoma secondary to" exact="cerebral venous sinus thrombosis" post="(CVST) - A Case Report Andrea Giorgetti (andrea.giorgetti@asst-ovestmi.it), Elena"/>
  <result pre="up then 15% of strokes. When hemorrhage is secondary to" exact="cerebral venous sinus thrombosis" post="(CVST) the diagnosis is sometimes difficult to establish. The"/>
  <result pre="involving left-side limbs. Recent past medical history was significant for" exact="ulcerative colitis" post="with ongoing steroid and anti-inflammatory therapy. Neurological evaluation revealed"/>
  <result pre="left-side limbs. Recent past medical history was significant for ulcerative" exact="colitis" post="with ongoing steroid and anti-inflammatory therapy. Neurological evaluation revealed"/>
  <result pre="upper limb weakness without Brudzinski and Kernig’s signs and no" exact="papilledema" post="on clinical examination. A cerebral computed tomography (CT) scan"/>
  <result pre="to develop CVST could be inflammatory bowel disease such as" exact="ulcerative colitis" post="and treatment like corticosteroids. The use of MRI is"/>
  <result pre="develop CVST could be inflammatory bowel disease such as ulcerative" exact="colitis" post="and treatment like corticosteroids. The use of MRI is"/>
  <result pre="To present the rare case of a 9-year-old girl with" exact="idiopathic intracranial hypertension" post="(IIH) secondary to hypoparathyroidism (HPTH) and our work-up, including"/>
  <result pre="a 9-year-old girl with idiopathic intracranial hypertension (IIH) secondary to" exact="hypoparathyroidism" post="(HPTH) and our work-up, including physical examination, blood tests,"/>
  <result pre="P66 Individual identification of factors associated with reduced risk of" exact="migraine" post="attacks: potential ‘protectors’ Stephen Donoghue 1, Francesc Peris 1,"/>
  <result pre="a digital platform that collects daily data about an individual’s" exact="migraine" post="attacks and up to 80 factors (mood, stress, diet,"/>
  <result pre="with episodic (EM) or chronic (CM) migraine. Methods Individuals with" exact="migraine" post="registered to use Curelator Headache via 1) a physician"/>
  <result pre="entering details about headaches and tracking factors that may affect" exact="migraine" post="attack occurrence, after which factor-attack associations were analyzed for"/>
  <result pre="days). Our data support what many clinicians and people with" exact="migraine" post="believe intuitively, i.e that moderate activity, staying relaxed, and"/>
  <result pre="17 (20.2%) References 1. Peris F et al. Towards improved" exact="migraine" post="management: determining potential trigger factors in individual patients. Cephalalgia"/>
  <result pre="Identification of ‘protectors’ - factors associated with reduced risk of" exact="migraine" post="attacks: some surprising observations and interpretations. Headache 2016; 56"/>
  <result pre="factors associated with attacks in individuals with episodic and chronic" exact="migraine" post="Stephen Donoghue 1, Gabriel Boucher 1, Francesc Peris 1,"/>
  <result pre="we compare in individuals with episodic (EM) or chronic (CM)" exact="migraine" post="their suspected, self-reported triggers versus risk factors identified statistically."/>
  <result pre="using a digital platform (Curelator Headache™) [3]. Methods Individuals with" exact="migraine" post="registered to use Curelator Headache via 1) a physician"/>
  <result pre="entering details about headaches and tracking factors that may affect" exact="migraine" post="attack occurrence. After 90 days factors were analyzed for"/>
  <result pre="were confirmed statistically or shown to have no association with" exact="migraine" post="attack risk. The CM group overall suspected more triggers"/>
  <result pre="per person but fewer of these were statistically associated with" exact="migraine" post="attacks ( p = 0.008). In the EM group"/>
  <result pre="Rep 2014; 18: 455-461. 2. Martin PR. Behavioural management of" exact="migraine" post="headache triggers: learning to cope with triggers. Curr Pain"/>
  <result pre="(Supp 1): 35. 4. Peris F et al. Towards improved" exact="migraine" post="management: determining potential trigger factors in individual patients. Cephalagia"/>
  <result pre="Trubetskaya st., Moscow 119991, Russia Correspondence: Tatiana Ivanova (itamail@mail.ru) Vestibular" exact="migraine" post="(VM) is the most common cause of episodic vertigo"/>
  <result pre="well as in children. (1).The exact neural mechanisms of vestibular" exact="migraine" post="are still unknown. Vestibular migraine often begins several years"/>
  <result pre="exact neural mechanisms of vestibular migraine are still unknown. Vestibular" exact="migraine" post="often begins several years after typical migraine and has"/>
  <result pre="still unknown. Vestibular migraine often begins several years after typical" exact="migraine" post="and has a variable clinical presentation. The neurological and"/>
  <result pre="presentation. The neurological and otoneurological examination of patients with vestibular" exact="migraine" post="is mostly normal and diagnosis are usually based on"/>
  <result pre="are usually based on clinical history. Treatment trials of vestibular" exact="migraine" post="are scarce and therapeutic recommendations are based on migraine"/>
  <result pre="vestibular migraine are scarce and therapeutic recommendations are based on" exact="migraine" post="guidelines. Objective: The aim of study is to determine"/>
  <result pre="is to determine the mechanisms of vertigo and dizziness in" exact="migraine" post="patients Methods: This study recruited 152 patients with migraine"/>
  <result pre="in migraine patients Methods: This study recruited 152 patients with" exact="migraine" post="with aura and migraine without aura as defined by"/>
  <result pre="This study recruited 152 patients with migraine with aura and" exact="migraine" post="without aura as defined by ICHD-3. VM was diagnosed"/>
  <result pre="by (ICHD-3) Diagnostic criteria.(2) We analyzed the medical history of" exact="migraine" post="patients with vertigo and dizziness, all patients had a"/>
  <result pre="Results: The main study group consisted of patients with vestibular" exact="migraine" post="(VM) – 13,8% (n=21), and controls were patients with"/>
  <result pre="HADS , HIT-6 in main and control group . Chronic" exact="migraine" post="and migraine without aura was more prevalent in patients"/>
  <result pre="HIT-6 in main and control group . Chronic migraine and" exact="migraine" post="without aura was more prevalent in patients with VM"/>
  <result pre="then in dizziness patients (15,43±5,9 vs 12,28±6,9,p&amp;lt;0,05) Vertigo manifest during" exact="migraine" post="attack and dizziness was permanent. VM patients have more"/>
  <result pre="attack and dizziness was permanent. VM patients have more often" exact="motion sickness" post=", subjective hearing loss, although otoneurologist found no current"/>
  <result pre="dizziness. Conclusion: VM is mostly observed in patients with chronic" exact="migraine" post="and migraine without aura. Our study suggests the role"/>
  <result pre="VM is mostly observed in patients with chronic migraine and" exact="migraine" post="without aura. Our study suggests the role of central"/>
  <result pre="part, of central sensitization in the genesis of vertigo in" exact="migraine" post="patients are warranted to pave the way to potential"/>
  <result pre="P69 Characterising the effect of lumbar puncture on headache in" exact="idiopathic intracranial hypertension" post="Andreas Yiangou 1,2, James Mitchell 1,3, Keira Annie Markey"/>
  <result pre="Yiangou (a.yiangou@bham.ac.uk) Introduction Headache is the most prevalent symptom in" exact="idiopathic intracranial hypertension" post="(IIH). This study aimed to evaluate the temporal change"/>
  <result pre="materials concerning headache ( more than 100 articles dedicated to" exact="migraine" post="aura, several books, many slide libraries on different headache"/>
  <result pre="5 - hydroxy tryptophan and magnesium (Aurastop©) efficacy in episodic" exact="migraine" post="prevention. A multicentric observational study Federico Mainardi 1, Paola"/>
  <result pre="to test the effectiveness of Aurastop© in the prophylaxis of" exact="migraine" post="without aura. Materials and methods: Sixty consecutive patients (F:"/>
  <result pre="mean age: 37.5±17.1) presenting with an ICHD-3 beta diagnosis of" exact="migraine" post="without aura (MO) were enrolled in the survey and"/>
  <result pre="Martelletti P. Altered kynurenine pathway metabolites in serum of chronic" exact="migraine" post="patients. J Headache Pain. 2015; 17: 47. Geppetti P,"/>
  <result pre="safety of 6,25 mg t.i.d feverfew CO2-extract ( MIG-99) in" exact="migraine" post="prevention – a randomized, double blind, multicenter, placebo controlled"/>
  <result pre="Tanacethum Parthenium, 5-Hydroxytryptophan and Magnesium (Aurastop®) in the treatment of" exact="migraine" post="aura: an observational study F. Antonaci 1-3, V.Rebecchi 4,"/>
  <result pre="mg) and Magnesium (185 mg) (Aurastop®) is now available for" exact="migraine" post="patients. The three components may tackle the main mechanisms"/>
  <result pre="may tackle the main mechanisms involved in the pathophysiology of" exact="migraine" post="with aura: Cortical Spreading Depression, sensitization of trigeminal vascular"/>
  <result pre="33.00 yrs ), 117 F and 83 M, suffering from" exact="migraine" post="with aura referred to 8 Lombardia Headache Centers. Patients"/>
  <result pre="and 5-HTP, (Aurastop®), could be an effective symptomatic treatment for" exact="migraine" post="aura. Randomised controlled trials are still required to confirm"/>
  <result pre="Martelletti P. Altered kynurenine pathway metabolites in serum of chronic" exact="migraine" post="patients. Journal of Headache pain 2015 Dec; 17(1):47. -"/>
  <result pre="Correspondence: Richard B. Lipton (Richard.Lipton@einstein.yu.edu) Background Many comorbidities associated with" exact="migraine" post="have a higher relative frequency in chronic migraine (CM)"/>
  <result pre="associated with migraine have a higher relative frequency in chronic" exact="migraine" post="(CM) than episodic migraine (EM). The objective of this"/>
  <result pre="a higher relative frequency in chronic migraine (CM) than episodic" exact="migraine" post="(EM). The objective of this study was to replicate"/>
  <result pre="Cardiovascular, and Gastrointestinal comorbidity categories. Results Available CaMEO respondents with" exact="migraine" post="(16,763) were sent the Comorbidities/Endophenotype module and 12,810 (76.4%)"/>
  <result pre="frequencies &amp;gt;10% higher in CM than EM included allergies/hay fever/allergic" exact="rhinitis" post="(EM, 37.4%; CM, 51.0%), sinusitis/sinus infection (EM, 47.3%; CM,"/>
  <result pre="Future analyses will address naturally occurring subgroups (taxa) defined by" exact="migraine" post="phenotypes and comorbidities and assess the relationships of these"/>
  <result pre="Development of a claims-based algorithm for use in patients with" exact="migraine" post="to identify potentially undiagnosed chronic migraine patients Jelena M."/>
  <result pre="use in patients with migraine to identify potentially undiagnosed chronic" exact="migraine" post="patients Jelena M. Pavlovic 1, Justin S. Yu 2,"/>
  <result pre="demonstrated that 75-80% of persons meeting the criteria for chronic" exact="migraine" post="(CM) do not report having received an accurate diagnosis"/>
  <result pre="to develop a claims-based algorithm for use in patients with" exact="migraine" post="to identify potentially undiagnosed CM patients. Materials and Methods"/>
  <result pre="States medical group. Eligible patients had continuous enrollment and a" exact="migraine" post="diagnosis (ICD-9/10 code of 346.xx/G43.xxx) in the 12-months prior"/>
  <result pre="were identified. Patients with ≥15 claims for acute treatment of" exact="migraine" post="(including opioids) were nearly six times as likely to"/>
  <result pre="CM (OR=9.17, 95% CI=1.26-66.51); patients with claims for ≥2 unique" exact="migraine" post="preventive classes were more than 4 times as likely"/>
  <result pre="2. Bigal M, Serrano D, Reed M, Lipton R. Chronic" exact="migraine" post="in the population. Neurology. 2008;71:559-566. P75 The relationship between"/>
  <result pre="various conditions, many with a greater relative frequency in chronic" exact="migraine" post="(CM) versus episodic migraine (EM). The objective of this"/>
  <result pre="a greater relative frequency in chronic migraine (CM) versus episodic" exact="migraine" post="(EM). The objective of this study was to replicate"/>
  <result pre="Psychiatric, and Endocrine/Neurological comorbidity categories. Results Available CaMEO respondents with" exact="migraine" post="(16,763) were sent the Comorbidities/Endophenotype module and 12,810 (76.4%:"/>
  <result pre="Preto-SP, Brazil Correspondence: Lidiane L. Florencio Background: Greater prevalence of" exact="migraine" post="in women and the fact that women seek out"/>
  <result pre="more often than men have lead to a presumption that" exact="migraine" post="is a female disorder. Possibly, this influenced to the"/>
  <result pre="female disorder. Possibly, this influenced to the actual under-diagnosis of" exact="migraine" post="and to the suboptimal headache management in men. Therefore,"/>
  <result pre="encouraged to enhance the knowledge among possible sex differences in" exact="migraine" post="clinical profile and comorbidities. Accordingly, the aim of the"/>
  <result pre="present study is to explore the self-related pain features, regarding" exact="migraine" post="and neck pain, among patients with migraine of both"/>
  <result pre="pain features, regarding migraine and neck pain, among patients with" exact="migraine" post="of both sexes. Materials and Methods: Patients with migraine,"/>
  <result pre="or head trauma. A structured questionnaire was applied to verify" exact="migraine" post="and neck pain characteristics. The outcomes of interest were"/>
  <result pre="conditions and its intensity. Severity of the disabilities related to" exact="migraine" post="and to neck pain were respectively assessed by the"/>
  <result pre="of significance of 0.05. Results: Groups did not differ regarding" exact="migraine" post="features and migraine related disability (p&amp;gt;0.05) (Table 1). Neck"/>
  <result pre="0.05. Results: Groups did not differ regarding migraine features and" exact="migraine" post="related disability (p&amp;gt;0.05) (Table 1). Neck pain was reported"/>
  <result pre="allodynia measured by the 12 item Allodynia Symptom Checklist (ASC-12);" exact="migraine" post="related disability assessed using the Migraine Disability Assessment (MIDAS)"/>
  <result pre="Sample characteristics considering self-report pain features and disability related to" exact="migraine" post="and neck pain Men with migraine (n=12) Women with"/>
  <result pre="and disability related to migraine and neck pain Men with" exact="migraine" post="(n=12) Women with migraine (n=12) Age (years) 34.2 (8.1)"/>
  <result pre="migraine and neck pain Men with migraine (n=12) Women with" exact="migraine" post="(n=12) Age (years) 34.2 (8.1) 34.3 (10.6) ASC-12 4.2"/>
  <result pre="capacity of cervical extensors and flexors muscles in individuals with" exact="migraine" post="and controls: a pilot study Iuri V De Oliveira"/>
  <result pre="Brazil Correspondence: Iuri V De Oliveira (iurivaloti@gmail.com) BACKGROUND Patients with" exact="migraine" post="often present neck pain. Additionally, migraine has been associated"/>
  <result pre="(iurivaloti@gmail.com) BACKGROUND Patients with migraine often present neck pain. Additionally," exact="migraine" post="has been associated to an altered neck muscle performance"/>
  <result pre="evaluate the endurance capacity of neck muscles in individuals with" exact="migraine" post="and controls. MATERIALS AND METHODS Fifteen subjects with migraine"/>
  <result pre="with migraine and controls. MATERIALS AND METHODS Fifteen subjects with" exact="migraine" post="were screened from a headache tertiary clinic and fifteen"/>
  <result pre="difference (Table 2). CONCLUSIONS Preliminary findings suggest that subjects with" exact="migraine" post="present worse performance of neck flexor endurance characterized by"/>
  <result pre="2008; (31):348-354 P78 Light-induced discomfort changes semi-static posture control of" exact="migraine" post="patients Carina F Pinheiro 1, Renato Moraes 2, Lais"/>
  <result pre="14049-900, Brazil Correspondence: Carina F Pinheiro (carinafp@hotmail.com) Background: Patients with" exact="migraine" post="have showed balance deficits with increased postural oscillation during"/>
  <result pre="in comparison to control subjects [1,2]. Light sensibility is a" exact="migraine" post="feature that happens mostly during headache attacks, but also"/>
  <result pre="present in lower intensity during the interictal period, contributing to" exact="migraine" post="disability [3]. However, it has not been established if"/>
  <result pre="to different light intensities modifies the semi-static posture control of" exact="migraine" post="patients in the interictal period. Our purpose was to"/>
  <result pre="period. Our purpose was to investigate bipedal postural control of" exact="migraine" post="women under different light intensities. Materials and Methods: Fourteen"/>
  <result pre="under different light intensities. Materials and Methods: Fourteen woman with" exact="migraine" post="[4] were selected from a headache tertiary clinic and"/>
  <result pre="Pinheiro CF, Gonçalves MC, Florencio LL, et al. Influence of" exact="migraine" post="and of migraine aura on balance and mobility -"/>
  <result pre="MC, Florencio LL, et al. Influence of migraine and of" exact="migraine" post="aura on balance and mobility - A controlled study."/>
  <result pre="knowledge of the association of poor sleep quality with probable" exact="migraine" post="(PM) in general population. In the present study, we"/>
  <result pre="proportional to population distribution in all Korean territories. Diagnoses of" exact="migraine" post="and PM were based on criteria A to D"/>
  <result pre="and PM were based on criteria A to D for" exact="migraine" post="without aura (code 1.1) in the International Classification of"/>
  <result pre="was lower among individuals with PM compared to those with" exact="migraine" post="(35.4% vs. 47.6%, p = 0.011) but higher than"/>
  <result pre="the total Korean population; and cases identified as migraine, probable" exact="migraine" post="and poor sleep quality Survey participants N (%) Total"/>
  <result pre="subcomponents score of PSQI of individual with non-headache, PM and" exact="migraine" post="Non-headache individuals N = 1,422 (52.8%) PM N ="/>
  <result pre="to individuals with non-headache bSignificantly different compared to individuals with" exact="migraine" post="References 1. Rains JC, Poceta JS, Penzien DB. Sleep"/>
  <result pre="fear of falling and disability among women and men with" exact="migraine" post="Gabriela Ferreira Carvalho 1; Lidiane L Florêncio 1, Carina"/>
  <result pre="balance such as kinesiophobia, fear of falling, dizziness handicap and" exact="migraine" post="disability are important for proper management among migraineurs. Objective:"/>
  <result pre="the presence of kinesiophobia, fear of falling, dizziness handicap and" exact="migraine" post="disability and its correlation among women and men with"/>
  <result pre="among women and men with migraine. Methods: Patients diagnosed with" exact="migraine" post="according with the ICHD-III were screened from a tertiary"/>
  <result pre="groups: women (n=38) and men (n=17). Subjects with systemic diseases," exact="vestibular disease" post="history, presence of other headache diagnosis or any musculoskeletal"/>
  <result pre="did differ in the following outcomes: age (p=0.12), BMI (p=0.13)," exact="migraine" post="frequency, intensity and headache onset (p&amp;gt;0.09). However, the level"/>
  <result pre="MIDAS (r=41) (Fig. 1). Conclusion: Few studies address men with" exact="migraine" post="and these results highlight the absence of significant differences"/>
  <result pre="questionnaires scores among men and women with migraine. Men with" exact="migraine" post="(n=17) Women with migraine (n=38) Age (years) 33.8 (7.3)"/>
  <result pre="and women with migraine. Men with migraine (n=17) Women with" exact="migraine" post="(n=38) Age (years) 33.8 (7.3) 34.2 (11.3) BMI 27.2"/>
  <result pre="it may mimic various serious, including life-threatening, diseases, such as" exact="stroke" post="and meningoencephalitis, which is why vigorous tests should be"/>
  <result pre="girl. Each patient presented with headache, altered conscious state and" exact="papilledema" post="associated with different neurological symptoms such as dysarthria, hemiplegia,"/>
  <result pre="meningeal irritation. They received Ceftriaxone, Aciclovir, and Dexamethasone for possible" exact="encephalitis" post="and/ or autoimmune disorders. Clinical manifestations were compatible with"/>
  <result pre="Correspondence: Tetiana Maikova (maykova@headache.com.ua) Background. The treatment and prevention of" exact="migraine" post="attacks has for long yielded insufficient results. A usual"/>
  <result pre="with the goal of increasing efficacy of the prevention of" exact="migraine" post="attacks using quetiapine as an additional (supplementary) medicine in"/>
  <result pre="high efficacy of quetiapine in resistant and chronic forms of" exact="migraine" post="(with and without aura). Referenses 1. Martelletti P., Katsarava"/>
  <result pre="6.8.2017). P84 Implementation of improved working practices in a chronic" exact="migraine" post="Botox® clinic has increased treatment capacity by up to"/>
  <result pre="NHS Trust, UK; 2ProcEx Solutions Ltd., Wales, UK Objective: Chronic" exact="migraine" post="is defined as headaches occurring on 15 or more"/>
  <result pre="more days each month, at least half of which have" exact="migraine" post="symptoms. Botox® (onabotulinum toxin A) is used extensively in"/>
  <result pre="are able to treat. P85 Zonisamide for headache prophylaxis in" exact="dementia" post="Yunju Choi 1, Seung H. Lee 2, Myeong K."/>
  <result pre="activity. Furthermore, recent studies have demonstrated additional therapeutic use in" exact="migraine" post="prophylaxis [1]. Zonisamide, a sulfonamide analog, is a drug"/>
  <result pre="Materials and Methods We enrolled 10 Alzheimer’s disease patients with" exact="migraine" post="headache, retrospectively. For headache, we investigated headache frequency with"/>
  <result pre="and visual analog scales (VAS). Mini-mental status examination (MMSE), clinical" exact="dementia" post="rating (CDR) was checked on visit and 3 months"/>
  <result pre="Rigshospitalet-Glostrup, Copenhagen, Denmark Correspondence: Vlasta Vukovic Cvetkovic (vlasta.vukovic@uclmail.net) Background: Retinal" exact="migraine" post="is a rare form of migraine. According to the"/>
  <result pre="has additional &quot;autonomic aura symptoms&quot;. A 69-year old man, with" exact="migraine" post="without aura and separately sudden attacks of complete visual"/>
  <result pre="aspirin had no effect on migraine. Conclusion: Although rare, retinal" exact="migraine" post="should not be misdiagnosed as amaurosis fugax, papilledema or"/>
  <result pre="rare, retinal migraine should not be misdiagnosed as amaurosis fugax," exact="papilledema" post="or optic disc disease, transient visual obscuration or Uhthoffs"/>
  <result pre="grey matter volume and functional connectivity in cluster headache versus" exact="migraine" post="Silvia Benemei 1, Antonio Giorgio 2, Jian Zhang 2,"/>
  <result pre="functional abnormalities in the brain of cluster headache (CH) and" exact="migraine" post="(M) patients. However, no between-group comparison of MRI measure"/>
  <result pre="key cognitive networks, with a possible maladaptive role. P89 Intercepting" exact="migraine" post="in its path towards chronicity Angela Koverech, Paolo Martelletti"/>
  <result pre="choice to treat with CGRP(r) mAbs the very low frequency" exact="migraine" post="subpopulation (4-6 migraine days per month). Unfortunately, the tight"/>
  <result pre="with CGRP(r) mAbs the very low frequency migraine subpopulation (4-6" exact="migraine" post="days per month). Unfortunately, the tight application of existing"/>
  <result pre="However, only 2% of the world's population suffers from chronic" exact="migraine" post="(with or without pharmacological abuse of acute drugs –"/>
  <result pre="burden, and who fluctuate in a pre-chronic phase with high-frequency" exact="migraine" post="crisis but who are not yet chronic. Only in"/>
  <result pre="this way will we reduce the huge number of chronic" exact="migraine" post="patients, who stray towards medication overuse headache (MOH) and"/>
  <result pre="priority, because we know that the rehabilitation procedures for chronic" exact="migraine" post="complicated by MOH present with relapse in 50% of"/>
  <result pre="migraine, as clinically defined by the European Headache Federation. Refractory" exact="migraine" post="is very hard to treat and has been the"/>
  <result pre="Reference Martelletti P. The application of CGRP(r) monoclonal antibodies in" exact="migraine" post="spectrum: needs and priorities. Biodrugs 2017 in press. P90"/>
  <result pre="Induction of migraine-like photophobia by PACAP-38: A potential target in" exact="migraine" post="treatment Adisa Kuburas 1, Bianca N. Mason 2, Maria-Christina"/>
  <result pre="Washington 98011 Correspondence: Andrew F. Russo Migraine is a disabling" exact="neurological disorder" post="and a significant public health problem. The pathophysiology of"/>
  <result pre="disorder and a significant public health problem. The pathophysiology of" exact="migraine" post="is not well understood, but studies have shown that"/>
  <result pre="Future work will attempt to understand more about PACAP38 in" exact="migraine" post="and to explore PACAP as a potential novel target"/>
  <result pre="and to explore PACAP as a potential novel target in" exact="migraine" post="therapy. P91 Burden and impact of migraine: a caregiver’s"/>
  <result pre="Migraine has far-reaching impacts on the family of individuals with" exact="migraine" post="but limited evidence is available to describe this reality."/>
  <result pre="of migraine, this study sought to describe the impact of" exact="migraine" post="from the caregiver’s perspective. Materials and Methods This cross-sectional"/>
  <result pre="Caregivers aged ≥25 years who were caring for an adult" exact="migraine" post="patient in their household were recruited to participate in"/>
  <result pre="where they were asked to respond to specific questions on" exact="migraine" post="and provide their perspectives on statements and other participants’"/>
  <result pre="reported that they were highly involved in the management of" exact="migraine" post="and that they spent an average of 15 hours/month"/>
  <result pre="being torn between commitment, self-sacrifice and resentment. All agreed that" exact="migraine" post="patients were thankful for their help and assistance. Conclusions"/>
  <result pre="a major impact on the lives of close relatives supporting" exact="migraine" post="patients. This study highlights how the burden of migraine"/>
  <result pre="supporting migraine patients. This study highlights how the burden of" exact="migraine" post="extends beyond the patients, with substantial functional and emotional"/>
  <result pre="experience and unmet needs in the current treatments available to" exact="migraine" post="patients. Funding This study was funded by Novartis AG,"/>
  <result pre="P93 Real-world patient perspective on the burden and impact of" exact="migraine" post="Elena Ruiz de la Torre 1, Paolo Martelletti 2,3,"/>
  <result pre="was undertaken to understand the full burden and impact of" exact="migraine" post="in everyday life from the patient’s point of view."/>
  <result pre="period of 4 consecutive days. Adults with chronic and episodic" exact="migraine" post="aged between 25 and 60 years old were recruited"/>
  <result pre="where they were asked to respond to specific questions on" exact="migraine" post="and to provide their perspective on statements and other"/>
  <result pre="by country and qualitatively analyzed. Results A total of 60" exact="migraine" post="patients participated in this pilot phase of a large"/>
  <result pre="1 st symptoms. Table 1 summarizes the 3 most common" exact="migraine" post="attack triggers, symptoms, and coping mechanisms reported by patients."/>
  <result pre="and frustration were most frequently reported as emotional consequences of" exact="migraine" post="in private/social life (92% and 72%) and work (97%"/>
  <result pre="88%). 87% of patients (n=52) had seen a physician for" exact="migraine" post="management but many (85%, n=51) did not consult regularly,"/>
  <result pre="Conclusions This study highlights the substantial functional and emotional burden" exact="migraine" post="exerts on individuals, as well as the significant unmet"/>
  <result pre="of Onabotulinumtoxin A and Physical Therapy combined treatment in chronic" exact="migraine" post="Antonio Granato 1; Antonella Monticco 2; Manuela Deodato 2;"/>
  <result pre="toxin A (BoNT-A) has proven to be effective in chronic" exact="migraine" post="(CM) prophylaxis. Currently no clinical studies about BoNT-A plus"/>
  <result pre="antimigraine action of butterbur. P96 Use of acute headache and" exact="migraine" post="medications in patients with episodic migrainein the STRIVE Phase"/>
  <result pre="episodic migrainein the STRIVE Phase 3 trial of erenumab for" exact="migraine" post="prevention Uwe Reuter 1, Jo Bonner 2, Gregor Broessner"/>
  <result pre="the STRIVE placebo-controlled Phase 3 trial in patients with episodic" exact="migraine" post="(EM; clinicaltrials.gov NCT02456740), erenumab 70 mg and 140 mg"/>
  <result pre="the primary endpoint of significantly reducing the number of monthly" exact="migraine" post="days versus placebo. Erenumab also achieved the secondary endpoint"/>
  <result pre="treatment, visit, treatment by visit interaction, stratification factors (region and" exact="migraine" post="prophylaxis medication status), and baseline value. Nominal p-values were"/>
  <result pre="Neurology, Evangelical Hospital Unna, Unna, Germany Background The evolution of" exact="migraine" post="(M) after the age of 50 has been insufficiently"/>
  <result pre="Results Compared to subjects with LLMAs in patients with CMR" exact="migraine" post="terminated a decade later (39±9 vs 49.7, p&amp;lt;0.05), in"/>
  <result pre="of both pain and aura. P98 Reducing the impact of" exact="migraine" post="on functioning: Results from the STRIVE trial, a phase"/>
  <result pre="randomised, double-blind, placebo-controlled study of erenumab in patients with episodic" exact="migraine" post="Dawn C Buse 1, Richard B Lipton 1, Daniel"/>
  <result pre="newly developed 31-item patient-reported outcome instrument assessing the impact of" exact="migraine" post="on functional outcomes over 7 days. The MFIQ includes"/>
  <result pre="erenumab, which is being developed as a preventive treatment for" exact="migraine" post="in adults, on functional outcomes using the MFIQ. Methods"/>
  <result pre="Methods In STRIVE, a total of 955 patients with episodic" exact="migraine" post="aged 18–65 years were randomised 1:1:1 to receive monthly"/>
  <result pre="greater reductions in the MFIQ scores, reflecting less impact of" exact="migraine" post="on their physical functioning, usual activity, and social and"/>
  <result pre="a phase 3, randomised, double-blind study of erenumab for episodic" exact="migraine" post="Asha Hareendran 1, Dawn C Buse 2, Richard B"/>
  <result pre="13-item patient-reported outcome (PRO) measure that assesses the impact of" exact="migraine" post="on Everyday Activities (EA) and Physical Impairment (PI) domains."/>
  <result pre="report the effect of erenumab, a preventive treatment for episodic" exact="migraine" post="(EM) in adults, on monthly days with impairment as"/>
  <result pre="standard efficacy measures. P100 Patient-reported outcomes in patients with chronic" exact="migraine" post="receiving placebo or erenumab (AMG 334) in a phase"/>
  <result pre="gene-related peptide (CGRP) receptor monoclonal antibody in clinical development for" exact="migraine" post="prevention. The objective of this study was to evaluate"/>
  <result pre="in a phase 2 clinical trial of erenumab for chronic" exact="migraine" post="(CM) (NCT02066415). Methods 667 adults with CM were randomised"/>
  <result pre="the calcitonin-gene related peptide (CGRP) ligand, a validated target for" exact="migraine" post="preventive therapy. Fremanezumab was found to be effective and"/>
  <result pre="to be effective and well-tolerated as a preventive treatment for" exact="migraine" post="in a high frequency episodic migraine (HFEM) phase 2"/>
  <result pre="a preventive treatment for migraine in a high frequency episodic" exact="migraine" post="(HFEM) phase 2 study. Study participants included patients classified"/>
  <result pre="2 study. Study participants included patients classified as having episodic" exact="migraine" post="(EM) per the ICHD III beta. Herein, we determined"/>
  <result pre="as having high frequency EM (HFEM) to moderate frequency episodic" exact="migraine" post="(MFEM) and low frequency episodic migraine (LFEM) during the"/>
  <result pre="to moderate frequency episodic migraine (MFEM) and low frequency episodic" exact="migraine" post="(LFEM) during the HFEM study. Methods Patients were randomized"/>
  <result pre="headache days (days of headaches lasting &amp;gt; 4 hours) and" exact="migraine" post="days (days with headaches classified as migraine, probable migraine"/>
  <result pre="and migraine days (days with headaches classified as migraine, probable" exact="migraine" post="or treated with triptan or ergot compounds) per month"/>
  <result pre="ergot compounds) per month were categorized into four types of" exact="migraine" post="classification: Chronic migraine (CM) as having ≥15 headache days"/>
  <result pre="month were categorized into four types of migraine classification: Chronic" exact="migraine" post="(CM) as having ≥15 headache days with 8 migraine"/>
  <result pre="Chronic migraine (CM) as having ≥15 headache days with 8" exact="migraine" post="days; HFEM 8 to 14 headache days with 8"/>
  <result pre="migraine days; HFEM 8 to 14 headache days with 8" exact="migraine" post="days; MFEM 4 to 7 headache days and 4-7"/>
  <result pre="migraine days; MFEM 4 to 7 headache days and 4-7" exact="migraine" post="days; LFEM 0 to 3 headache days and 0-3"/>
  <result pre="migraine days; LFEM 0 to 3 headache days and 0-3" exact="migraine" post="days. Analyses on the shifts for migraine classification from"/>
  <result pre="days and 0-3 migraine days. Analyses on the shifts for" exact="migraine" post="classification from baseline to month 3 were performed to"/>
  <result pre="HFEM. Results Overall, the fremanezumab arms showed significant improvement in" exact="migraine" post="classification compared to the placebo arm at month 3"/>
  <result pre="Table 1A). Chi square analyses indicated that the shift of" exact="migraine" post="classification during the study was not independent of treatment,"/>
  <result pre="patients on fremanezumab 225mg and 675mg showed a shift in" exact="migraine" post="category from HFEM to LFEM in 3 months compared"/>
  <result pre="study suggests that fremanezumab may potentially prevent the progression of" exact="migraine" post="to more chronic forms. Table 1 (abstract P101). Patient"/>
  <result pre="more chronic forms. Table 1 (abstract P101). Patient classification in" exact="migraine" post="categories during the HFEM study Table 1A. Overall shift"/>
  <result pre="categories during the HFEM study Table 1A. Overall shift in" exact="migraine" post="category a Placebo n = 104 Fremanezumab 225 mg"/>
  <result pre="(23%)  LFEM 20 (20%) 40 (45%) 47 (52%) aShift in" exact="migraine" post="category, worsen = HFEM to CM, stable = HFEM"/>
  <result pre="calcitonin gene-related peptide (CGRP) receptor and is under investigation for" exact="migraine" post="prevention. As the ligand CGRP is a vasodilator, inhibition"/>
  <result pre="mg had no relevant effect on BP in subjects with" exact="migraine" post="over 12 weeks versus placebo, and was not associated"/>
  <result pre="CGRP on the vasculature in a preclinical mouse model of" exact="migraine" post="Bianca Mason The neuropeptide calcitonin gene-related peptide (CGRP) is"/>
  <result pre="gene-related peptide (CGRP) is a key player in migraine. While" exact="migraine" post="can be induced by peripherally administered CGRP (intravenous) and"/>
  <result pre="levels of light and is experienced by approximately 90% of" exact="migraine" post="patients. We have previously shown that peripheral (intraperitoneal, IP)"/>
  <result pre="seen following central (intracerebroventricular, ICV) injection. Importantly, two clinically effective" exact="migraine" post="drugs, the 5-HT 1B/D agonist sumatriptan and a CGRP-blocking"/>
  <result pre="vagal nerve stimulation (nVNS) as a novel treatment approach for" exact="migraine" post="and cluster-headache patients [2-4]. However, nVNS seems to be"/>
  <result pre="RB, Grosberg B, Cady R, Dorlas S, et al. Chronic" exact="migraine" post="headache prevention with noninvasive vagus nerve stimulation The EVENT"/>
  <result pre="Neurobiol Dis. 2017;102:96-104. P106 Obesity is more prevalent in chronic" exact="migraine" post="than in episodic migraine Brad D Torphy 1, Nicole"/>
  <result pre="Obesity is more prevalent in chronic migraine than in episodic" exact="migraine" post="Brad D Torphy 1, Nicole Montes Buckley 2 1Diamond"/>
  <result pre="IL, 60602, USA Correspondence: Brad D Torphy BACKGROUND: Migraine and" exact="obesity" post="are two major public health problems in the USA"/>
  <result pre="around the world. In the USA 12% of individuals have" exact="migraine" post="and 37% of adults are obese 1. Evidence suggests"/>
  <result pre="adults are obese 1. Evidence suggests a possible link between" exact="migraine" post="and obesity, but research has been mixed. There are"/>
  <result pre="STUDY: The purpose of our study was to determine if" exact="obesity" post="is more prevalent in chronic migraine than in episodic"/>
  <result pre="was to determine if obesity is more prevalent in chronic" exact="migraine" post="than in episodic migraine. RESULTS: We analyzed the body"/>
  <result pre="a period of one year. The mean BMI of chronic" exact="migraine" post="(CM) patients was 28.8% versus 25.3% for episodic migraine"/>
  <result pre="chronic migraine (CM) patients was 28.8% versus 25.3% for episodic" exact="migraine" post="(EM) patients, both of which are defined as &quot;overweight.&quot;"/>
  <result pre="B Lipton Background As the seventh most disabling condition globally," exact="migraine" post="adversely affects the health-related quality of life (HRQoL) of"/>
  <result pre="the frequency of headaches and migraines in patients with episodic" exact="migraine" post="(EM). For a comprehensive understanding of the impact of"/>
  <result pre="confirmed EM (headache on 6–14 days and ≥4 days fulfilling" exact="migraine" post="criteria per month) were randomized 1:1:1 to receive subcutaneous"/>
  <result pre="mixed-effects model for repeated-measures, both with years since onset of" exact="migraine" post="and baseline MSQoL domain score as covariates. Results A"/>
  <result pre="Frazer, Pennsylvania, 19355, USA Correspondence: Paul K Winner Background Episodic" exact="migraine" post="(EM), characterized by attacks on ≤15 days per month,"/>
  <result pre="days per month, is a risk for transition to chronic" exact="migraine" post="and adversely affects daily functioning. In clinical trials, fremanezumab,"/>
  <result pre="frequency of headaches in patients with EM. The impact of" exact="migraine" post="can be more comprehensively understood through disability assessment. In"/>
  <result pre="analysis of covariance, with baseline disability score and years since" exact="migraine" post="onset as covariates. P-values for treatment comparisons were based"/>
  <result pre="on work productivity and activity impairment in patients with chronic" exact="migraine" post="Richard B Lipton 1; Sanjay K Gandhi 2; Timothy"/>
  <result pre="cost burden. In the EU, the total annual cost of" exact="migraine" post="among persons aged 18–65 years was estimated at €111"/>
  <result pre="with 93% of these costs attributed to indirect costs. Chronic" exact="migraine" post="(CM) creates an especially high burden. In clinical trials,"/>
  <result pre="study, eligible patients with CM (≥15 headache days and ≥8" exact="migraine" post="days per month), were randomized 1:1:1 to receive subcutaneous"/>
  <result pre="for publication. P111 Headache secondary to subarachnoid haemorrhage due to" exact="arteriovenous malformation" post="can be presented as migraine in its clinical phenotype"/>
  <result pre="subarachnoid haemorrhage due to arteriovenous malformation can be presented as" exact="migraine" post="in its clinical phenotype Srdjan Ljubisavljevic (srljub@gmail.com) Faculty of"/>
  <result pre="have been analyzed in reference to headache attributes according to" exact="arteriovenous malformation" post="(AVM) persistence. Results: The persistence of AVM was not"/>
  <result pre="AVM were significantly associated with previous history of headache with" exact="migraine" post="features, OR 1.74 [95%CI: 1.11-3.03], p=0.046. Also, the findings"/>
  <result pre="existence could be associated with previous history of headache with" exact="migraine" post="features. These facts could provide physicians to good evidence"/>
  <result pre="consider SAH in patients with previous history of headache with" exact="migraine" post="features newly presented with worst headache of their life,"/>
  <result pre="angiography in all SAH suggestive headaches which are accompanied with" exact="migraine" post="symptoms. Keywords: Migraine, Subarachnoid Hemorrhage P112 Decreased medial prefrontal"/>
  <result pre="Migraine, Subarachnoid Hemorrhage P112 Decreased medial prefrontal cortex volume in" exact="migraine" post="without aura: a multispectral MRI study Sourena Soheili-Nezhad 1,"/>
  <result pre="two-fold of its prevalence in the male population [1]. Although" exact="migraine" post="is classically considered an episodic disorder with no long-term"/>
  <result pre="in brain function. Similar to various neurodevelopmental and neurodegenerative disorders," exact="migraine" post="is predisposed by a strong genetic component (&amp;gt;50% [2])."/>
  <result pre="by a strong genetic component (&amp;gt;50% [2]). Quantitative neuroimaging of" exact="migraine" post="has recently revealed disrupted functional brain networks and abnormal"/>
  <result pre="changes in brain structure, and discovering such neuroimaging biomarkers of" exact="migraine" post="may enlighten disease mechanisms and guide future clinical trials."/>
  <result pre="future clinical trials. Materials and methods We enrolled 36 female" exact="migraine" post="without-aura patients (36.6 ± 8.8 years) and 33 age-matched"/>
  <result pre="[5] were explored in order to characterize MRI correlates of" exact="migraine" post="by using various statistical neuroimaging toolboxes including ANTS, FSL,"/>
  <result pre="of brain volume in right medial prefrontal cortex (mPFC) of" exact="migraine" post="patients (corrected p&amp;lt;0.05, Fig. 1) and suggestive loss of"/>
  <result pre="results demonstrate promise of quantitative neuroimaging in exploring pathophysiology of" exact="migraine" post="and identifying the dysfunctional pain network in patients. P113"/>
  <result pre="present report was to describe the features of chronic paroxysmal" exact="migraine" post="in four pediatric patients. Results. We detected 4 patients"/>
  <result pre="intended to reduce the frequency, severity, and disability associated with" exact="migraine" post="attacks, and faster onset of action could increase benefit"/>
  <result pre="regimens of fremanezumab and placebo (PBO) in adults with episodic" exact="migraine" post="(EM). Patients assigned randomly to 1:1:1 ratio to 1"/>
  <result pre="mean change from baseline in the monthly average number of" exact="migraine" post="days were assessed using a mixed-effect model for repeated"/>
  <result pre="Results: Statistically significant reduction in the monthly average number of" exact="migraine" post="days was experienced during the 12-week period after 1st"/>
  <result pre="dosing resulted in significant reduction in the weekly number of" exact="migraine" post="days: At Week 1, (-0.9 days; p&amp;lt;0.0001) versus placebo"/>
  <result pre="dosing resulted in significant reduction in the weekly number of" exact="migraine" post="days: At Week 1, (-0.8 days; p&amp;lt;0.0001) versus placebo"/>
  <result pre="(-0.6 days) Posthoc analysis indicated that more patients reported no" exact="migraine" post="days with fremanezumab monthly dosing (79.4%; p=0.0002) and fremanezumab"/>
  <result pre="dose regimens of fremanezumab in the preventive treatment of episodic" exact="migraine" post="(EM). Methods: 16-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study"/>
  <result pre="period) to 12-week randomization period in monthly average number of" exact="migraine" post="days was analyzed using an analysis of covariance method"/>
  <result pre="the Wilcoxon rank sum test. Results: The mean number of" exact="migraine" post="days was 9.1 days during the 28-day baseline period."/>
  <result pre="with fremanezumab had significant reductions in the number of monthly" exact="migraine" post="days during the 12-week period vs. placebo (-2.2 days"/>
  <result pre="days). A ≥50% reduction in the monthly average number of" exact="migraine" post="days was significantly improved with both dosing regimens [monthly"/>
  <result pre="dose regimens of fremanezumab in the preventive treatment of chronic" exact="migraine" post="(CM). Methods: 16-week, multicenter, randomized double-blind, placebo-controlled, parallel-group adult"/>
  <result pre="fremanezumab had statistically significant reductions in the number of monthly" exact="migraine" post="days during the 12-week period after the 1st dose,"/>
  <result pre="of six pharmacy-based surveys with 6.985 patients with headache or" exact="migraine" post="Marius Dörr, Uwe Gessner, Christoph Theurer Scientific Affairs Consumer"/>
  <result pre="from six pharmacy-based surveys in the self-treatment of headache or" exact="migraine" post="with Aspirin. Materials and methods The individual data of"/>
  <result pre="efficacy of Botox has been established in adults with chronic" exact="migraine" post="[1,2]. The injection procedure is superficial and does not"/>
  <result pre="chronic migraine. Neurology 2011;77:1465-72. P119 Impaired cholinergic transmission during the" exact="migraine" post="cycle: a short-latency afferent inhibition (SAI) study Davide Di"/>
  <result pre="(mostly GABAa) cortical networks. Materials and methods We recruited 30" exact="migraine" post="without aura patients (16 between [MO] and 14 during"/>
  <result pre="effectiveness and safety of real-life use of onabotulinumtoxinA for chronic" exact="migraine" post="(CM). Materials and Methods Adults prescribed onabotulinumtoxinA for CM"/>
  <result pre="to moderate severity, were reported by 18.3% of patients; eyelid" exact="ptosis" post="(5.4%), neck pain (3.0%), and musculoskeletal stiffness (2.7%) were"/>
  <result pre="Outcomes (CaMEO) Study assessed the relationship of sleep disturbances and" exact="sleep apnea" post="as comorbidities of episodic (EM) and chronic migraine (CM)."/>
  <result pre="and sleep apnea as comorbidities of episodic (EM) and chronic" exact="migraine" post="(CM). Materials and Methods CaMEO participants were recruited from"/>
  <result pre="over 1 year. The Comorbidities/Endophenotypes survey assessed the risk of" exact="sleep apnea" post="using the Berlin Scale for Sleep Apnea (&quot;yes&quot;=high risk;"/>
  <result pre="&quot;No&quot;=low risk) and a self-report of a physician diagnosis of" exact="sleep apnea." post="Sleep disturbances were measured using the Medical Outcomes Study"/>
  <result pre="on the Berlin Scale, 37.0% were &quot;at high risk&quot; for" exact="sleep apnea" post="(EM, 35.6%; CM, 51.8%; chi-square, 113.7; P&amp;lt;0.001). Sleep apnea"/>
  <result pre="10.2%, 14.4%, 29.8%, and 74.1% of respondents at risk for" exact="sleep apnea" post="when stratified by underweight (n=489), normal (n=4,813), overweight (n=3,534),"/>
  <result pre="overweight (n=3,534), and obese categories (n=3,974). 10.1% of respondents self-reported" exact="sleep apnea" post="(n=1,293: EM, 9.7%; CM, 14.1%; P&amp;lt;0.001) (Table 1). Among"/>
  <result pre="EM, 9.7%; CM, 14.1%; P&amp;lt;0.001) (Table 1). Among those reporting" exact="sleep apnea," post="75.7% also reported a physician diagnosis (EM, 74.7%; CM,"/>
  <result pre="reported general prevalence estimates ranging from 1.0% to 6.0% for" exact="sleep apnea," post="we found an increased risk and potential underdiagnosis of"/>
  <result pre="apnea, we found an increased risk and potential underdiagnosis of" exact="sleep apnea" post="and sleep disturbances among those with migraine, especially CM."/>
  <result pre="(100.0) 1,111 (100.0) 12,810 (100.0) Among those reporting ever having" exact="sleep apnea," post="&quot;Has this condition been diagnosed or confirmed by a"/>
  <result pre="in using Affective Neuroscience Personality Scales [4] in 48 chronic" exact="migraine" post="sufferers (21 males, mean age 37.1 ±3.5 SD) for"/>
  <result pre="started in December 2016. It has to include 400 chronic" exact="migraine" post="sufferers refractory to topiramate, known to antagonize glutamatergic receptor"/>
  <result pre="to antagonize glutamatergic receptor subgroups. Following data concern 102 chronic" exact="migraine" post="sufferers reporting topiramate – induced relief -14.2 ± 0.7"/>
  <result pre="-14.2 ± 0.7 hours with pain, -0.9 ±1 severity of" exact="migraine" post="attacks. Seventy-five out of them (43 females, 32 males"/>
  <result pre="in age, gender, ethnicity or medical history, including diagnosis of" exact="migraine" post="or TTH, between patients with occipital headaches and other"/>
  <result pre="were the most prevalent final diagnosis (97; 31%), followed by" exact="migraine" post="(37; 11.8%). Among the occipital group, viral infection was"/>
  <result pre="right forehead and the right hand in a cohort of" exact="migraine" post="patients. Materials and methods: Twenty-eight migraine patients were selected"/>
  <result pre="in a cohort of migraine patients. Materials and methods: Twenty-eight" exact="migraine" post="patients were selected and randomly assigned to active or"/>
  <result pre="are few data about adherence to preventive treatments in chronic" exact="migraine" post="[6], no one is aimed specifically to MOH patients."/>
  <result pre="hemodynamics in the anterior and posterior circulation in patients with" exact="migraine" post="with aura, stroke and controls Altamura Claudia 1, Paolucci"/>
  <result pre="anterior and posterior circulation in patients with migraine with aura," exact="stroke" post="and controls Altamura Claudia 1, Paolucci Matteo 2, Brunelli"/>
  <result pre="Department, Campus Bio-Medico University of Rome Background Patients affected by" exact="migraine" post="present a higher cerebrovascular risk and a more sever"/>
  <result pre="aimed at comparing VMR in patients with MA, patients with" exact="stroke" post="and controls. Materials and Methods We consecutively enrolled 32"/>
  <result pre="MA patients, 10 young (under 55 years) patients with cryptogenetic" exact="stroke" post="and 16 controls. To assess VMR, Breath Holding Index"/>
  <result pre="(MCA) and posterior (PCA) cerebral arteries in all subjects. In" exact="stroke" post="patients, VMR was assessed within 7 days from stroke"/>
  <result pre="In stroke patients, VMR was assessed within 7 days from" exact="stroke" post="onset. Results MA patients were more frequently female (F/M=5:1)"/>
  <result pre="patients were more frequently female (F/M=5:1) than controls (F/M=2:1) and" exact="stroke" post="patients (F/M=1:1). Stroke patients (49 ys) on average were"/>
  <result pre="patients displaying the highest VMR (MCA 1,72; PCA 1,73) and" exact="stroke" post="patients the poorest (MCA 1,34; PCA 1,38). Controls VMR"/>
  <result pre="resulted 1,47 in MCA and 1,45 PCA. Conclusions Differently from" exact="stroke" post="patients, migraneurs with aura present a higher VMR to"/>
  <result pre="P, Rossini PM, Silvestrini M. Increased cerebral vasomotor reactivity in" exact="migraine" post="with aura: an autoregulation disorder? A transcranial Doppler and"/>
  <result pre="Development of a claims-based algorithm for use in patients with" exact="migraine" post="to identify potentially undiagnosed chronic migraine patients Jelena M."/>
  <result pre="use in patients with migraine to identify potentially undiagnosed chronic" exact="migraine" post="patients Jelena M. Pavlovic 1, Justin S. Yu 2,"/>
  <result pre="demonstrated that 75-80% of persons meeting the criteria for chronic" exact="migraine" post="(CM) do not report having received an accurate diagnosis"/>
  <result pre="to develop a claims-based algorithm for use in patients with" exact="migraine" post="to identify potentially undiagnosed CM patients. Materials and Methods"/>
  <result pre="States medical group. Eligible patients had continuous enrollment and a" exact="migraine" post="diagnosis (ICD-9/10 code of 346.xx/G43.xxx) in the 12-months prior"/>
  <result pre="were identified. Patients with ≥15 claims for acute treatment of" exact="migraine" post="(including opioids) were nearly six times as likely to"/>
  <result pre="CM (OR=9.17, 95% CI=1.26-66.51); patients with claims for ≥2 unique" exact="migraine" post="preventive classes were more than 4 times as likely"/>
  <result pre="2. Bigal M, Serrano D, Reed M, Lipton R. Chronic" exact="migraine" post="in the population. Neurology. 2008;71:559-566. P135 Antibodies in patients"/>
  <result pre="maximal excursion and final excursion of the group control (CG)," exact="migraine" post="without aura (MoA), migraine with aura (MA) and chronic"/>
  <result pre="excursion of the group control (CG), migraine without aura (MoA)," exact="migraine" post="with aura (MA) and chronic migraine (CM) in the"/>
  <result pre="migraine without aura (MoA), migraine with aura (MA) and chronic" exact="migraine" post="(CM) in the eight test directions: forward (F), right"/>
  <result pre="changes of autoantibodies level against: Total number of patients Chronic" exact="migraine" post="Chronic tension type headache NF-200 11 (25%) 9 *"/>
  <result pre="Parthasarathy V. Reduction of CD4+CD25+ regulatory T-cells in migraine: Is" exact="migraine" post="an autoimmune disorder? Journal of Neuroimmunology. 2016, 290:54. 5."/>
  <result pre="only specific preventative treatment approved for adult patients with chronic" exact="migraine" post="(CM) [1-3]. Both experimental and real-life data show that"/>
  <result pre="P=0.010) (Table 2). We found a trend towards lower chronic" exact="migraine" post="duration and more depressive and anxiety symptoms in super-responders"/>
  <result pre="predictor of excellent responde to BoNT-A treatment as also shorter" exact="migraine" post="duration and lower burden in terms of psychiatric symptoms."/>
  <result pre="years, median (IQR) 44.5 (38-51) 27 (23-45) 0.144 - Chronic" exact="migraine" post="duration (months), median (IQR) 8.5 (5-12) 120 (24-120) 0.056"/>
  <result pre="years, median (IQR) 44.5 (38-51) 30 (23-45) 0.204 - Chronic" exact="migraine" post="duration (months), median (IQR) 8.5 (5-12) 60 (24-120) 0.061"/>
  <result pre="the symptomatology of existing comorbidities [1]. In real life setting," exact="migraine" post="patients can be affected by various different diseases not-related"/>
  <result pre="study we considered the available guidelines for therapy choices in" exact="migraine" post="(level of recommendation I &amp;amp; II) and we proposed"/>
  <result pre="each patient as a unique entity. Personalized Medicine applied to" exact="migraine" post="requires new models that consider the comorbidity with other"/>
  <result pre="G, Martelletti P. Choosing the safest acute therapy during chronic" exact="migraine" post="prophylactic treatment: pharmacokinetic and pharmacodynamic consideration. Exp Opin Drug"/>
  <result pre="advice of counselling avoidance of the triggers of headache and" exact="migraine" post="[1,2]. Problems with this approach include the danger of"/>
  <result pre="published [5]. Participants were included if they had suffered from" exact="migraine" post="or tension-type headache over a period of at least"/>
  <result pre="to investigate the prevalence of sleep disturbances in children with" exact="migraine" post="and TTH using a validated sleep screening instrument, and"/>
  <result pre="and a standardized questionnaire regarding headache characteristics. Results: Children with" exact="migraine" post="scored significantly higher than children with tension type headache"/>
  <result pre="meters (P = .02), and in those with noctur- nal" exact="hypoglycemia" post="vs those without (P = .023). The percentage of"/>
  <result pre="found in the other two age groups. Conclusions: Children with" exact="migraine" post="headaches have a high prevalence of sleep disturbances. This"/>
  <result pre="P143 Validity of the ICHD-IIIb criteria in the diagnosis of" exact="migraine" post="with aura in children and adolescents Martina Balestri, Alessandro"/>
  <result pre="Federico Vigevano, M. Valeriani Objective. Though common in pediatric age," exact="migraine" post="with aura (MA) has been scarcely studied in children."/>
  <result pre="the headache type was classified according to the ICHD-IIIb criteria," exact="migraine" post="was diagnosed only in 40.2% of patients and the"/>
  <result pre="duration was not considered, the headache could be classified as" exact="migraine" post="in 67% of patients and in no child the"/>
  <result pre="Danish group of healthy adults (RG). Materials and Methods Eighty" exact="migraine" post="patients without medication overuse and 80 MOH patients seen"/>
  <result pre="of men were identified in the MOH group 32.5% vs." exact="migraine" post="12.5% (p=0.002). There were no statistically significant differences between"/>
  <result pre="Neurological Institute in Pavia, Italy. All consecutive patients with chronic" exact="migraine" post="and medication overuse headache undergoing an inpatient detoxification program"/>
  <result pre="Cephalalgia. 2016; 36: 1356-1365. P148 Comorbidities in chronic and episodic" exact="migraine" post="Mansoureh Togha 1, Zahra Yari 1,2, Reza Rahmanzadeh 1,"/>
  <result pre="Correspondence:Mansoureh Togha Background: It has been known for years that" exact="migraine" post="is comorbid with a number of other diseases, which"/>
  <result pre="headache clinic, Tehran, Iran. A total of 370 (60%) episodic" exact="migraine" post="and 240 (40%) chronic migraine (with and without aura)"/>
  <result pre="total of 370 (60%) episodic migraine and 240 (40%) chronic" exact="migraine" post="(with and without aura) were diagnosed according to ICHD"/>
  <result pre="episodic, in terms of gastrointestinal diseases (including IBS, constipation, heartburn," exact="peptic ulcer" post="disease, dyspepsia and non-alcoholic fatty liver disease), thyroid disorders"/>
  <result pre="of gastrointestinal diseases (including IBS, constipation, heartburn, peptic ulcer disease," exact="dyspepsia" post="and non-alcoholic fatty liver disease), thyroid disorders (hypo- and"/>
  <result pre="is no significant difference between chronic and episodic type of" exact="migraine" post="regarding comorbidities but considering the number of headache days"/>
  <result pre="more digestive problems occur. These findings represent the importance of" exact="migraine" post="management and its effect on general health. Further studies"/>
  <result pre="the relationship between frequency and intensity of different subtypes of" exact="migraine" post="and its comorbidities. Keywords: Comorbidity, Migraine, Chronic, Episodic, Days"/>
  <result pre="2Neuropsychiatric, Insubria University, Varese, Italy Correspondence:Massimiliano Valeriani (m.valeriani@tiscali.it) Background: Chronic" exact="migraine" post="(CM), Chronic tension-type headache (CTTH) and new daily persistent"/>
  <result pre="percentage of patients. P150 Postural control impairment in patients with" exact="migraine" post="with and without aura and chronic migraine Gabriela Ferreira"/>
  <result pre="in patients with migraine with and without aura and chronic" exact="migraine" post="Gabriela Ferreira Carvalho 1; Lidiane L Florêncio 1, Carina"/>
  <result pre="To investigate the performance of patients with different subtypes of" exact="migraine" post="in two clinical balance tests. Methods: Women with migraine"/>
  <result pre="of migraine in two clinical balance tests. Methods: Women with" exact="migraine" post="were screened from a tertiary headache center and sorted"/>
  <result pre="was included migraineurs with aura (n=35), without aura (n=35), chronic" exact="migraine" post="(n=35) and headache-free controls (n=35). Subjects with systemic diseases,"/>
  <result pre="migraine (n=35) and headache-free controls (n=35). Subjects with systemic diseases," exact="vestibular disease" post="history, presence of other headache diagnosis, BMI over 30"/>
  <result pre="with a fixed significant level at 5%. Results: Patients with" exact="migraine" post="presented slower LOS reaction time for all directions, with"/>
  <result pre="time for all directions, with differences between all the three" exact="migraine" post="groups compared to controls for 5 of 8 directions,"/>
  <result pre="The LOS velocity was greater in controls compared to all" exact="migraine" post="groups for 6 of 8 directions (p&amp;lt;0.04). Furthermore, for"/>
  <result pre="for 5 of 8 directions in controls compared to all" exact="migraine" post="groups, p&amp;lt;0.02 (Fig. 1). At the condition firmOE of"/>
  <result pre="was not observed differences among groups. At the firmCE condition," exact="migraine" post="with aura and chronic migraine groups presented larger displacement"/>
  <result pre="groups. At the firmCE condition, migraine with aura and chronic" exact="migraine" post="groups presented larger displacement area than controls (p&amp;lt;0.02). For"/>
  <result pre="than controls (p&amp;lt;0.02). For the both foamOE and foamCE conditions," exact="migraine" post="with aura and chronic migraine groups also presented larger"/>
  <result pre="both foamOE and foamCE conditions, migraine with aura and chronic" exact="migraine" post="groups also presented larger displacement area than controls (p&amp;lt;0.005)"/>
  <result pre="of stability and static balance in migraineurs, mostly in chronic" exact="migraine" post="and migraine with aura, for almost all outcomes assessed."/>
  <result pre="and static balance in migraineurs, mostly in chronic migraine and" exact="migraine" post="with aura, for almost all outcomes assessed. The balance"/>
  <result pre="posturography displacement area (cm 2) in controls (CG), patients with" exact="migraine" post="without aura (MoA), with aura (MA) and chronic migraine"/>
  <result pre="with migraine without aura (MoA), with aura (MA) and chronic" exact="migraine" post="(CM) CG MoA MA CM FirmOE 1.20 (1.05 to"/>
  <result pre="needs to be unraveled in headache disorders. Acute attacks of" exact="migraine" post="and cluster headache are both associated with CGRP and"/>
  <result pre="levels are elevated in some studies during episodic and chronic" exact="migraine" post="compared to healthy human subjects. Pathophysiological alterations (e.g. functional"/>
  <result pre="and vascular function comes from recent genome-wide association studies investigating" exact="migraine" post="and cluster headache. Several underlying candidate headache genes (e.g."/>
  <result pre="spontaneous intracranial hypotension. Eur J Neurol 17:715–719. P154 Women with" exact="migraine" post="present hyperactivity of neck extensors muscles during maximal and"/>
  <result pre="Background: Despite of the confirmed association between neck pain and" exact="migraine" post="investigations of neck muscles controls in this population is"/>
  <result pre="compare activity of neck muscles in women with migraine, chronic" exact="migraine" post="and non-headache women during low load and maximal contractions."/>
  <result pre="without history of headache (age: 31 years old); 31 with" exact="migraine" post="(age: 33 years old) and 21 with chronic migraine"/>
  <result pre="with migraine (age: 33 years old) and 21 with chronic" exact="migraine" post="(age: 34 years old), diagnosed according to the third"/>
  <result pre="pregnancy, history of head or neck trauma, cervical spine diseases," exact="fibromyalgia" post="syndrome, medication overuse, or anesthetic blocks in the past"/>
  <result pre="level of 0.05. Results: In the low load task, chronic" exact="migraine" post="group demonstrated greater activity of upper trapezius in all"/>
  <result pre="control (p&amp;lt;0.001) (Fig. 1). No differences could be observed between" exact="migraine" post="and control groups not even among three groups regarding"/>
  <result pre="regarding superficial flexors activity (Fig. 1). Extensors activities of both" exact="migraine" post="groups were significant higher than controls during MIVC in"/>
  <result pre="hyperactivity of neck extensor can be observed only in chronic" exact="migraine" post="group. Fig. 2 (abstract P154). Normalized activity of the"/>
  <result pre="P157). Forest plots of the meta-analyses P155 The role of" exact="sexual dysfunction" post="and attachment style in migraine related quality of life"/>
  <result pre="P155 The role of sexual dysfunction and attachment style in" exact="migraine" post="related quality of life Maria Pia Prudenzano 1, Maria"/>
  <result pre="studies have focused on the occurrence and possible role of" exact="sexual dysfunction" post="in migraine patients quality of life [1,2]. Attachment behaviour"/>
  <result pre="on the occurrence and possible role of sexual dysfunction in" exact="migraine" post="patients quality of life [1,2]. Attachment behaviour is supposed"/>
  <result pre="Objectives: This study was conducted to investigate the association among" exact="sexual dysfunction," post="psychological factors, attachment style and quality of life, in"/>
  <result pre="attachment style and quality of life, in a sample of" exact="migraine" post="patients. Patients and Methods: 70 adult migraine outpatients (14"/>
  <result pre="a sample of migraine patients. Patients and Methods: 70 adult" exact="migraine" post="outpatients (14 males; 56 females, mean age 39,56±12,55) consecutively"/>
  <result pre="p=0,38), without difference according to age, marital status, job and" exact="migraine" post="type (with or without aura). Sexual Dysfunction was observed"/>
  <result pre="without aura). Sexual Dysfunction was observed more frequently in chronic" exact="migraine" post="patients than in episodic ones (73,07% vs 40,62%, p=0.02)."/>
  <result pre="in episodic ones (73,07% vs 40,62%, p=0.02). Migraine patients with" exact="sexual dysfunction" post="showed significantly lower scores in SF-36 Mental Component Summary"/>
  <result pre="dysfunction as an independent factor than anxiety and depression in" exact="migraine" post="related quality of life. Migraine patients with insecure attachment"/>
  <result pre="life. Migraine patients with insecure attachment both with and without" exact="sexual dysfunction" post="showed worse quality of life. Future longitudinal studies including"/>
  <result pre="P156 Migraine: a possible risk factor for the development of" exact="hypothyroidism" post="in women Carlo Lisotto 1, Federico Mainardi 2, Ferdinando"/>
  <result pre="Hospital of Venice, Venice, Italy Correspondence:Carlo Lisotto Background Migraine and" exact="hypothyroidism" post="(HT) are frequent disorders. Migraine occurs in about 15%"/>
  <result pre="headache sufferers. Results The population consisted of 2,640 patients with" exact="migraine" post="without aura (MO), 303 with migraine with aura (MA),"/>
  <result pre="of 2,640 patients with migraine without aura (MO), 303 with" exact="migraine" post="with aura (MA), 235 with MO + MA, 207"/>
  <result pre="TTH (2 males). The prevalence of HT was 5.4% in" exact="migraine" post="women, while it was 0.6% in men. The onset"/>
  <result pre="women, while it was 0.6% in men. The onset of" exact="migraine" post="occurred prior to HT in 97.5% of women, whereas"/>
  <result pre="headache in 78.2% of female patients. The mean age of" exact="migraine" post="onset was 23.9 ± 8.5 in women and 25.6"/>
  <result pre="women. Our results are consistent with past clinic-based studies demonstrating" exact="migraine" post="and HT to be comorbid conditions [2]. In migraineurs"/>
  <result pre="of cases. In a recent cohort study, patients with pre-existing" exact="migraine" post="showed a 41% increased risk of developing new onset"/>
  <result pre="41% increased risk of developing new onset HT, thus suggesting" exact="migraine" post="to be a possible risk factor for this endocrinopathy"/>
  <result pre="[3]. A plausible proposed mechanism to explain the association between" exact="migraine" post="and HT include alterations in the immune system, predisposing"/>
  <result pre="C, Mainardi F, Maggioni F, Zanchin G. The comorbidity between" exact="migraine" post="and hypothyroidism. J Headache Pain. 2013; 1:P138. 3. Martin"/>
  <result pre="P157 Contribution of hormonal contraceptives to the risk of ischemic" exact="stroke" post="in women with migraine: a meta-analysis of current data"/>
  <result pre="Correspondence: Simona Sacco (simona.sacco@univaq.it) Background According to current literature, both" exact="migraine" post="and hormonal contraceptive (HC) use are risk factors for"/>
  <result pre="and hormonal contraceptive (HC) use are risk factors for ischemic" exact="stroke" post="(IS). HC use and migraine likely interact in increasing"/>
  <result pre="are risk factors for ischemic stroke (IS). HC use and" exact="migraine" post="likely interact in increasing the risk of IS in"/>
  <result pre="was conducted to identify key papers addressing the association between" exact="migraine" post="and IS in women using HC. The reference lists"/>
  <result pre="binary outcome data [1-6]. When considering female patients with IS," exact="migraine" post="and HC use were not associated in cohort or"/>
  <result pre="[CI], 0.74-2.10; P=0.40 (Fig. 1). When considering women using HC," exact="migraine" post="and IS were not associated in case-control studies (OR"/>
  <result pre="1.82; 95% CI, 1.34-2.47; P&amp;lt;0.001) (Fig. 1). The combination of" exact="migraine" post="and HC use was strongly associated with IS in"/>
  <result pre="Our findings suggest that the combination between HC use and" exact="migraine" post="contributes to increase the risk of IS in women."/>
  <result pre="1) to formally assess the interaction between HC use and" exact="migraine" post="in the risk of IS in women; 2) to"/>
  <result pre="cardiovascular risk factors in the IS risk of women with" exact="migraine" post="using HC; 3) to clarify whether migraine with aura"/>
  <result pre="of women with migraine using HC; 3) to clarify whether" exact="migraine" post="with aura and migraine without aura carry the same"/>
  <result pre="using HC; 3) to clarify whether migraine with aura and" exact="migraine" post="without aura carry the same risk of IS in"/>
  <result pre="a condition References 1. Collaborative group for the study of" exact="stroke" post="in young women. Oral contraceptives and stroke in young"/>
  <result pre="the study of stroke in young women. Oral contraceptives and" exact="stroke" post="in young women. Associated risk factors. JAMA 1975; 231:718-722."/>
  <result pre="29:2277–2284. 3. Chang CL, Donaghy M, Poulter N. Migraine and" exact="stroke" post="in young women: case–control study. The World Health Organization"/>
  <result pre="Milhaud D, Bogousslavsky J, van Melle G, Liot P. Ischemic" exact="stroke" post="and active migraine. Neurology. 2001; 57:1805-1811. 5. Pezzini A,"/>
  <result pre="Italian Project on Stroke in Young Adults Investigators. Predictors of" exact="migraine" post="subtypes in young adults with ischemic stroke: the italian"/>
  <result pre="in young adults with ischemic stroke: the italian project on" exact="stroke" post="in young adults. Stroke. 2011; 42:17-21 6. Champaloux SW,"/>
  <result pre="USA Correspondence:Richard B. Lipton (Richard.Lipton@einstein.yu.edu) Background Many comorbidities associated with" exact="migraine" post="have a higher relative frequency in chronic migraine (CM)"/>
  <result pre="associated with migraine have a higher relative frequency in chronic" exact="migraine" post="(CM) than episodic migraine (EM). The objective of this"/>
  <result pre="a higher relative frequency in chronic migraine (CM) than episodic" exact="migraine" post="(EM). The objective of this study was to replicate"/>
  <result pre="Cardiovascular, and Gastrointestinal comorbidity categories. Results Available CaMEO respondents with" exact="migraine" post="(16,763) were sent the Comorbidities/Endophenotype module and 12,810 (76.4%)"/>
  <result pre="frequencies &amp;gt;10% higher in CM than EM included allergies/hay fever/allergic" exact="rhinitis" post="(EM, 37.4%; CM, 51.0%), sinusitis/sinus infection (EM, 47.3%; CM,"/>
  <result pre="Future analyses will address naturally occurring subgroups (taxa) defined by" exact="migraine" post="phenotypes and comorbidities and assess the relationships of these"/>
  <result pre="30-day headache diary was given to patients to report the" exact="migraine" post="characteristics including the intensity of headaches, the number of"/>
  <result pre="headache days per month (- 9.67±6.69, P value ≤0.000). The" exact="migraine" post="severity (VAS) and attacks duration also significantly reduced with"/>
  <result pre="probiotic on inflammatory markers in patients with CM. Keywords: chronic" exact="migraine" post="headache, probiotic, MIDAS, abortive drugs, frequency of headache days."/>
  <result pre="increased release at trigeminal nerve endings during both cluster and" exact="migraine" post="attacks [4]. Nonetheless, tachykinins’ release seems not pivotal in"/>
  <result pre="Observation -April 2016- March 2017. Entry criteria: Diagnosis of chronic" exact="migraine" post="(IHCD III b), exemption from other diseases. Drugs:100 μl"/>
  <result pre="consisted in test-retest acutely performed during headache attacks of chronic" exact="migraine" post="sufferers (n= 48, 20 males, mean age 31.8 ±"/>
  <result pre="peptide) andvasoactive intestinal polypeptide in human saliva: their pattern in" exact="migraine" post="and cluster headache. Cephalalgia 1990;10: 39-50. 5. Nicolodi M."/>
  <result pre="children. The most common primary headache syndromes in childhood are" exact="migraine" post="and TTH. However many times they seem to overlap."/>
  <result pre="children, 5-18 years of age, who met the criteria for" exact="migraine" post="were included. Results: Of 262 children (54% female) who"/>
  <result pre="Of 262 children (54% female) who had migraine, 26.2% had" exact="migraine" post="with aura. 59 children (22.5% of the full sample)"/>
  <result pre="aura, whereas gender was not significant (p&amp;gt;0.20). Children who had" exact="migraine" post="with aura were less likely to have mixed headaches"/>
  <result pre="mixed headaches were 2.7 times more likely to have a" exact="learning disability" post="than children with migraine alone. Conclusions: Episodic TTH and"/>
  <result pre="more likely to have a learning disability than children with" exact="migraine" post="alone. Conclusions: Episodic TTH and migraine without aura (mixed"/>
  <result pre="disability than children with migraine alone. Conclusions: Episodic TTH and" exact="migraine" post="without aura (mixed headaches) in children might be part"/>
  <result pre="explain the high incidence of their co-occurrence as opposed to" exact="migraine" post="with aura. Children with mixed headaches have a higher"/>
  <result pre="aura. Children with mixed headaches have a higher incidence of" exact="learning disability" post="compare to those with migraine alone. SISC POSTER PRESENTATIONS"/>
  <result pre="a higher incidence of learning disability compare to those with" exact="migraine" post="alone. SISC POSTER PRESENTATIONS P162 Clinical features of headache"/>
  <result pre="&amp;gt; 1 hour. In 50% headache features are similar to" exact="migraine" post="con nausea-vomiting, photophobia and phonophobia. In addition, patients may"/>
  <result pre="most common phenotypes represented by chronic tension type headache, chronic" exact="migraine" post="and chronic daily headache. A phenotypic classification is useful"/>
  <result pre="Exclusion criteria included other primary headaches, medication overuse headache, whiplash," exact="fibromyalgia" post="or any neurological disorder. A 1-month headache diary was"/>
  <result pre="other primary headaches, medication overuse headache, whiplash, fibromyalgia or any" exact="neurological disorder." post="A 1-month headache diary was used to collect clinical"/>
  <result pre="to lower widespread pressure pain sensitivity. P165 Recurrent painful ophthalmoplegic" exact="neuropathy" post="(RPON), can cerebrospinal fluid (CSF) analysis aid the diagnosis,"/>
  <result pre="Medicine, University of Pisa, Pisa, Italy Background Recurrent painful ophthalmoplegic" exact="neuropathy" post="(RPON) represents a condition, characterized by recurring headaches and"/>
  <result pre="pressure-like and holocranial with diplopia in all gaze directions and" exact="ptosis" post="of the left eye. The patient described a similar"/>
  <result pre="in 3 weeks, without therapy. He had no history of" exact="migraine" post="and never suffered of headache with similar characteristics. He"/>
  <result pre="a left third nerve palsy without pupil asymmetry, an incomplete" exact="ptosis" post="and inability to adduct or lower his left eye."/>
  <result pre="mg/dl). Blood routine tests and other investigations including autoimmune, sarcoidosis," exact="tuberculosis" post="and venereal disease screens, viral genome on CSF, antiganglioside"/>
  <result pre="Activation of meningeal nociceptors by cortical spreading depression: Implications to" exact="migraine" post="with aura. The Journal of neuroscience : the official"/>
  <result pre="symptoms ant it can be erroneously mistaken for an acute" exact="stroke" post="(AS) [1]. A complete diagnostic workup in Emergency Department"/>
  <result pre="after 70-120 minutes from symptoms onset. Two patients presented with" exact="aphasia" post="[5, 6], one patient with aphasia and right hemiparesis"/>
  <result pre="Two patients presented with aphasia [5, 6], one patient with" exact="aphasia" post="and right hemiparesis [7] and the last one with"/>
  <result pre="thrombolysis was given. Patient were discharged with final diagnosis of" exact="migraine" post="with aura. Cases report We report six cases accessed"/>
  <result pre="had mild headache (Table 1). All patients had history of" exact="migraine" post="in the past. Unenhanced CT, Angio-CT of intra and"/>
  <result pre="normal in all cases. Patients were discharged with diagnosis of" exact="migraine" post="with aura, probable sporadic hemiplegic migraine and probable first"/>
  <result pre="discharged with diagnosis of migraine with aura, probable sporadic hemiplegic" exact="migraine" post="and probable first attack of migraine with visual aura,"/>
  <result pre="aura, probable sporadic hemiplegic migraine and probable first attack of" exact="migraine" post="with visual aura, according with ICHD-3 beta criteria. Conclusions"/>
  <result pre="minutes no 2 hours 5 81 F yes (with aura)" exact="aphasia" post="no 4 60 minutes no 2 hours 6 91"/>
  <result pre="minutes no 2 hours 6 91 F yes (with aura)" exact="aphasia" post="no 3 90 minutes no 10 hours References 1."/>
  <result pre="A Koyfman A. Clinical mimics: an emergency medicine-focused review of" exact="stroke" post="mimics. The Journal of Emergency Medicine, 2017 Feb;52(2):176-183. 2."/>
  <result pre="2.71 years; 116 males and 126 females), 152 (62.81%) had" exact="migraine" post="(23 with aura), 24 (9.92%) had tension-type headache, 32"/>
  <result pre="patients with neuropsychiatric disorders, 120 (81.08%) had at least one" exact="sleep disorder," post="14 (9.46%) a neuropsychiatric disorder without any sleep disturbance"/>
  <result pre="disorder was significantly higher in the group of patients with" exact="migraine" post="with aura: this applies to both neuropsychiatric disorders considered"/>
  <result pre="found. Conclusions In this study we demonstrated that children with" exact="migraine" post="with aura significantly more probably have neuropsychiatric disorders in"/>
  <result pre="TanacethumPartenium, 5-Hydrossitriptophan (5-Http) and Magnesium (AURASTOP®) in children with episodic" exact="migraine" post="without aura: an observational study Antonia Versace, Barbara Lauria,"/>
  <result pre="now, the nutraceutical preparation have been given to adults with" exact="migraine" post="with aura as symptomatic treatment and as prophylactic treatment"/>
  <result pre="symptomatic treatment and as prophylactic treatment in those with episodic" exact="migraine" post="without aura, with several benefits. In this study we"/>
  <result pre="intensity, duration, frequency and analgesics use in children with episodic" exact="migraine" post="without aura. Materials and methods In this open prospective"/>
  <result pre="selected 21 children (age range: 6-16 years) suffering from episodic" exact="migraine" post="without aura for at least 6 months followed at"/>
  <result pre="the Regina Margherita Children’s Hospital of Turin, Italy.The diagnosis of" exact="migraine" post="without aura was done on HIS criteria (ICH-III b)"/>
  <result pre="a reduction in frequency and 4 (19.05%) in duration of" exact="migraine" post="episodes. A decrease in intensity was detected in 16"/>
  <result pre="represent an efficient prophylactic therapy also for children with episodic" exact="migraine" post="without aura. However, a large randomised control trial should"/>
  <result pre="beta version, ICHD-3 beta) are considered different disorders other than" exact="trigeminal neuralgia" post="(TN) 1. However clinical and terapheutic similarites let us"/>
  <result pre="on the symptoms. His medical history was remarkable for shoulders" exact="periarthritis" post="and renal colics. After the assessment in our Centre,"/>
  <result pre="and conclusion. Headache current 2017, 10.1111/head.13099. P170 Cerebral vasoreactivity in" exact="migraine" post="patients affected by Ehlers-Danlos syndromes Giada Giuliani 1, Massimiliano"/>
  <result pre="both headache frequency and its characteristics [1]. Altered autoregulation in" exact="migraine" post="with aura patients, possibly secondary to impaired cerebrovascular autonomic"/>
  <result pre="elasticity, we investigate by Transcranial Doppler if EDS patients with" exact="migraine" post="had the same vasoreactivity than controls. Materials and methods"/>
  <result pre="than controls. Materials and methods We recruited EDS patients with" exact="migraine" post="and sex and age matched healthy controls. Patients had"/>
  <result pre="patients (mean age 32±12 years, F/M:17/4) affected by EDS and" exact="migraine" post="(9 without and 12 with aura) and twenty healthy"/>
  <result pre="age 37±6 years, F/M:15/5) have been enrolled. At rest, EDS" exact="migraine" post="patients presented a significant higher mean flow velocities (p&amp;lt;0.01)"/>
  <result pre="controls (Table 1). After hypercapnia, vasomotor response (BHI) of EDS" exact="migraine" post="patients differ with respect to controls according to the"/>
  <result pre="without aura (p&amp;lt;0.001) whereas it was higher in EDS with" exact="migraine" post="with aura and lateralized pain (p&amp;lt;0.001) (Fig. 1). Conclusions"/>
  <result pre="disorder. After hypercapnia, TCD variations are more suggestive for the" exact="migraine" post="features. Increased BHI in patients affected by aura and"/>
  <result pre="predominance reflects alterations of intracranial vessel tone already observed in" exact="migraine" post="with aura [2]. In conclusion, in EDS migraine patients"/>
  <result pre="observed in migraine with aura [2]. In conclusion, in EDS" exact="migraine" post="patients TCD study showed two different responses, mainly reflecting"/>
  <result pre="responses, mainly reflecting the EDS disease at rest and the" exact="migraine" post="component during hypercapnia. Fig. 1 (abstract P171). Sustained Response"/>
  <result pre="B, Toscano M, Vicenzini E, et al. A study of" exact="migraine" post="characteristics in joint hypermobility syndrome a.k.a. Ehlers–Danlos syndrome, hypermobility"/>
  <result pre="E, et al. A study of migraine characteristics in joint" exact="hypermobility syndrome" post="a.k.a. Ehlers–Danlos syndrome, hypermobility type. Neurol. Sci. 2015 36(8):1417-1424."/>
  <result pre="P, Rossini PM, Silvestrini M. Increased cerebral vasomotor reactivity in" exact="migraine" post="with aura: an autoregulation disorder? A transcranial Doppler and"/>
  <result pre="- University of Insubria, Varese Background: BoNT-A effectiveness in chronic" exact="migraine" post="(CM) with or without medication overuse (MO) has been"/>
  <result pre="assessment in G1 vs G2 Fig. 1 (abstract P177). Ischemic" exact="stroke" post="of the right brachium pontis, corresponding to the trigeminal"/>
  <result pre="17:1-9 P172 Pharmacologically- controlled withdrawal from medication overuse in chronic" exact="migraine" post="does not improve the therapeutic response to long-term onabotulinumtoxin"/>
  <result pre="S, Guerriero R, Como G, Del Carro U, Refractrory chronic" exact="migraine" post=": is drug withdrawal necessary before starting a therapy"/>
  <result pre="major constituents of butterbur [ Petasites hybridus (L.) Gaertn.], in" exact="migraine" post="prevention has been obtained with a preparation that contains"/>
  <result pre="However, none of these actions seems to be relevant for" exact="migraine" post="pathophysiology. Petasin and its cross-conjugated isomer, isopetasin, contain electrophilic"/>
  <result pre="which mediate neurogenic inflammation. The possible role of TRPA1 in" exact="migraine" post="is supported by its co-expression in the same nociceptor"/>
  <result pre="nociceptor subpopulation with CGRP, the neuropeptide that markedly contributes to" exact="migraine" post="pain. Given the role of electrophilic compounds for the"/>
  <result pre="release CGRP and signal pain. Successful treatment and prevention of" exact="migraine" post="by targeting of TRPA1 ion channels and the ensuing"/>
  <result pre="at the root entry zone. There are anecdotal reports of" exact="herpes zoster," post="schwannoma or Lyme disease involving nervus intermedius [2]. Nervus"/>
  <result pre="root entry zone. There are anecdotal reports of herpes zoster," exact="schwannoma" post="or Lyme disease involving nervus intermedius [2]. Nervus intermedius"/>
  <result pre="cold air and chewing. The patient suffered also from episodic" exact="migraine" post="without aura, gastritis and he recently underwent dental implantation."/>
  <result pre="chewing. The patient suffered also from episodic migraine without aura," exact="gastritis" post="and he recently underwent dental implantation. Different clinical and"/>
  <result pre="J. 2017 Jun 8;4(3):75-78. P175 Impact of visceral pain on" exact="migraine" post="symptoms in comorbid patients Giannapia Affaitati 1, Raffaele Costantini"/>
  <result pre="very often coexists with visceral pain of various origin, e.g.," exact="irritable bowel syndrome" post="(IBS), primary dysmenorrhea (Dys) or pelvic pain from endometriosis"/>
  <result pre="bowel syndrome (IBS), primary dysmenorrhea (Dys) or pelvic pain from" exact="endometriosis" post="(Endo) [1,2]. The clinical observation suggests that visceral pain"/>
  <result pre="observation suggests that visceral pain episodes in comorbid patients trigger/exacerbate" exact="migraine" post="symptoms but systematic studies are still lacking with this"/>
  <result pre="the impact of visceral pain comorbidities and their treatment on" exact="migraine" post="symptoms and pain sensitivity in somatic tissues of extracranial"/>
  <result pre="and methods Female patients [18-43 years] with high frequency episodic" exact="migraine" post="were examined, who presented concurrent: IBS [n.37], Dys [n.35]"/>
  <result pre="conditions all comorbid patients vs M-only patients presented significantly higher" exact="migraine" post="pain and somatic tissue hypersensitivity (0.05 Conclusions Visceral pain"/>
  <result pre="M-only patients presented significantly higher migraine pain and somatic tissue" exact="hypersensitivity" post="(0.05 Conclusions Visceral pain significantly contributes to migraine pain,"/>
  <result pre="somatic tissue hypersensitivity (0.05 Conclusions Visceral pain significantly contributes to" exact="migraine" post="pain, probably through enhancement of the level of central"/>
  <result pre="empirical operation and set up rational therapeutic strategies. P177 A" exact="migraine" post="attack as onset of trigeminal root entry zone ischemic"/>
  <result pre="University of Padua, Padua, Italy Correspondence:VirginiaBozzoni (virginia.bozzoni@gmail.com) Background. Painful trigeminal" exact="neuropathy" post="and &quot;orofacial pain&quot; due to brain stem stroke have"/>
  <result pre="Painful trigeminal neuropathy and &quot;orofacial pain&quot; due to brain stem" exact="stroke" post="have already been described [1,2,3]. We report a case"/>
  <result pre="already been described [1,2,3]. We report a case of pontine" exact="stroke" post="presented as a migrainous attack with subsequent onset of"/>
  <result pre="(ICHD-III) [4] presented with sudden onset of a severe right" exact="migraine" post="attack with nausea, phono and photophobia stopped after NSAIDs"/>
  <result pre="pseudo-peripheral trigeminal symptoms and to determine a post-stroke painful trigeminal" exact="neuropathy" post="[3]. Here we described a trigeminal sensory deficit due"/>
  <result pre="selective trigeminal root entry zone ischemic lesion onset after a" exact="migraine" post="attack. Consent for publication: The authors declare that written"/>
  <result pre="importance of a multidisciplinary approach in the management of pediatric" exact="migraine" post="Marcuzzi E 1, Saretta F 1, Savi L 2"/>
  <result pre="are the goals of chosen therapies. The &quot;red flags&quot; for" exact="migraine" post="must be particularly highlighted and indications, on when and"/>
  <result pre="plays an irreplaceable role in the management of headache and" exact="migraine" post="in childhood on which physician should be properly educated."/>
  <result pre="AL, et al. Outcome of a multidisciplinary approach ti pediatric" exact="migraine" post="at 1,2 and 5 years. Headache 2005; 45:1298-303. P179"/>
  <result pre="of metacognitive executive dysfunctions in the pathogenic mechanism that underlies" exact="substance abuse" post="in MOH. Material &amp;amp; Methods: Fifty-two patients were selected"/>
  <result pre="coping behavior predisposes MOH patients to a relapse of chronic" exact="substance abuse." post="Additional studies are needed to confirm our data. References"/>
  <result pre="Headache Clinic - IRCCS Neuromed, Pozzilli (Isernia), Italy Prevalence of" exact="migraine" post="in women is almost three times greater than in"/>
  <result pre="This is true particularly in the childbearing age, whereas the" exact="migraine" post="prevalence tends to be similar in both genders during"/>
  <result pre="during the childhood and in the elderly patients. Although the" exact="migraine" post="disease is known to run in families, and it"/>
  <result pre="it is thus suggested to have a strong genetic predisposition," exact="migraine" post="attacks are usually started by external/internal triggers, among which"/>
  <result pre="among which the hormonal cycle plays a major role. Menstrual-related" exact="migraine" post="attacks are known to be longer and more severe"/>
  <result pre="during oral contraceptive treatments, and a significant amelioration of their" exact="migraine" post="frequency and severity during pregnancy and in menopause. This"/>
  <result pre="severity during pregnancy and in menopause. This strict correlation between" exact="migraine" post="and the hormonal cycle represents usually a therapeutic challenge"/>
  <result pre="and symptomatic strategies are unsuccessful when applied to control hormonal-related" exact="migraine" post="attacks. P181 Role of the transient receptor potential ankyrin"/>
  <result pre="of the transient receptor potential ankyrin type-1 (TRPA1) channel in" exact="migraine" post="pain: evaluation in an animal model Chiara Demartini 1,2,"/>
  <result pre="Florence, Italy Introduction - To date, the pharmacological treatment of" exact="migraine" post="remains somewhat unsatisfactory, partly because the pathophysiology of this"/>
  <result pre="of the transient receptor potential ankyrin type-1 (TRPA1) channels in" exact="migraine" post="pain. To further investigate the role of TRPA1 in"/>
  <result pre="further investigate the role of TRPA1 in the mechanisms of" exact="migraine" post="pain in an animal model of migraine using a"/>
  <result pre="the mechanisms of migraine pain in an animal model of" exact="migraine" post="using a novel TRPA1 antagonist (ADM_12) as a probe."/>
  <result pre="substance P (SP) in peripheral and central areas relevant for" exact="migraine" post="pain were analyzed. CGRP and SP protein immunoreactivity was"/>
  <result pre="in c-Fos and CGRP gene expression in areas involved in" exact="migraine" post="pain Rosaria Greco 1, Chiara Demartini 1,2, Anna Maria"/>
  <result pre="the trigeminovascular nociceptive system and it is likely implicated in" exact="migraine" post="chronicization. In the present study we investigated the role"/>
  <result pre="the present study we investigated the role of CGRP in" exact="migraine" post="chronicization in an animal model that mimics the condition"/>
  <result pre="underline the possibility and opportunity to pharmacologically intercept and prevent" exact="migraine" post="chronification. P183 Psychopathological profile of Medication Overuse Headache patients,"/>
  <result pre="M, Eusebi P, Sarchielli P, et al. Obsessive-compulsive disorder and" exact="migraine" post="with medication-overuse headache. Headache 2009, 49:1005–13. 3. Sarchielli P,"/>
  <result pre="J Neurol 2016, 23:85–91. P184 Education of the patient with" exact="migraine" post="Barbara Vitrani 1, Lidia Savi 2 1Master’s Degree in"/>
  <result pre="with M and 29% of F). The insomnia and the" exact="bruxism" post="are factors of chronification and aggravation of headache.We found"/>
  <result pre="Headache. 2008;48:1005-11. P187 Efficacy of KUZIK® in the prophylaxis of" exact="migraine" post="without aura: a retrospective observational study E.Pucci 1, F."/>
  <result pre="outpatient clinic, Verona; 7Gam Farma Srl. Milan Correspondence:E.Pucci Background A" exact="migraine" post="without aura is the most common type of migraine"/>
  <result pre="A migraine without aura is the most common type of" exact="migraine" post="headache ( about 60% to 80% of all migraines)."/>
  <result pre="and Methods Between January and April 2017, 30 patients with" exact="migraine" post="without aura were treated with Kuzik, once a day"/>
  <result pre="safety, and good tolerability of Kuzik in the prophylaxis of" exact="migraine" post="without aura and the use of this medication should"/>
  <result pre="serious clinical situation. References 1. Sanchez G et al.Course of" exact="migraine" post="in pregnancy and postpartum:a prospective study. Cephal 2003;23:197-205. 2."/>
  <result pre="Neurol Sci. May;2007;34:187-192. 4. Kvisik E et al Headache and" exact="migraine" post="during pregnancy and puerperium :the MIGRA-study.J Headache Pain 2011"/>
  <result pre="EV et al. Trends in pregnancy hospitalization that included a" exact="stroke" post="in USA from1994 to 2007 Stroke 2011;42: 2564-2570. P190"/>
  <result pre="Stroke 2011;42: 2564-2570. P190 Botulinum toxins for the prevention of" exact="migraine" post="in adults: the experience in headache Unit of Cassino"/>
  <result pre="Di Mauro, Fernando Ferrauti ASL Frosinone Correspondence:Ottavio Di Marco Background:" exact="migraine" post="is a severely debilitating desease, causing significant morbidity and"/>
  <result pre="toxin was shown to be effective in treatment of chronic" exact="migraine" post="(Kollowe, 2016) Materials and methods: 24 patients, suffering from"/>
  <result pre="(Kollowe, 2016) Materials and methods: 24 patients, suffering from chronic" exact="migraine" post="as defined by ICHD-3 ß criteria, subjected to at"/>
  <result pre="± 2,88). At T0 the sample had 13,6 days/month with" exact="migraine" post="and hight vaue of disability expecially in work and"/>
  <result pre="higher level of disability at DISS and average frequency of" exact="migraine" post="episodes of 15.87 (ds ± 4.2) days per month."/>
  <result pre="References Bigal ME, Serrano D, Reed M, Lipton RB. Chronic" exact="migraine" post="in the population - Burden, diagnosis, and satisfaction with"/>
  <result pre="D, Paracka L, Mohammadi B, KarstM. Long-term treatment of chronic" exact="migraine" post="with OnabotulinumtoxinA: efficacy, quality of life and tolerability in"/>
  <result pre="recent study, we found an association between ambivalent attachment style," exact="migraine" post="severity and psychological symptoms in children/adolescents. There is evidence"/>
  <result pre="role of maternal alexithymia and attachment style on their children’s" exact="migraine" post="severity (intensity and frequency) and psychological profile (anxiety, depression,"/>
  <result pre="Materials and methods. We enrolled 84 consecutive patients suffering from" exact="migraine" post="without aura (female: 45, male: 39; age range 8-18"/>
  <result pre="were divided into two groups according to frequency of the" exact="migraine" post="episodes (high or low). According to headache attack intensity,"/>
  <result pre="show any relationship between TAS-20 and ASQ questionnaires and children’s" exact="migraine" post="intensity and frequency. Conclusions. Maternal alexithymia and attachment style"/>
  <result pre="Maternal alexithymia and attachment style have no impact on children's" exact="migraine" post="frequency and intensity. However, our results suggest that, although"/>
  <result pre="maternal alexithymic traits don’t play a causative role on children’s" exact="migraine" post="severity, they show a relationship with patients’ attachment style"/>
  <result pre="style and psychological symptoms, which in turn may impact on" exact="migraine" post="severity. P192 Vitamin D as a possible new treatment"/>
  <result pre="severity. P192 Vitamin D as a possible new treatment for" exact="migraine" post="Baoran Yang 1,2, Giorgia Leodori 1,2, Emma De Maio"/>
  <result pre="Methods: 45 patients aged 18-50 years and suffering from primary" exact="migraine" post="were enrolled in the study. Patients were divided into"/>
  <result pre="into three main subgroup: Group 1: patients suffering from mild" exact="migraine" post="(no more than 4 days of disability per month"/>
  <result pre="with vitamin D administration only. Group 2: patients with moderate-severe" exact="migraine" post="(more than 4 days of disability per month or"/>
  <result pre="Pain Rating scale ranging from 0 to 10) of the" exact="migraine" post="attacks during the month. These two values were then"/>
  <result pre="1, treated with vitamin D administration only, a reduction in" exact="migraine" post="severity of 67% was observed at the end of"/>
  <result pre="combined treatment (group 3) resulted 1,24 more effective in reducing" exact="migraine" post="severity than traditional therapy alone (group 2) (Fig. 1)."/>
  <result pre="during the study was not statistically significative. Conclusion: Currently, mild" exact="migraine" post="is normally treated with once-a-need anti-inflammatory drugs. In our"/>
  <result pre="our study Vitamin D administration for the treatment of mild" exact="migraine" post="resulted effective, with a decrease in the number of"/>
  <result pre="tone. Combined treatment with vitamin D plus traditional therapy improved" exact="migraine" post="symptoms of 69%, and this result suggests that vitamin"/>
  <result pre="may improve the efficacy of traditional therapy alone for severe" exact="migraine" post="(Fig. 2). Fig. 2 (abstract P192). See text for"/>
  <result pre="Photobiol B 2010;101:142–149. P193 Clinical presentation and diagnostic evaluation of" exact="idiopathic intracranial hypertension" post="in children and adolescents Barbara Battan, Laura Papetti, Irene"/>
  <result pre="present report was to describe the features of chronic paroxysmal" exact="migraine" post="in four pediatric patients. Objectives. Chronic paroxysmal hemicrania (CPH)"/>
  <result pre="present report was to describe the features of chronic paroxysmal" exact="migraine" post="in four pediatric patients. Results. We detected 4 patients"/>
  <result pre="its possible correlation with cognitive impairment and driving performance in" exact="migraine" post="patients; pilot study Matteo Bellamio 1, Federico Mainardi 2,"/>
  <result pre="cases. Most prevalent primary forms are tension type headache and" exact="migraine" post="without aura and there are specific criteria and guidelines"/>
  <result pre="other trigeminal autonomic cephalalgias, as well (2). As far as" exact="migraine" post="pathophysiology is studied, it remains poorly defined and partially"/>
  <result pre="partially understood: although the areas involved in the development of" exact="migraine" post="attacks are mainly localized in the brainstem (3), other"/>
  <result pre="included the basal ganglia, seem to play a role during" exact="migraine" post="attacks (4). Because of this pathogenetic complexity, there are"/>
  <result pre="patients. Therefore the few observations we have about DBS in" exact="migraine" post="derived from case reports conducted on patients with different"/>
  <result pre="example, a recent case reported a significant improvement of chronic" exact="migraine" post="after anterior thalamic DBS, performed for drug-resistant idiopathic generalized"/>
  <result pre="particular in the movement impairment. The patient suffered from chronic" exact="migraine" post="too: prophylactic treatments with topiramate 50 mg x 2"/>
  <result pre="justified: results of a real-life monocentric prospective study in chronic" exact="migraine" post="Michele Romoli 1, Ilenia Corbelli 1, Laura Bernetti 1,"/>
  <result pre="Santa Lucia, Rome, Italy Correspondence: Michele Romoli (romoli.mic@gmail.com) Background Chronic" exact="migraine" post="(CM) is a highly disabling headache disorder (1). Onabotulinum"/>
  <result pre="to 9.2 ± 3.6; p&amp;lt;0.001). During 12 months (5 cycles)," exact="migraine" post="days per month progressively abated (from 18.5 to 8.7;"/>
  <result pre="2). Over 5 cycles, patients regressing from CM to episodic" exact="migraine" post="doubled (from 32% to 66%), with 78% of them"/>
  <result pre="to 66%), with 78% of them reaching less than 9" exact="migraine" post="days/month. Conclusions The positive effect of OnabotA treatment seems"/>
  <result pre="5-hydroxy tryptophan and magnesium (Aurastop®) in the prophylaxis of episodic" exact="migraine" post="without aura in a adult population Alessandra Mandelli, Natascia"/>
  <result pre="magnesium 185 mg (TP-5HT-M) Aurastop ® in the prophylaxis of" exact="migraine" post="without aura with an episodic pattern. Materials and methods"/>
  <result pre="age 32.9) presenting with a ICHD 3 βeta diagnosis of" exact="migraine" post="without aura with a frequency of less than 10"/>
  <result pre="were enrolled in the survey. Patients were suffering from episodic" exact="migraine" post="for at least 6 months and they were not"/>
  <result pre="at least 6 months and they were not assuming any" exact="migraine" post="preventive therapy. Patients were asked to report in the"/>
  <result pre="tablet bid for the following 3 months. The reduction of" exact="migraine" post="attacks per month was assessed as the primary end-point,"/>
  <result pre="5 was the maximum satisfaction. Results A significant reduction of" exact="migraine" post="attacks per month (mean 2.8 vs 6.6) and number"/>
  <result pre="mg) and Magnesium (185 mg) (Aurastop®) is now available for" exact="migraine" post="patients. The three components may tackle the main mechanisms"/>
  <result pre="may tackle the main mechanisms involved in the pathophysiology of" exact="migraine" post="with aura: Cortical Spreading Depression, sensitization of trigeminal vascular"/>
  <result pre="(mean age:33.00 yrs), 117 F and 83 M, suffering from" exact="migraine" post="with aura referred to 8 Lombardia Headache Centers. Patients"/>
  <result pre="and 5-HTP (Aurastop®) could be an effective symptomatic treatment for" exact="migraine" post="aura. Randomised controlled trials are still required to confirm"/>
  <result pre="Martelletti P. Altered kynurenine pathway metabolites in serum of chronic" exact="migraine" post="patients. Journal of Headache pain 2015 Dec; 17(1):47. -"/>
  <result pre="To present the rare case of a 9-year-old girl with" exact="idiopathic intracranial hypertension" post="(IIH) secondary to hypoparathyroidism (HPTH) and our work-up, including"/>
  <result pre="a 9-year-old girl with idiopathic intracranial hypertension (IIH) secondary to" exact="hypoparathyroidism" post="(HPTH) and our work-up, including physical examination, blood tests,"/>
  <result pre="J Neurol Neurosurg Psychiatry 1977; 40:1015-7. P202 Efficacy in episodic" exact="migraine" post="prevention of a combination of Tanacethum Parthenium, 5 -"/>
  <result pre="to test the effectiveness of Aurastop© in the prophylaxis of" exact="migraine" post="without aura. Materials and methods: Sixty consecutive patients (F:"/>
  <result pre="mean age: 37.5±17.1) presenting with an ICHD-3 beta diagnosis of" exact="migraine" post="without aura (MO) were enrolled in the survey and"/>
  <result pre="Martelletti P. Altered kynurenine pathway metabolites in serum of chronic" exact="migraine" post="patients. J Headache Pain. 2015; 17: 47. Geppetti P,"/>
  <result pre="safety of 6,25 mg t.i.d feverfew CO2-extract ( MIG-99) in" exact="migraine" post="prevention – a randomized, double blind, multicenter, placebo controlled"/>
  <result pre="prophylactic treatment of cluster headache (CH) is to produce a" exact="suppression" post="of attacks and to maintain a remission until the"/>
  <result pre="on the four main mechanisms involved in the pathophysiology of" exact="migraine" post="with aura: Cortical Spreading Depression, sensitization of trigeminal vascular"/>
  <result pre="is well known to interact with the aura phenomena and" exact="migraine" post="itself.With this study we want to compare the efficacy"/>
  <result pre="31 years ), 27 women and 23 men, suffering from" exact="migraine" post="with aura, not assuming migraine preventive therapy. They have"/>
  <result pre="and 23 men, suffering from migraine with aura, not assuming" exact="migraine" post="preventive therapy. They have to refer of an aura"/>
  <result pre="Martelletti P. Altered kynurenine pathway metabolites in serum of chronic" exact="migraine" post="patients. Journal of Headache pain 2015 Dec; 17(1):47. Geppetti"/>
  <result pre="Tanacethum Parthenium, 5-hydroxy tryptophan and magnesium in the prophylaxis of" exact="migraine" post="without aura Federico Mainardi 1, Giorgio Zanchin 2, Carlo"/>
  <result pre="an extensive literature supporting their role in the prophylaxis of" exact="migraine" post="without aura. Aim of this study is to prove"/>
  <result pre="mg and magnesium 185 mg (TP-5HT-M) in the prophylaxis of" exact="migraine" post="without aura. Materials and methods: Twenty consecutive patients (F:"/>
  <result pre="M: n=3) presenting with a ICHD 3 beta diagnosis of" exact="migraine" post="without aura (MO) were enrolled in the survey. Age"/>
  <result pre="for a status migrainosus. She was previously followed for episodic" exact="migraine" post="without aura (ICHD-3). During the month preceding hospital-admission, the"/>
  <result pre="Yang CY. Reversible splenial lesion of the corpus callosum in" exact="migraine" post="with aura. Neurologist. 2011; 17:157-159. 4. Agarwal A, Kanupriya"/>
  <result pre="restricted diffusion in the splenium of the corpus callosum in" exact="migraine" post="with aura. Wien Klin Wochenschr. 2012; 124:146-147. 5. Samanta"/>
  <result pre="During pregnancy, headache is mostly due to primary disorders, including" exact="migraine" post="and tension-type headache. Pregnancy tends to ameliorate migraine that"/>
  <result pre="disorders, including migraine and tension-type headache. Pregnancy tends to ameliorate" exact="migraine" post="that however may also begin or worsen in this"/>
  <result pre="to the foetus, should be avoided during pregnancy. However, severe" exact="migraine" post="is often not controlled by nonpharmacologic strategies, and many"/>
  <result pre="women before pregnancy received a diagnosis by a physician of" exact="migraine" post="(n=15) or tension-type headache (n=3). The mean frequency of"/>
  <result pre="2. Nezvalová-Henriksen K, Spigset O, Nordeng H. Maternal characteristics and" exact="migraine" post="pharmacotherapy during pregnancy: cross-sectional analysis of data from a"/>
  <result pre="In the second, episodic forms of tension type headache or" exact="migraine" post="(with or without aura). We have tested the CDSS"/>
  <result pre="a diagnosis of episodic forms of tension type headache or" exact="migraine" post="with or without aura (Simplex category); 86 patients have"/>
  <result pre="1 (abstract P219). A representative report of a single chronic" exact="migraine" post="patient, female, 43 years old, showing the reduction of"/>
  <result pre="Not P212 Withdrawn P213 Non pharmacological preventive therapy to chronic" exact="migraine" post="in the real world: a Short-Term Psychodynamic Psychotherapy approach"/>
  <result pre="(IREP), 00187 - Rome, Italy Correspondence:Barbara Petolicchio (barbara.petolicchio@uniroma1.it) Background Chronic" exact="migraine" post="(CM) represents one of the leading causes of disability."/>
  <result pre="study. J Headache Pain 2013; 14 (S13-S41): 31 P214 Chronic" exact="migraine" post="preventive treatment by prefrontal-occipital transcranial direct current stimulation (TDCS):"/>
  <result pre="without medication overuse headache (MOH), represents a therapeutic challenge in" exact="migraine" post="management. These patients have frequently psychiatric comorbidities that may"/>
  <result pre="20 min, three times a week for four weeks). Clinical" exact="migraine" post="data were recorded at baseline (t-0), at the end"/>
  <result pre="without MOH were studied. We found 6 patients affected by" exact="bipolar disorder" post="(BD), and 5 other patients with bipolar spectrum. In"/>
  <result pre="CM is higher than expected in both general population and" exact="migraine" post="patients. BD patients showed a worse baseline headache burden"/>
  <result pre="current International Classification of Headaches Disorders (ICHD-3 beta, 2013) of" exact="migraine" post="without or with aura (&amp;gt; 4 attacks/month), chronic migraine,"/>
  <result pre="The last is the only drug licensed in Italy for" exact="migraine" post="prophylaxis in children. Outcomes: headache diary; PedMidas and CBCL"/>
  <result pre="Neurological Institute in Pavia, Italy. All consecutive patients with chronic" exact="migraine" post="and medication overuse headache undergoing an inpatient detoxification program"/>
  <result pre="with several conditions including cardiovascular diseases [1,2]. The association between" exact="migraine" post="and several thrombophilic alterations has been studied in migraineurs,"/>
  <result pre="of the present study was to assess the association between" exact="migraine" post="and some thrombophilic disorders. Methods We included consecutive migraine"/>
  <result pre="between migraine and some thrombophilic disorders. Methods We included consecutive" exact="migraine" post="patients referring to a tertiary headache center between September"/>
  <result pre="1 st 2008 and March 31 st 2010. For each" exact="migraine" post="patient a control subject without migraine, matched by age"/>
  <result pre="μmol/L). Results We included in the study 329 subjects with" exact="migraine" post="(37.7% with aura) and 329 controls. Mean age±SD was"/>
  <result pre="OR 2.6; 95% CI 1.5-4.7; P=0.001) were more common in" exact="migraine" post="patients than in control subjects whereas we found no"/>
  <result pre="cerebrovascular diseases (OR 4.8, 95% CI 1.6-16.9; P=0.004) and ischemic" exact="heart disease" post="(OR 22.7, 95% CI 2.3-223.4; P=0.008) than those not"/>
  <result pre="find any difference in the thrombophilic disorders between subjects with" exact="migraine" post="with and without aura. Discussion Migraine is comorbid with"/>
  <result pre="history as an analgesic medication in chronic pain, neuralgia and" exact="migraine" post="[1]. It contains more than 60 phytocannabinoids, all ligands"/>
  <result pre="increasing, because they have improved post-surgical pain, as well as" exact="migraine" post="symptoms, with a safety profile comparable to the most"/>
  <result pre="Background Onabotulintoxin A (BONTA) is a treatment recommended for chronic" exact="migraine" post="CM). Its efficacy in reducing migraine frequency and disability"/>
  <result pre="treatment recommended for chronic migraine CM). Its efficacy in reducing" exact="migraine" post="frequency and disability was fully demonstrated (1), though its"/>
  <result pre="paper pain diaries. Results. A significant and progressive reduction of" exact="migraine" post="episodes was observed from the paper and the electronic"/>
  <result pre="groups,R group was significantly older and with more years of" exact="migraine" post="in history than SF group.Moreover, in R group, the"/>
  <result pre="diagnosis (young age and/or few years of episodic and chronic" exact="migraine" post="in history) of MOH is needed to ensure a"/>
  <result pre="(SIH) complicated with convexity subaracnoid haemorragy (SAH) in patient with" exact="lung cancer" post="Francesca Marsili 1, Antonio Matera 1, Luca Onofrio Scappatura"/>
  <result pre="complicated with convexity subaracnoid haemorragy (SAH) in patient with lung" exact="cancer" post="Francesca Marsili 1, Antonio Matera 1, Luca Onofrio Scappatura"/>
  <result pre="of a cortical bridging vein. We describe one patient with" exact="lung cancer" post="who had orthostatic headache secondary to SIH complicated with"/>
  <result pre="a cortical bridging vein. We describe one patient with lung" exact="cancer" post="who had orthostatic headache secondary to SIH complicated with"/>
  <result pre="A 64 years old male undergone to left pneumectomy for" exact="lung cancer" post="one year before, presented with one month history of"/>
  <result pre="64 years old male undergone to left pneumectomy for lung" exact="cancer" post="one year before, presented with one month history of"/>
  <result pre="intracranial hypotension. Eur J Neurol 2010; 17:715-719 P223 Awareness of" exact="migraine" post="in Neo-Latin countries: a study in 12 headache centers"/>
  <result pre="Pavia, Italy Correspondence:Michele Viana Objectives To assess the awareness of" exact="migraine" post="(M) and previous diagnostic and therapeutic paths in naïf"/>
  <result pre="Italy), tension-type headache (3%, mostly in Mexico, Chile and Uruguay)," exact="sinusitis" post="(1%). After multivariate analysis factors associated with the awareness"/>
  <result pre="to radiation. 28% of patients had previously received a symptomatic" exact="migraine" post="specific medication and 29% had received at least one"/>
  <result pre="P223). Association between sociodemographical and clinical factors and awarness of" exact="migraine" post="Sign OR (95% CI) High educational level &amp;lt;0.001 1.97"/>
  <result pre="educational level &amp;lt;0.001 1.97 (1.43-2.78) Number of family members with" exact="migraine" post="0.005 1.17 (1.04-1.31) Duration of attacks (hours) 0.001 0.98"/>
  <result pre="afferent inhibition discloses abnormal fluctuations of cholinergic transmission during the" exact="migraine" post="cycle Davide Di Lenola 1, Gianluca Coppola 2, Francesca"/>
  <result pre="(mostly GABAa) cortical networks. Materials and methods We recruited 30" exact="migraine" post="without aura patients (16 between [MO] and 14 during"/>
  <result pre="attack. P227 The clinical efficacy of short-lasting ketogenic diet in" exact="migraine" post="is due to a general normalization of the interictal"/>
  <result pre="period of ketogenic diet (KD) regimen can help to prevent" exact="migraine" post="and can normalize its interictal abnormal cortical hyperresponsivity. Here,"/>
  <result pre="the right supraorbital division of the trigeminal nerve in 18" exact="migraine" post="without aura patients before and after 1-month of KD,"/>
  <result pre="that the clinical efficacy of a short-lasting KD regimen in" exact="migraine" post="can be primarily due to a general normalization of"/>
  <result pre="activation. P228 Cerebral grey matter density is reduced in chronic" exact="migraine" post="patients: correlations with clinical features Gianluca Coppola 1, Barbara"/>
  <result pre="studies have explored brain morphometry in patients affected by chronic" exact="migraine" post="(CM). Most of these studies were performed in patients"/>
  <result pre="ORAL PRESENTATIONS O1 Efficacy of erenumab in subjects with episodic" exact="migraine" post="with prior preventive treatment failure(s) Koen Paemeleire 1, Gregor"/>
  <result pre="Background There is a high unmet need for new preventive" exact="migraine" post="treatments, especially for patients who have failed existing migraine"/>
  <result pre="preventive migraine treatments, especially for patients who have failed existing" exact="migraine" post="therapies. Erenumab is a fully human monoclonal antibody that"/>
  <result pre="mg and 140 mg demonstrated efficacy in subjects with episodic" exact="migraine" post="and showed a safety profile similar to placebo. Here"/>
  <result pre="and/or intolerability. Analyses included change from baseline in mean monthly" exact="migraine" post="days (MMDs) and achievement of ≥50% reduction from baseline"/>
  <result pre="140 mg erenumab in subjects who had previously failed preventive" exact="migraine" post="treatments. For 140 mg, effects were numerically greater in"/>
  <result pre="for reducing raised intracranial pressure (ICP) in conditions such as" exact="idiopathic intracranial hypertension" post="have limited efficacy and tolerability. As such, there is"/>
  <result pre="novel therapeutic strategy for conditions of raised ICP such as" exact="idiopathic intracranial hypertension." post="Additionally, GLP-1R agonist therapy promotes weight loss, which would"/>
  <result pre="agonist therapy promotes weight loss, which would be advantageous in" exact="idiopathic intracranial hypertension." post="O3 Phase 3, randomised, double-blind, placebo-controlled study to evaluate"/>
  <result pre="evaluate the efficacy and safety of erenumab (AMG 334) in" exact="migraine" post="prevention: Primary results of the STRIVE trial Uwe Reuter"/>
  <result pre="a human anti-CGRP receptor monoclonal antibody, were evaluated in episodic" exact="migraine" post="(EM) subjects in a multinational, phase 3 trial (NCT02456740)."/>
  <result pre="The primary endpoint was change from baseline in mean monthly" exact="migraine" post="days (MMDs) over weeks 13-24. Secondary endpoints were ≥50%"/>
  <result pre="sinusitis. Conclusion Erenumab 70 mg and 140 mg significantly reduced" exact="migraine" post="frequency and use of migraine-specific medications, reducing migraine’s impact"/>
  <result pre="of distributed neural excitability: correlation with clinical features in single" exact="migraine" post="with aura patients Marina de Tommaso 1,2, Julia Maria"/>
  <result pre="(marina.detommaso@uniba.it) Background Cortical spreading depression (SD) is thought to underlie" exact="migraine" post="aura but mechanisms of triggering SD and propagation in"/>
  <result pre="triggering SD and propagation in the structurally normal cortex of" exact="migraine" post="patients is still unknown. Some studies showed that the"/>
  <result pre="still unknown. Some studies showed that the sensory predominance of" exact="migraine" post="aura is likely due to a greater susceptibility of"/>
  <result pre="their structural complexity [1]. We used MRI imaging registration in" exact="migraine" post="with aura patients to elaborate a CSD propagation logarithm"/>
  <result pre="1, 2, 3, 4, 44, 45, 17, 18) in five" exact="migraine" post="with aura patients. According to the map of the"/>
  <result pre="blockades. Botulinum toxin injections are also approved effective methods for" exact="migraine" post="all over the World. There is some other indications"/>
  <result pre="and methods Eligible patients 18-65 years of age with chronic" exact="migraine" post="(≥15 headache days per month, of which at least"/>
  <result pre="was the overall mean change-from-baseline in the number of monthly" exact="migraine" post="headache days (MHD) during the 3-month double-blind treatment period."/>
  <result pre="as well as the changes in monthly MHD with acute" exact="migraine" post="treatments, the Role Function-Restrictive domain score of the Migraine-Specific"/>
  <result pre="≥75% response (p&amp;lt;.001), greater reductions in monthly MHD with acute" exact="migraine" post="treatment (p&amp;lt;.001), and greater improvement in the MSQ-RFR (p&amp;lt;.001)"/>
  <result pre="of injection site reaction (p&amp;lt;.05), injection site erythema (p&amp;lt;.01), and" exact="sinusitis" post="(p&amp;lt;.05) all in the 240-mg dose-group relative to placebo."/>
  <result pre="as NCT02614261 at ClinicalTrials.gov. O7 Improving the differential diagnosis between" exact="migraine" post="with aura and transient ischemic attacks Elena R Lebedeva"/>
  <result pre="Denmark Correspondence:Elena R Lebedeva (cosmos@k66.ru) Background The differential diagnosis between" exact="migraine" post="with aura (MA) and transient ischemic attacks (TIA) is"/>
  <result pre="clinical characteristics. Eligible patients with TIA had focal brain or" exact="retinal ischemia" post="with resolution of symptoms without presence of new infarction"/>
  <result pre="for specificity against TIA patients and for sensitivity against the" exact="migraine" post="materials. We developed explicit diagnostic criteria for TIA and"/>
  <result pre="and specificity. We strongly recommend implementation of these criteria in" exact="migraine" post="and cerebrovascular clinics. References 1. Easton JD, Saver JL,"/>
  <result pre="been demonstrated in clinical practice and pilot studies of acute" exact="migraine" post="treatment [1,2]. The ease of use, flexibility, and favourable"/>
  <result pre="double-blind, randomised, controlled trial (RCT) included 248 patients with episodic" exact="migraine" post="with or without aura from 10 Italian tertiary headache"/>
  <result pre="and those of previous nVNS studies. Within 20 minutes from" exact="migraine" post="pain onset, patients self-administered bilateral 120-second stimulations to the"/>
  <result pre="before 120 minutes was considered treatment failure. Up to 5" exact="migraine" post="attacks were treated in the double-blind period. Results Acute"/>
  <result pre="higher pain-free rates than sham (n=123) for the first treated" exact="migraine" post="attack at 30 minutes (12.7% vs 4.2%; P=0.012) and"/>
  <result pre="well tolerated, and practical for the acute treatment of episodic" exact="migraine" post="with or without aura. Significant benefits of nVNS versus"/>
  <result pre="J Headache Pain. 2015;16:61-65. O10 Differences between episodic and chronic" exact="migraine" post="in white-matter tracts: a diffusion-tensor imaging study Claudia Marsecano"/>
  <result pre="L’Aquila, Italy Correspondence:Simona Sacco (simona.sacco@univaq.it) Background Several studies indicated that" exact="migraine" post="patients have tract-specific alterations in several white-matter tracts as"/>
  <result pre="controls [1-12]. We investigated differences in white-matter tracts between episodic" exact="migraine" post="(EM) patients and chronic migraine (CM) patients. Materials and"/>
  <result pre="in white-matter tracts between episodic migraine (EM) patients and chronic" exact="migraine" post="(CM) patients. Materials and methods We included consecutive eligible"/>
  <result pre="and 20 CM patients (mean age±SD 43.8±6.9). Years lived with" exact="migraine" post="were similar in EM (mean±SD 14.3±7.0) and CM (mean±SD"/>
  <result pre="patients showed a negative age-adjusted correlation between years lived with" exact="migraine" post="and FA in the uncinate fasciculus (r=-.501; P=.048). CM"/>
  <result pre="patients showed a positive age-adjusted correlation between years lived with" exact="migraine" post="and MD in the corpus callosum forceps major (r=.500;"/>
  <result pre="P=.050). We did not find any correlation between frequency of" exact="migraine" post="attacks and MD or FA nor in the EM"/>
  <result pre="results also indicate that the longer the years lived with" exact="migraine" post="the greater is the impairment in selected white-matter tracts."/>
  <result pre="in selected white-matter tracts. In summary, our data suggest that" exact="migraine" post="type and number of years with migraine affects white-matter"/>
  <result pre="data suggest that migraine type and number of years with" exact="migraine" post="affects white-matter tract status. References 1. Chong CD, Schwedt"/>
  <result pre="Bianco F, Pierelli F. Dynamic changes in thalamic microstructure of" exact="migraine" post="without aura patients: A diffusion tensor magnetic resonance imaging"/>
  <result pre="N. Anatomical alterations of the visual motion processing network in" exact="migraine" post="with and without aura. PLoS Med 2006;3:e402. 4. Kara"/>
  <result pre="Ulusoy L, Mutlu A, Sirvanci M. DTI findings during spontaneous" exact="migraine" post="attacks. Clin Neuroradiol 2013;23:31-36. 5. Liu J, Lan L,"/>
  <result pre="Tian J. White matter integrity affected by depressive symptoms in" exact="migraine" post="without aura: a tract-based spatial statistics study. NMR Biomed"/>
  <result pre="Deneen KM, Tian J. Axonal loss of white matter in" exact="migraine" post="without aura: A tract-based spatial statistics study. Cephalalgia 2013;"/>
  <result pre="of corpus callosum modulates inter-hemispheric resting state functional connectivity in" exact="migraine" post="patients without aura. PloS One 2012;7:e45476. O11 Headache following"/>
  <result pre="O12 Cerebral grey matter density is abnormally reduced in chronic" exact="migraine" post="patients: correlations with clinical features Gianluca Coppola 1, Barbara"/>
  <result pre="studies have explored brain morphometry in patients affected by chronic" exact="migraine" post="(CM). Most of these studies were performed in patients"/>
  <result pre="various conditions, many with a greater relative frequency in chronic" exact="migraine" post="(CM) versus episodic migraine (EM). The objective of this"/>
  <result pre="a greater relative frequency in chronic migraine (CM) versus episodic" exact="migraine" post="(EM). The objective of this study was to replicate"/>
  <result pre="Psychiatric, and Endocrine/Neurological comorbidity categories. Results Available CaMEO respondents with" exact="migraine" post="(16,763) were sent the Comorbidities/Endophenotype module and 12,810 (76.4%:"/>
  <result pre="gene-related peptide (CGRP) and sildenafil are vasoactive substances that induce" exact="migraine" post="attacks in patients. The intradural arteries are thought to"/>
  <result pre="never been examined in vivo. Furthermore, sildenafil is the only" exact="migraine" post="inducing compound, where cephalic dilation is not reported. Here,"/>
  <result pre="sildenafil dilate intradural arteries, supporting the notion that all pharmacological" exact="migraine" post="triggers, so far, do indeed dilate cephalic vessels. We"/>
  <result pre="University of L’Aquila, L’Aquila, Italy Correspondence:Francesca Pistoia (francesca.pistoia@univaq.it) Background Chronic" exact="migraine" post="(CM) may be associated to specific cortical and subcortical"/>
  <result pre="causal relationship between these changes and the clinical course of" exact="migraine" post="or whether they are rather an epiphenomenon. The objective"/>
  <result pre="Materials and methods We included consecutive eligible patients with episodic" exact="migraine" post="(EM) or CM referring to a tertiary headache center."/>
  <result pre="and 17 CM patients (mean age±SD 43.1±6.4). Years lived with" exact="migraine" post="were not significantly different in EM (mean±SD 18.2±10.6) as"/>
  <result pre="disease duration, a negative age-adjusted correlation between years lived with" exact="migraine" post="and volumetric reduction was found in right (p&amp;lt;0.001) and"/>
  <result pre="Regions showing a volumetric reduction might represent crucial hubs in" exact="migraine" post="activity and pathophysiology. A better understanding of their role"/>
  <result pre="provide a model to improve treatment options in patients with" exact="migraine" post="[8]. References 1. Bilgiç B, Kocaman G, Arslan AB,"/>
  <result pre="population) and of Cluster Headache 0.01% (n=0.74K of population). Chronic" exact="migraine" post="one-year prevalence was 1% (n=0.7K of population). Females tend"/>
  <result pre="EVOLVE-2) to determine superiority to placebo in the prevention of" exact="migraine" post="headache. Methods EVOLVE-1 and EVOLVE-2 were double-blind, 6-month studies"/>
  <result pre="and EVOLVE-2 were double-blind, 6-month studies in patients with episodic" exact="migraine" post="(4 to 14 monthly migraine headache days [MHD]) conducted"/>
  <result pre="studies in patients with episodic migraine (4 to 14 monthly" exact="migraine" post="headache days [MHD]) conducted in North America and globally,"/>
  <result pre="overall mean change from baseline in monthly MHD with acute" exact="migraine" post="treatments, and mean change from baseline over Months 4-6"/>
  <result pre="overall mean reduction of monthly number of MHD with acute" exact="migraine" post="treatment for both galcanezumab doses relative to placebo (both"/>
  <result pre="effectiveness and safety of real-life use of onabotulinumtoxinA for chronic" exact="migraine" post="(CM). Materials and Methods Adults prescribed onabotulinumtoxinA for CM"/>
  <result pre="to moderate severity, were reported by 18.3% of patients; eyelid" exact="ptosis" post="(5.4%), neck pain (3.0%), and musculoskeletal stiffness (2.7%) were"/>
  <result pre="(* P&amp;lt;0.001) O20 Abnormal peripheral and central visual processing in" exact="migraine" post="Filippo Brighina, Elisa Catalano, Viviana Firpo, Giuseppe Cosentino, Salvatore"/>
  <result pre="recent study with SIFI confirmed hyperexcitability of visual cortex in" exact="migraine" post="[2]; patients with migraine show abnormality of chromatic perception"/>
  <result pre="confirmed hyperexcitability of visual cortex in migraine [2]; patients with" exact="migraine" post="show abnormality of chromatic perception with a more relevant"/>
  <result pre="with migraine, with and without aura examined interictally. Subjects: 15" exact="migraine" post="patients with aura (MWA) and 15 without aura(MWoA) were"/>
  <result pre="Baschi R, Vallar G, Fierro B. Visual cortex hyperexcitability in" exact="migraine" post="in response to sound-induced flash illusions. Neurology. 2015 May"/>
  <result pre="firing rate and might be involved in the pathogenesis of" exact="migraine" post="[1]. We sought to determine the relationship between plasma"/>
  <result pre="the relationship between plasma levels of neurosteroids in patients with" exact="migraine" post="and cluster headache. Materials and Methods Patients with episodic"/>
  <result pre="migraine and cluster headache. Materials and Methods Patients with episodic" exact="migraine" post="(EM, n=19), chronic migraine and medication overuse headache (CM,"/>
  <result pre="Materials and Methods Patients with episodic migraine (EM, n=19), chronic" exact="migraine" post="and medication overuse headache (CM, n=51), and cluster headache"/>
  <result pre="respectively. This suggests an attempt to modulate neuronal hyperexcitability in" exact="migraine" post="patients. Changes of neurosteroids concentrations in CH patients were"/>
  <result pre="and 100 mg) compared to placebo for acute treatment of" exact="migraine" post="Bernice Kuca 1; Linda Wietecha 2; Paul H Berg"/>
  <result pre="or photophobia) at 2 hours post dose, time course of" exact="migraine" post="response, rescue, and safety following treatment with lasmiditan 200"/>
  <result pre="mg) or placebo within 4 hours of onset of a" exact="migraine" post="attack (moderate severity or worse and not improving). Subjects"/>
  <result pre="assigned lasmiditan dose or placebo for rescue or recurrence of" exact="migraine" post="if needed (2 to 24 hours post initial dose);"/>
  <result pre="via logistic regression with terms for treatment group and background" exact="migraine" post="preventative use. Lasmiditan 100 mg and placebo were also"/>
  <result pre="which there are ample of evidence in human subjects suffering" exact="epilepsy" post="(and PIH), and thus, it bypass the bitter debate"/>
  <result pre="debate over the validity of studying the headache phase of" exact="migraine" post="using the controversial cortical spreading depression model – to"/>
  <result pre="actual occurrence in humans are scarce. O24 Association between subclinical" exact="hypothyroidism" post="and migraine Innocenzo Rainero 1,2*, Flora Govone 1, Francesca"/>
  <result pre="in humans are scarce. O24 Association between subclinical hypothyroidism and" exact="migraine" post="Innocenzo Rainero 1,2*, Flora Govone 1, Francesca Garino 3,"/>
  <result pre="increased attention has been devoted to the potential association between" exact="migraine" post="and thyroid function, with conflicting results. A few studies"/>
  <result pre="thyroid function, with conflicting results. A few studies found that" exact="migraine" post="may be associated with an increased risk for the"/>
  <result pre="increased risk for the development of both overt and subclinical" exact="hypothyroidism" post="(SH). On the contrary, the risk of developing migraine"/>
  <result pre="subclinical hypothyroidism (SH). On the contrary, the risk of developing" exact="migraine" post="in patients with hypothyroidism has been scarcely investigated. Therefore,"/>
  <result pre="the contrary, the risk of developing migraine in patients with" exact="hypothyroidism" post="has been scarcely investigated. Therefore, the main purpose of"/>
  <result pre="of our study was to investigate the association between subclinical" exact="hypothyroidism" post="and migraine in adults, using a case-control strategy. Materials"/>
  <result pre="study was to investigate the association between subclinical hypothyroidism and" exact="migraine" post="in adults, using a case-control strategy. Materials and methods"/>
  <result pre="9.19 years) were recruited for the study. In all subjects," exact="migraine" post="characteristics were collected through a direct face-to-face interview, using"/>
  <result pre="and anti-peroxidase antibodies) were compared between SH patients with comorbid" exact="migraine" post="and SH patients without migraine. Results The prevalence of"/>
  <result pre="and SH patients without migraine. Results The prevalence of lifetime" exact="migraine" post="was significantly higher in SH patients in comparison with"/>
  <result pre="vs 13%, p&amp;lt; 0.001; OR 5.80; 95% CI= 3.35-10.34). Both" exact="migraine" post="without aura and migraine with aura were significantly higher"/>
  <result pre="OR 5.80; 95% CI= 3.35-10.34). Both migraine without aura and" exact="migraine" post="with aura were significantly higher in SH patients than"/>
  <result pre="and antibodies levels were not different between SH patients with" exact="migraine" post="and those SH patients without migraine. Finally, a higher"/>
  <result pre="comorbidity for autoimmune diseases was found in SH patients with" exact="migraine" post="respect to SH patients without migraine. Conclusions Our data"/>
  <result pre="to SH patients without migraine. Conclusions Our data suggest that" exact="migraine" post="is significantly more frequent in patients with subclinical hypothyroidism"/>
  <result pre="that migraine is significantly more frequent in patients with subclinical" exact="hypothyroidism" post="respect to controls. Additional studies are needed in order"/>
  <result pre="that is involved in Cl - ions transport. Coexistence of" exact="cystic fibrosis" post="and sporadic hemiplegic migraine (SHM) has been reported in"/>
  <result pre="- ions transport. Coexistence of cystic fibrosis and sporadic hemiplegic" exact="migraine" post="(SHM) has been reported in only two cases in"/>
  <result pre="an unknown mutation on the other allele. He also had" exact="patent foramen ovale" post="that was surgically closed when he was 26-y.o. The"/>
  <result pre="was 26-y.o. The patient reported occasional cough bouts, triggering hemiplegic" exact="migraine" post="attacks In March 2017 a such cough bout, lasting"/>
  <result pre="the patient, suggests a migrainous infarction, since it followed the" exact="migraine" post="aura symtpoms and occurred in the brain regions implied"/>
  <result pre="from hypoxia due to cough bout and hemoptysis. In fact," exact="cerebral infarction," post="with prompt expansion of the core infarct, following mild"/>
  <result pre="Rao DS, Infeld MD, Stern RC, Chelimsky TC Cough-induced hemiplegic" exact="migraine" post="with impaired consciousness in cystic fibrosis. Pediatr Pulmonol. 2006"/>
  <result pre="RC, Chelimsky TC Cough-induced hemiplegic migraine with impaired consciousness in" exact="cystic fibrosis." post="Pediatr Pulmonol. 2006 Feb;41(2):171-6 2) Eikermann-Haerter K, Lee JH,"/>
  <result pre="K, Lee JH, Yuzawa I, et al. Migraine mutations increase" exact="stroke" post="vulnerability by facilitating ischemic depolarizations. Circulation 2012; 125(2): 335–345."/>
  <result pre="Gesù Children Hopsital, Rome, Italy Correspondence: Massimiliano Valeriani Objectives: Chronic" exact="migraine" post="(CM), Chronic tension-type headache (CTTH) and new daily persistent"/>
  <result pre="missing patients by improving patients’compliance and promoting the concept of" exact="migraine" post="as a disease that can cause relevant disability. Disclosure"/>
  <result pre="Medicine and Surgery, University of Parma, Parma, Italy Background Chronic" exact="migraine" post="(CM) is a disabling neurologic condition that affects 2-3%"/>
  <result pre="C was satisfied by having ≥8 days per month with" exact="migraine" post="without aura by the overwhelming majority of patients (95.5%),"/>
  <result pre="majority of patients (95.5%), while a not negligible percentage had" exact="migraine" post="with aura (9.1%) or headache relieved by a triptan"/>
  <result pre="allodynia (14.1%), life events (11.5%), excessive caffeine intake (10.4%), sleep" exact="bruxism" post="(9.1%), panic disorder (7.2%), and obesity (6.2%). Most represented"/>
  <result pre="life events (11.5%), excessive caffeine intake (10.4%), sleep bruxism (9.1%)," exact="panic disorder" post="(7.2%), and obesity (6.2%). Most represented comorbid disorders were:"/>
  <result pre="caffeine intake (10.4%), sleep bruxism (9.1%), panic disorder (7.2%), and" exact="obesity" post="(6.2%). Most represented comorbid disorders were: anxiety (32.3%), sleep"/>
  <result pre="disorders (32.2%), depression (25.4%), hypertension (20.5%), irritable bowel (8.4%), and" exact="fibromyalgia" post="(6.6%). CM was highly disabling in our population: mean"/>
  <result pre="number of symptomatic drugs was 28.8 (range 0-270). Refractory chronic" exact="migraine" post="(no MOH, unsuccessful use of at least 3 preventive"/>
  <result pre="Società Italiana per lo Studio delle Cefalee (SISC). O28 Prolonged" exact="migraine" post="aura: prevalence and comparison with &quot;normal&quot; auras Michele Viana"/>
  <result pre="diary-aided study. Methods: We recruited 224 consecutive patients affected by" exact="migraine" post="aura attending the Headache Centers of Pavia and Trondheim."/>
  <result pre="to report on an ad hoc diary, during three consecutive" exact="migraine" post="with aura attacks, quality of each aura symptom (AS),"/>
  <result pre="be. O29 Microvascular vasospasm of cerebral cortex in &quot;prolonged&quot; aura" exact="migraine" post="Stefano Viola 1*, Paolo Viola 2, Maria. P. Buongarzone"/>
  <result pre="authors have found a coronary microvascular endothelial dysfunction (CMED) in" exact="migraine" post="patients compared with control group suggesting that there would"/>
  <result pre="and 5 F, age range 21-41 years) during spontaneous &quot;prolonged&quot;" exact="migraine" post="aura in according to ICHD criteria and compared the"/>
  <result pre="compared with the headache-free periods. Conclusions: In conclusion during &quot;prolonged&quot;" exact="migraine" post="aura we find cortical areas of microvascular vasospasm corresponding"/>
  <result pre="Background: A wide range of medications is now available for" exact="migraine" post="prophylaxis but some patients don’t show a significant improvement"/>
  <result pre="date available in favour of and against their use in" exact="migraine" post="prophylaxis [1,2]. Objectives: To compare efficacy and tolerability of"/>
  <result pre="vs Amitriptyline 25 mg/die (AMI) for 3 months, as prophylactic" exact="migraine" post="therapy in a sample of adult outpatients. Patients and"/>
  <result pre="(52 females and 10 males), who received the diagnosis of" exact="migraine" post="with or without aura and were submitted to a"/>
  <result pre="Spitaleri D, Casucci G, Bussone G. Usefulness of nutraceuticals in" exact="migraine" post="prophylaxis. Neurol Sci. 2017 May;38(Suppl 1):117-120. O31 Comorbidity profiles"/>
  <result pre="prophylaxis. Neurol Sci. 2017 May;38(Suppl 1):117-120. O31 Comorbidity profiles of" exact="migraine" post="sufferers in headache center Alessandro Panconesi, Maria L Bartolozzi,"/>
  <result pre="prospectively the prevalence of some comorbidities in the first 1000" exact="migraine" post="patients (aged 15-65 years), afferent to Headache Center in"/>
  <result pre="district of Empoli Health Authority, classified with a diagnosis of" exact="migraine" post="without aura (MO), migraine with aura (MA), and chronic"/>
  <result pre="Authority, classified with a diagnosis of migraine without aura (MO)," exact="migraine" post="with aura (MA), and chronic migraine (CM) that also"/>
  <result pre="migraine without aura (MO), migraine with aura (MA), and chronic" exact="migraine" post="(CM) that also includes patients with medication overuse headache"/>
  <result pre="(mean age 38.2). This population included 866 patients with episodic" exact="migraine" post="(EM) (666 ♀ and 200 ♂, mean age 38.2)"/>
  <result pre="was: depression 5.6 %, hypertension, 9.3 %, diabetes 1.2 %," exact="asthma" post="3.3 %, hypothyroidism 6.4 %, hypercholesterolemia 0.5 %. Out"/>
  <result pre="%, hypertension, 9.3 %, diabetes 1.2 %, asthma 3.3 %," exact="hypothyroidism" post="6.4 %, hypercholesterolemia 0.5 %. Out of 56 patients"/>
  <result pre="carvedilol). Patients who assumed thyroid hormones were 64: they referred" exact="thyroiditis" post="(28), thyroidectomy (13), other (primitive, post-hyperthyroidism, etc) hypothyroidisms (16),"/>
  <result pre="post-hyperthyroidism, etc) hypothyroidisms (16), goitre in euthyroidism (7). Patients with" exact="asthma" post="were 65: 33 in current treatment and 32 in"/>
  <result pre="patients suffering of allergies were 198: 132 rhinitis, 42 drugs" exact="allergy" post="and 19 food allergy. Other somatic CC were: gallstones"/>
  <result pre="allergies were 198: 132 rhinitis, 42 drugs allergy and 19" exact="food allergy." post="Other somatic CC were: gallstones (5.4%), kidney stones (5.7%),"/>
  <result pre="inflammatory bowel disease (0.5%) including Crohn disease (3 patients) and" exact="ulcerative colitis" post="(2 patients), celiac disease (0.5%, all females), endometriosis (1.0%),"/>
  <result pre="bowel disease (0.5%) including Crohn disease (3 patients) and ulcerative" exact="colitis" post="(2 patients), celiac disease (0.5%, all females), endometriosis (1.0%),"/>
  <result pre="and ulcerative colitis (2 patients), celiac disease (0.5%, all females)," exact="endometriosis" post="(1.0%), psoriasis (0.7%), cardiac diseases (1.0%), rheumatic/autoimmune diseases (0.7%)"/>
  <result pre="colitis (2 patients), celiac disease (0.5%, all females), endometriosis (1.0%)," exact="psoriasis" post="(0.7%), cardiac diseases (1.0%), rheumatic/autoimmune diseases (0.7%) including lupus"/>
  <result pre="diseases (0.7%) including lupus (0.2%), Behcet disease, mixed connective disease," exact="rheumatoid arthritis," post="scleroderma, and Sjogren syndrome (0.1%).Vitiligo (0.2%), endometrial/breast cancer (0.5%),"/>
  <result pre="disease, rheumatoid arthritis, scleroderma, and Sjogren syndrome (0.1%).Vitiligo (0.2%), endometrial/breast" exact="cancer" post="(0.5%), meningioma (0.2%), hyperthyroidism (0.3%), restless legs syndrome (0.3%),"/>
  <result pre="arthritis, scleroderma, and Sjogren syndrome (0.1%).Vitiligo (0.2%), endometrial/breast cancer (0.5%)," exact="meningioma" post="(0.2%), hyperthyroidism (0.3%), restless legs syndrome (0.3%), fibromyalgia (0.2%),"/>
  <result pre="and Sjogren syndrome (0.1%).Vitiligo (0.2%), endometrial/breast cancer (0.5%), meningioma (0.2%)," exact="hyperthyroidism" post="(0.3%), restless legs syndrome (0.3%), fibromyalgia (0.2%), were also"/>
  <result pre="syndrome (0.1%).Vitiligo (0.2%), endometrial/breast cancer (0.5%), meningioma (0.2%), hyperthyroidism (0.3%)," exact="restless legs syndrome" post="(0.3%), fibromyalgia (0.2%), were also detected. Other CC whit"/>
  <result pre="cancer (0.5%), meningioma (0.2%), hyperthyroidism (0.3%), restless legs syndrome (0.3%)," exact="fibromyalgia" post="(0.2%), were also detected. Other CC whit a prevalence"/>
  <result pre="patients (Table 1). Conclusions The percentages of treated CC in" exact="migraine" post="patients in our survey, in particular those involved in"/>
  <result pre="same district [1,2]. In this comparison, the higher prevalence of" exact="hypothyroidism" post="was not statistically significant when migraine patients were considered"/>
  <result pre="the higher prevalence of hypothyroidism was not statistically significant when" exact="migraine" post="patients were considered by gender (♀ p = 0.067,"/>
  <result pre="(abstract O31). Percentage of treated diseases and lifetime allergies in" exact="migraine" post="patients All subjects ♂ ♀ EM CM Depression 5.6"/>
  <result pre="Mennuti N, Bartolozzi ML, Benemei S, Guidi L. Evaluation of" exact="migraine" post="comorbidities through clinical and pharmaceutical data. J Headache Pain"/>
  <result pre="KML, Ratanayake PD, Fagan E, Antony J. High-dose riboflavin for" exact="migraine" post="prophylaxis in children: a double-blind, randomized, placebo-controlled trial. J"/>
  <result pre="A, Luchetti A, Paolino MC, Villa MP. Melatonin to prevent" exact="migraine" post="or tension-type headache in children. Neurol Sci. 2008;29:285–7. 13."/>
  <result pre="16. Usai S, Grazzi L, Bussone G. Gingkolide B as" exact="migraine" post="preventive treatment in young age: results at 1-year follow-up."/>
  <result pre="Carotenuto M. Ginkgolide B complex efficacy for brief prophylaxis of" exact="migraine" post="in school-aged children: An open-label study. Neurol Sci. 2011;32:79–81."/>
  <result pre="Ruberto M, Pascotto A, Carotenuto M. Nutraceutical preparations in childhood" exact="migraine" post="prophylaxis: Effects on headache outcomes including disability and behaviour."/>
 </snippets>
</snippetsTree>
